Document:

Unassociated Document

    Exhibit
      10.1

     

    HEALTH
      SYSTEMS SOLUTIONS, INC.

    a
      Nevada corporation

    

    PREFERRED
      STOCK PURCHASE AGREEMENT

    

    THIS
      PREFERRED STOCK PURCHASE AGREEMENT,
      dated
      as of 17th day of August 2007 (the “Agreement”),
      is
      entered into by and between Health Systems Solutions, Inc., a Nevada corporation
      (the “Company”),
      and
      Stanford International Bank Ltd., an Antiguan banking corporation (the
“Purchaser”).

    

    WITNESSETH:

    

    WHEREAS,
      pursuant to a Preferred Stock Purchase Agreement, dated as of October 31, 2005,
      by and between the Company and the Purchaser (the “Existing
      Facility”),
      the
      Purchaser agreed to purchase (i) up to 4,625,000 shares of the Company’s
      Series C $2.00 Convertible Preferred Stock, $0.001 par value per share (the
      “Series
      C Preferred Stock”)
      and
      (ii) warrants to purchase an aggregate of up to 2,775,000 shares of the
      Company’s common stock, $.001 par value per share (the “Common
      Stock”);
      and

    

    WHEREAS,
      as of
      the date hereof, there remain warrants to purchase an aggregate of 172,500
      shares of Common Stock under the terms of the Existing Facility (the
“Existing
      Facility Warrants”);
      and

    

    WHEREAS,
      the
      Company and the Purchaser are executing and delivering this Agreement in
      reliance upon the exemptions from registration provided by Regulation D
      (“Regulation
      D”)
      promulgated by the Securities and Exchange Commission (the “Commission”)
      under
      the Securities Act of 1933, as amended (the “Securities
      Act”),
      and/or Section 4(2) of the Securities Act; and

    

    WHEREAS,
      upon
      the terms and conditions of this Agreement, the Purchaser has agreed to
      purchase, and the Company wishes to issue and sell, for an aggregate purchase
      price of up to $2,850,000 (i) up to 1,425,000 shares of the Company’s Series D
      $2.00 Convertible Preferred Stock, $0.001 par value per share (the “Series
      D Preferred Stock”),
      the
      terms of which are as set forth in the Certificate of Designation of Series
      D
      $2.00 Convertible Preferred Stock attached hereto as Exhibit A (the
“Series
      D Certificate of Designation”)
      and
      (ii) warrants (the “Warrants”)
      to
      purchase an aggregate of up to 427,500 shares of Common Stock, which Warrants
      will be in the form attached hereto as Exhibit B; and

    

    WHEREAS,
      the
      Series D Preferred Stock shall be convertible into shares of Common Stock
      pursuant to the terms set forth in the Series D Certificate of Designation,
      and
      the Warrants may be exercised for the purchase of Common Stock, pursuant to
      the
      terms set forth therein; and

    

    NOW,
      THEREFORE,
      in
      consideration of the premises and the mutual covenants contained herein and
      other good and valuable consideration, the receipt and sufficiency of which
      are
      hereby acknowledged, the parties agree as follows:

    
      

      
        	 	
                1.

              	
                
                  AGREEMENT
                    TO PURCHASE; PURCHASE
                    PRICE

                

              

      

      
         

        (a) Purchase
          of Preferred Stock and the Warrants.
          Subject
          to the terms and conditions in this Agreement, the Purchaser hereby agrees
          to
          purchase from the Company, and the Company hereby agrees to issue and sell
          to
          the Purchaser (i) up to 1,425,000 shares of Series D Preferred Stock and
          (ii)
          Warrants to purchase up to 427,500 shares of Common Stock based on a ratio
          of
          3/10 Warrant share for each Series D Preferred Stock share issued, for
          an
          aggregate maximum purchase price of $2,850,000 ($2.00 per share of Series
          D
          Preferred Stock), which shall be payable in immediately available funds
          on the
          applicable closing dates as determined pursuant to Section 1(b)
          below.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) Closings.
      Delivery of the shares of Series D Preferred Stock to be purchased by the
      Purchaser hereunder shall be made in the form of one or more stock certificates,
      registered in such names as the Purchaser may specify and in each case dated
      as
      of each Closing Date (as defined below). Delivery of the Warrants to be
      purchased by the Purchaser hereunder shall be made in the form of one or more
      Warrants, registered in such names as specified in Schedule A hereto (based
      on
      the percentages listed therein). Payment of the aggregate purchase price for
      such shares of Series D Preferred Stock and Warrants shall be made by the
      Purchaser in the form specifically agreed by the parties or by wire transfer
      to
      an account of the Company, by 5:00 PM, Eastern Standard Time, on the applicable
      closing date, and any such closing date being referred to herein as a
“Closing
      Date.”
      Closings shall occur as and when agreed by the parties in order to finance
      the
      Company’s needs for working capital. The Company shall submit each sale request
      (a “Request”)
      to
      Purchaser at least two weeks before the desired Closing Date. In connection
      with
      each Request, the Company shall state the number of shares of Series D Preferred
      Stock to be sold, in increments of 50,000 shares, and shall provide to Purchaser
      the proposed use of proceeds, together with such information relating to the
      transaction and the Company’s business and financial condition as Purchaser
      shall request. Purchaser shall have the right to accept or reject any Request
      in
      its sole discretion; provided, however, that the Purchaser shall not be
      permitted to reject Requests to sell up to an aggregate of 250,000 shares of
      Series D Preferred Stock (the “Minimum
      Shares”)
      after
      the initial Closing Date provided that the Company is in compliance with this
      Agreement in all material respects as of each relevant Request Date and Closing
      Date.

     

    (c) Initial
      Closing.
      The
      initial Closing Date shall occur upon the execution of this Agreement. At such
      time, the Company shall deliver all of the Warrants purchased hereunder
      registered in such names as specified in Schedule A hereto. In addition, the
      parties agree that, notwithstanding the provisions of the Existing Facility,
      the
      Existing Facility Warrants (with respect to 172,500 shares of Common Stock)
      shall also be delivered by the Company on the initial Closing Date and
      registered in such names as specified in Schedule B hereto.

     

    (d) Purchaser’s
      Option. Notwithstanding
      any provision of this Agreement to the contrary, Purchaser may, at any time
      with
      two years from the date of this Agreement, require the Company to sell to
      Purchaser, consistent with Sections 1(a) and (b) above, shares of Series D
      Preferred Stock remaining available hereunder in increments of 50,000 shares
      on
      two weeks prior written notice to the Company.

     

    
      
        
        

      

      
        2

        
          

        

      

       

      
        
        

      

    

    
      	 	
              2.

            	
              REPRESENTATIONS
                AND WARRANTIES OF THE PURCHASER; ACCESS TO INFORMATION; INDEPENDENT
                INVESTIGATION

            

    

     

    The
      Purchaser represents and warrants to, and covenants and agrees with, the Company
      as follows:

    

    (a) Qualified
      Investor.
      The
      Purchaser is (i) experienced in making investments of the kind described in
      this
      Agreement and the related documents, (ii) able to afford the entire loss of
      its
      investment in the Series D Preferred Stock and the Warrants, and (iv) an
“Accredited
      Investor”
as
      defined in Rule 501(a) of Regulation D and knows of no reason to anticipate
      any
      material change in its financial condition for the foreseeable future.

     

    (b) Restricted
      Securities.
      The
      securities are “restricted securities” as defined in Rule 144 promulgated under
      the Securities Act. All subsequent offers and sales by the Purchaser of the
      Note, the Series D Preferred Stock and the Warrants and the Common Stock
      issuable upon conversion of the Series D Preferred Stock or exercise of the
      Warrants shall be made pursuant to an effective registration statement under
      the
      Securities Act or pursuant to an applicable exemption from such registration.
      

     

    (c) Reliance
      on Representations.
      The
      Purchaser understands that the Series D Preferred Stock and the Warrants are
      being offered and sold to it in reliance upon exemptions from the registration
      requirements of the United States federal securities laws, and that the Company
      is relying upon the truthfulness and accuracy of the Purchaser’s representations
      and warranties, and the Purchaser’s compliance with its covenants and
      agreements, each as set forth herein, in order to determine the availability
      of
      such exemptions and the eligibility of the Purchaser to acquire the Series
      D
      Preferred Stock and the Warrants. 

     

    (d) Access
      to Information.
      The
      Purchaser (i) has been provided with sufficient information with respect to
      the
      business of the Company for the Purchaser to determine the suitability of making
      an investment in the Company and such documents relating to the Company as
      the
      Purchaser has requested and the Purchaser has carefully reviewed the same,
      (ii)
      has been provided with such additional information with respect to the Company
      and its business and financial condition as the Purchaser, or the Purchaser’s
      agent or attorney, has requested, and (iii) has had access to management of
      the
      Company and the opportunity to discuss the information provided by management
      of
      the Company and any questions that the Purchaser had with respect thereto have
      been answered to the full satisfaction of the Purchaser. 

     

    (e) Legality.
      The
      Purchaser has the requisite corporate power and authority to enter into this
      Agreement. 

     

    (f) Authorization.
      This
      Agreement and any related agreements, and the transactions contemplated hereby
      and thereby, have been duly and validly authorized by the Purchaser, and such
      agreements, when executed and delivered by each of the Purchaser and the Company
      will each be a valid and binding agreement of the Purchaser, enforceable in
      accordance with their respective terms, except to the extent that enforcement
      of
      each such agreement may be limited by bankruptcy, insolvency, reorganization,
      moratorium, fraudulent conveyance or other similar laws now or hereafter in
      effect relating to creditors rights generally and to general principles of
      equity.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    (g) Adequate
      Resources.
      The
      Purchaser, or an affiliate of the Purchaser, has sufficient liquid assets to
      deliver the aggregate purchase price during the term of the
      Agreement.

     

    (h) Investment.
      The
      Purchaser is acquiring the Series D Preferred Stock and the Warrants for
      investment for the Purchaser’s own account, not as a nominee or agent, and not
      with the view to, or for resale in connection with, any distribution thereof,
      nor with any present intention of distributing or selling such Series D
      Preferred Stock or Warrants. The Purchaser is aware of the limits on resale
      imposed by virtue of the transaction contemplated by this Agreement and is
      aware
      that the Series D Preferred Stock and the Warrants will bear restrictive
      legends.

     

    (i) Litigation.
      There
      is no action, suit, proceeding or investigation pending or, to the Knowledge
      of
      the Purchaser (as defined herein), currently threatened against the Purchaser
      that questions the validity of the Primary Documents (as defined below) or
      the
      right of Purchaser to enter into any such agreements or to consummate the
      transactions contemplated hereby and thereby, nor, to the Knowledge of
      Purchaser, is there any basis for the foregoing. All references to the
“Knowledge”
means
      the actual knowledge of the person in question or the knowledge such person
      could reasonably be expected to have each after reasonable investigation and
      due
      diligence.

     

    (j) Broker’s
      Fees and Commissions.
      Neither
      the Purchaser nor any of its officers, partners, employees or agents has
      employed any investment banker, broker, or finder in connection with the
      transactions contemplated by the Primary Documents. 

     

    
      	 	
              3.

            	
              REPRESENTATIONS
                OF THE COMPANY 

            

    

     

    The
      Company represents and warrants to, and covenants and agrees with, the Purchaser
      that:

    

    (a) Organization.
      The
      Company is a corporation duly organized and validly existing and in good
      standing under the laws of the State of Nevada and has all requisite corporate
      power and authority to carry on its business as now conducted. The Company
      has
      no other interest in any other entities except for Healthcare Quality Solutions,
      Inc. (“HQS”), VHT Acquisition Company and Carekeeper Solutions, Inc. The Company
      is duly qualified as a foreign corporation and in good standing in all
      jurisdictions in which either the ownership or use of the properties owned
      or
      used by it, or the nature of the activities conducted by it, requires such
      qualification. The minute books and stock record books and other similar records
      of the Company have been provided or made available to the Purchaser or its
      counsel prior to the execution of this Agreement, are complete and correct
      in
      all material respects and have been maintained in accordance with sound business
      practices. Such minute books contain true and complete records of all actions
      taken at all meetings and by all written consents in lieu of meetings of the
      directors, stockholders and committees of the board of directors of the Company
      from the date of organization through the date hereof. The Company has, prior
      to
      the execution of this Agreement, delivered to the Purchaser true and complete
      copies of the Company’s Articles of Incorporation, and Bylaws, each as amended
      through the date hereof. The Company is not in violation of any provisions
      of
      its Articles of Incorporation or Bylaws. 

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    (b) Capitalization.
      Capitalization.
      On the
      date hereof, the authorized capital of the Company consists of:
      (i) 150,000,000 shares of Common Stock, par value $0.001 per share, of
      which 6,689,111 shares are issued and outstanding and (ii) 15,000,000
      shares of preferred stock, par value $0.001 per share, of which 4,050,000 shares
      of Series C Preferred Stock are issued and outstanding and - 0 - shares of
      Series D Preferred Stock are outstanding. The Company’s filings with the
      Commission (the “Commission
      Filings”)
      accurately disclose the outstanding capital stock of the Company and all
      outstanding options, warrants, notes, or any other rights or instruments which
      would entitle the holder thereof to acquire shares of the Common Stock or other
      equity interests in the Company upon conversion or exercise, setting forth
      for
      each such holder the type of security, number of equity shares covered
      thereunder, the exercise or conversion price thereof, the vesting schedule
      thereof (if any), and the issuance date and expiration date thereof. Other
      than
      as disclosed in the Commission Filings, there are no outstanding rights,
      agreements, arrangements or understandings to which the Company is a party
      (written or oral) which would obligate the Company to issue any equity interest,
      option, warrant, convertible note, or other types of securities or to register
      any shares in a registration statement filed with the Commission. Other than
      as
      disclosed in the Commission Filings, there is no agreement, arrangement or
      understanding between or among any entities or individuals which affects,
      restricts or relates to voting, giving of written consents, dividend rights
      or
      transferability of shares with respect to any voting shares of the Company,
      including without limitation any voting trust agreement or proxy. The Commission
      Filings accurately disclose all the shares subject to “lock-up” or similar
      agreements or arrangements by which any equity shares are subject to resale
      restrictions and the Company has provided the Purchaser complete and accurate
      copies of all such agreements, which agreements are in full force and effect.
      Except as set forth in the Commission Filings, there are no outstanding
      obligations of the Company to repurchase, redeem or otherwise acquire for value
      any outstanding shares of capital stock or other ownership interests of the
      Company or to provide funds to or make any investment (in the form of a loan,
      capital contribution or otherwise) in any other entity. There are no
      anti-dilution or price adjustment provisions regarding any security issued
      by
      the Company (or in any agreement providing rights to security holders) that
      will
      be triggered by the issuance of the Securities (as defined below). 

     

    (c) Concerning
      the Common Stock, the Preferred Stock and the Warrants.
      The
      Series D Preferred Stock, the Warrants, the Existing Facility Warrants and
      the
      Common Stock issuable upon conversion of the Series D Preferred Stock and upon
      exercise of the Warrants and the Existing Facility Warrants when issued, shall
      be duly and validly issued, fully paid and non-assessable and will not subject
      the holder thereof to personal liability by reason of being such a holder.
      

     

    (d) Authorized
      Shares.
      The
      Company shall have available a sufficient number of authorized and unissued
      shares of Common Stock as may be necessary to effect conversion of the Series
      D
      Preferred Stock and the exercise of the Warrants and the Existing Facility
      Warrants. The Company understands and acknowledges the potentially dilutive
      effect to the Common Stock of the issuance of shares of Common Stock upon the
      conversion of the Series D Preferred Stock and the exercise of the Warrants
      and
      the Existing Facility Warrants. The Company further acknowledges that its
      obligation to issue shares of Common Stock upon conversion of the Series D
      Preferred Stock and upon exercise of the Warrants or the Existing Facility
      Warrants is absolute and unconditional regardless of the dilutive effect that
      such issuance may have on the ownership interests of other stockholders of
      the
      Company. 

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    (e) Legality.
      The
      Company has the requisite corporate power and authority to enter into this
      Agreement, and to issue and deliver the Series D Preferred Stock, the Warrants,
      the Existing Facility Warrants and the Common Stock issuable upon conversion
      of
      the Series D Preferred Stock and the exercise of the Warrants and the Existing
      Facility Warrants. 

     

    (f) Transaction
      Agreements.
      This
      Agreement, the Warrants, the Registration Rights Agreement (as defined below)
      and the Series D Certificate of Designation (collectively, the “Primary
      Documents”),
      and
      the transactions contemplated hereby and thereby, have been duly and validly
      authorized by the Company; this Agreement has been duly executed and delivered
      by the Company and this Agreement is, and the other Primary Documents, when
      executed and delivered by the Company, will each be, a valid and binding
      agreement of the Company, enforceable in accordance with their respective terms,
      except to the extent that enforcement of each of the Primary Documents may
      be
      limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent
      conveyance or other similar laws now or hereafter in effect relating to
      creditors’ rights generally and to general principles of equity. 

     

    (g) Financial
      Statements.
      The
      financial statements and related notes thereto contained in the Company’s
      filings with the Commission (the “Company
      Financials”)
      are
      correct and complete in all material respects, comply in all material respects
      with the Securities Exchange Act of 1934, as amended (the “Exchange
      Act”),
      and
      the rules and regulations of the Commission promulgated thereunder and have
      been
      prepared in accordance with United States generally accepted accounting
      principles applied on a basis consistent throughout the periods indicated and
      consistent with each other. The Company Financials present fairly and accurately
      the financial condition and operating results of the Company in all material
      respects as of the dates and during the periods indicated therein and are
      consistent with the books and records of the Company. Except as set forth in
      the
      Company Financials, the Company has no material liabilities, contingent or
      otherwise, other than liabilities disclosed on the balance sheet as of
      June 30, 2006. Since
      January 1, 2004, there has been no change in any accounting policies,
      principles, methods or practices, including any change with respect to reserves
      (whether for bad debts, contingent liabilities or otherwise), of the Company.
      

     

    (h) Commission
      Filings.
      The
      Company has made all filings with the Commission that it has been required
      to
      make under the Securities Act and the Exchange Act and has furnished or made
      available to the Purchaser true and complete copies of all the documents it
      has
      filed with the Commission since its inception, all in the forms so filed. As
      of
      their respective filing dates, such filings already filed by the Company or
      to
      be filed by the Company after the date hereof but before the initial Closing
      Date complied or, if filed after the date hereof, will comply in all material
      respects with the requirements of the Securities Act and the Exchange Act,
      and
      the rules and regulations of the Commission promulgated thereunder, as the
      case
      may be, and none of the filings with the Commission contained or will contain
      any untrue statement of a material fact or omitted or will omit any material
      fact required to be stated therein or necessary to make the statements made
      therein, in light of the circumstances in which they were made, not misleading,
      except to the extent such filings have been all prior to the date of this
      Agreement corrected, updated or superseded by a document subsequently filed
      with
      Commission.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    (i) Non-Contravention.
      The
      execution and delivery of this Agreement and each of the other Primary
      Documents, and the consummation by the Company of the transactions contemplated
      by this Agreement and each of the other Primary Documents, do not and will
      not
      conflict with, or result in a breach by the Company of, or give any third party
      any right of termination, cancellation, acceleration or modification in or
      with
      respect to, any of the terms or provisions of, or constitute a default under,
      (A) its Articles of Incorporation or Bylaws, as amended through the date hereof,
      (B) any material indenture, mortgage, deed of trust, lease or other agreement
      or
      instrument to which the Company is a party or by which it or any of its
      properties or assets are bound, or (C) any existing applicable law, rule, or
      regulation or any applicable decree, judgment or order of any court or federal,
      state, securities industry or foreign regulatory body, administrative agency,
      or
      any other governmental body having jurisdiction over the Company or any of
      their
      properties or assets (collectively, “Legal
      Requirements”),
      other
      than those which have been waived or satisfied on or prior to the initial
      Closing Date. 

     

    (j) Approvals
      and Filings.
      Other
      than the completion of the filing of the Series D Certificate of Designation,
      no
      authorization, approval or consent of any court, governmental body, regulatory
      agency, self-regulatory organization, stock exchange or market or the
      stockholders of the Company is required to be obtained by the Company for the
      entry into or the performance of this Agreement and the other Primary Documents.
      

     

    (k) Compliance
      With Legal Requirements.
      Except
      as disclosed in the Commission Filings, the Company has not violated in any
      material respect, and is not currently in material default under, any Legal
      Requirement applicable to the Company, or any of the assets or properties of
      the
      Company, where such violation could reasonably be expected to have material
      adverse effect on the business or financial condition of the
      Company. 

     

    (l) Absence
      of Certain Changes.
      Since
      January 1, 2007, except as previously disclosed in the Commission Filings,
      there
      has been no material adverse change nor any material adverse development in
      the
      business, properties, operations, financial condition, prospects, outstanding
      securities or results of operations of the Company, and no event has occurred
      or
      circumstance exists that may result in such a material adverse
      change. 

     

    (m) Indebtedness
      to Officers, Directors and Stockholders.
      The
      Company is not indebted to any of the Company’s stockholders, officers or
      directors or their Affiliates in any amount whatsoever (including, without
      limitation, any deferred compensation, salaries or rent payable). 

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    (n) Relationships
      with Related Persons.
      Except
      as disclosed in the Commission Filings, no officer, director, or principal
      stockholder of the Company nor any Related Person (as defined below) of any
      of
      the foregoing has, or since December 31, 2002, has had, any interest in any
      property (whether real, personal, or mixed and whether tangible or intangible)
      used in or pertaining to the business of the Company. Except disclosed in the
      Commission Filings, no officer, director, or principal stockholder of the
      Company nor any Related Person of the any of the foregoing is, or since December
      31, 2002, has owned an equity interest or any other financial or profit interest
      in, a Person (as defined below) that has (i) had business dealings or a material
      financial interest in any transaction with the Company, or (ii) engaged in
      competition with the Company with respect to any line of the merchandise or
      services of such company (a “Competing
      Business”)
      in any
      market presently served by such company except for ownership of less than one
      percent of the outstanding capital stock of any Competing Business that is
      publicly traded on any recognized exchange or in the over-the-counter market.
      Except as disclosed in the Commission Filings, no director, officer, or
      principal stockholder of the Company nor any Related Person of any of the
      foregoing is a party to any Contract with, or has claim or right against, the
      Company. As used in this Agreement, “Person”
means
      any individual, corporation (including any non-profit corporation), general
      or
      limited partnership, limited liability company, joint venture, estate, trust,
      association, organization, labor union, or other entity or any governmental
      body; “Related
      Person”
means,
      (X) with respect to a particular individual, (a) each other member of such
      individual’s Family (as defined below); (b) any Person that is directly or
      indirectly controlled by such individual or one or more members of such
      individual’s Family; (c) any Person in which such individual or members of such
      individual’s Family hold (individually or in the aggregate) a Material Interest
      (as defined below); and (d) any Person with respect to which such individual
      or
      one or more members of such individual’s Family serves as a director, officer,
      partner, executor, or trustee (or in a similar capacity); (Y) with respect
      to a
      specified Person other than an individual, (a) any Person that directly or
      indirectly controls, is directly or indirectly controlled by, or is directly
      or
      indirectly under common control with such specified Person; (b) any Person
      that
      holds a Material Interest in such specified Person; (c) each Person that serves
      as a director, officer, partner, executor, or trustee of such specified Person
      (or in a similar capacity); (d) any Person in which such specified Person holds
      a Material Interest; (e) any Person with respect to which such specified Person
      serves as a general partner or a trustee (or in a similar capacity); and (f)
      any
      Related Person of any individual described in clause (b) or (c). For purposes
      of
      the foregoing definition, (a) the “Family”
of
      an
      individual includes (i) the individual, (ii) the individual’s spouse and former
      spouses, (iii) any other natural person who is related to the individual or
      the
      individual’s spouse within the second degree, and (iv) any other natural person
      who resides with such individual, and (b) “Material
      Interest”
means
      direct or indirect beneficial ownership (as defined in Rule 13d-3 under the
      Exchange Act) of voting securities or other voting interests representing at
      least 1% of the outstanding voting power of a Person or equity securities or
      other equity interests representing at least 1% of the outstanding equity
      securities or equity securities in a Person. 

     

    (o) Title
      to Properties; Liens and Encumbrances.
      The
      Company has good and marketable title to all of its material properties and
      assets, both real and personal, and has good title to all its leasehold
      interests. Except as disclosed in the Commission Filings, all material
      properties and assets reflected in the Company Financials are free and clear
      of
      all Encumbrances (as defined below) except liens for current Taxes not yet
      due.
      As used in this Agreement, “Encumbrance”
means
      any charge, claim, community property interest, condition, equitable interest,
      lien, pledge, security interest, right of first refusal, or restriction of
      any
      kind, including any restriction on use, voting, transfer, receipt of income,
      or
      exercise of any other attribute of ownership. 

     

    (p) Permits.
      The
      Company has all permits, licenses and any similar authority necessary for the
      conduct of its business as now conducted, the lack of which would materially
      and
      adversely affect the business or financial condition of such company. The
      Company is not in default in any respect under any of such permits, licenses
      or
      similar authority. 

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    (q) Absence
      of Litigation.
      There
      is no action, suit, proceeding, inquiry or investigation before or by any court,
      public board or body, or arbitration tribunal pending or, to the Knowledge
      of
      the Company, threatened, against or affecting the Company, in which an
      unfavorable decision, ruling or finding would have a material adverse effect
      on
      the properties, business, condition (financial or other) or results of
      operations of the Company, taken as a whole, or the transactions contemplated
      by
      the Primary Documents, or which would adversely affect the validity or
      enforceability of, or the authority or ability of the Company to perform its
      obligations under, the Primary Documents.
      All
      references to the “Knowledge
      of the Company”
in
      this
      Agreement shall mean the actual knowledge of the Company or the knowledge that
      the Company could reasonably be expected to have, after reasonable investigation
      and due diligence.

     

    (r) No
      Default.
      The
      Company is not in default in the performance or observance of any obligation,
      covenant or condition contained in any indenture, mortgage, deed of trust or
      other instrument or agreement to which it is a party or by which it or its
      property may be bound. 

     

    (s) Taxes.

     

    (i) All
      Tax
      Returns (as defined below) required to have been filed by or with respect to
      the
      Company (including any extensions) have been filed. All such Tax Returns are
      true, complete and correct in all material respects. All Taxes (as defined
      below) due and payable by the Company, whether or not shown on any Tax Return,
      or claimed to be due by any Taxing Authority (as defined below), have been
      paid
      or accrued on the balance sheet included in the Company’s latest filing with the
      Commission. 

     

    (ii) The
      Company does not have any material liability for Taxes outstanding other than
      as
      reflected in the balance sheet included in the Company’s latest filing with the
      Commission or incurred subsequent to the date of such filing in the ordinary
      course of business. The unpaid Taxes of the Company (i) did not, as of the
      most
      recent fiscal month end, exceed by any material amount the reserve for liability
      for income tax (other than the reserve for deferred taxes established to reflect
      timing differences between book and tax income) set forth on the face of the
      balance sheet included in the Company’s latest filing with the Commission, and
      (ii) will not exceed by any material amount that reserve as adjusted for
      operations and transactions through the initial Closing Date. 

     

    (iii) The
      Company is not a party to any agreement extending the time within which to
      file
      any Tax Return. No claim has ever been made by a Taxing Authority of any
      jurisdiction in which the Company does not file Tax Returns that the Company
      is
      or may be subject to taxation by that jurisdiction. 

     

    (iv) The
      Company has withheld and paid all Taxes required to have been withheld and
      paid
      in connection with amounts paid or owing to any employee, creditor or
      independent contractor. 

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    (v) There
      has
      been no action by any Taxing Authority in connection with assessing additional
      Taxes against, or in respect of, the Company for any past period. There is
      no
      dispute or claim concerning any Tax liability of the Company either (i) claimed,
      raised or, to the Knowledge of the Company, threatened by any Taxing Authority
      or (ii) of which the Company is otherwise aware. There are no liens for Taxes
      upon the assets and properties of the Company other than liens for Taxes not
      yet
      due. None of the Tax Returns of the Company have been audited or examined by
      Taxing Authorities, and none of the Tax Returns of the Company currently are
      the
      subject of audit or examination. The Company has made available to the Purchaser
      complete and correct copies of all federal, state, local and foreign income
      Tax
      Returns filed by, and all Tax examination reports and statements of deficiencies
      assessed against or agreed to by, the Company since the fiscal year ended
      December 31, 1998.

     

    (vi) There
      are
      no outstanding agreements or waivers extending the statutory period of
      limitation applicable to any Tax Returns required to be filed by, or which
      include or are treated as including, the Company or with respect to any Tax
      assessment or deficiency affecting the Company.

     

    (vii) The
      Company has not received any written ruling related to Taxes or entered into
      any
      agreement with a Taxing Authority relating to Taxes.

     

    (viii) Except
      for the liabilities, if any, of HQS, the Company does not have any liability
      for
      the Taxes of any person or entity other than the Company (i) under Section
      1.1502-6 of the Treasury regulations (or any similar provision of state, local
      or foreign Legal Requirements), (ii) as a transferee or successor, (iii) by
      contract or (iv) otherwise. 

     

    (ix) The
      Company (i) has not agreed to make nor is required to make any adjustment under
      Section 481 of the Internal Revenue Code by reason of a change in accounting
      method and (ii) is not a “consenting corporation” within the meaning of Section
      341(f)(1) of the Internal Revenue Code. 

     

    (x) The
      Company is not a party to or bound by any obligations under any tax sharing,
      tax
      allocation, tax indemnity or similar agreement or arrangement. 

     

    (xi) The
      Company is not involved in, subject to, or a party to any joint venture,
      partnership, contract or other arrangement that is treated as a partnership
      for
      federal, state, local or foreign Tax purposes. 

     

    (xii) The
      Company was not included nor is includible, in the Tax Return of any other
      entity.

     

    As
      used
      in this Agreement, a “Tax
      Return”
means
      any return, report, information return, schedule, certificate, statement or
      other document (including any related or supporting information) filed or
      required to be filed with, or, where none is required to be filed with a Taxing
      Authority, the statement or other document issued by, a Taxing Authority in
      connection with any Tax; “Tax”
means
      any and all taxes, charges, fees, levies or other assessments, including,
      without limitation, income, gross, receipts, excise, real or personal property,
      sales, withholding, social security, retirement, unemployment, occupation,
      use,
      service, service use, license, net worth, payroll, franchise, transfer and
      recording taxes, fees and charges, imposed by Taxing Authority, whether computed
      on a separate, consolidated, unitary, combined or any other basis; and such
      term
      includes any interest whether paid or received, fines, penalties or additional
      amounts attributable to, or imposed upon, or with respect to, any such taxes,
      charges, fees, levies or other assessments; and “Taxing
      Authority”
means
      any governmental agency, board, bureau, body, department or authority of any
      United States federal, state or local jurisdiction or any foreign jurisdiction,
      having or purporting to exercise jurisdiction with respect to any
      Tax.

    

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    (t) Certain
      Prohibited Activities.
      Neither
      the Company nor any of its directors, officers or other employees has (i) used
      any Company funds for any unlawful contribution, endorsement, gift,
      entertainment or other unlawful expense relating to any political activity,
      (ii)
      made any direct or indirect unlawful payment of Company funds to any foreign
      or
      domestic government official or employee, (iii) violated or is in violation
      of
      any provision of the Foreign Corrupt Practices Act of 1977, as amended, or
      (iv)
      made any bribe, rebate, payoff, influence payment, kickback or other similar
      payment to any person.

     

    (u) Agent
      Fees.
      The
      Company has not incurred any liability for any finder’s or brokerage fees or
      agent’s commissions in connection with the transactions contemplated by this
      Agreement.

     

    (v) Employee
      Benefits.

     

    (i) The
      Company does not have, and has not at any time since December 31, 1998 had,
      Plans (as defined below).

     

    As
      used
      in this Agreement, “Plan”
means
      (i) each of the “employee benefit plans” (as such term is defined in Section
      3(3) of the Employee Retirement Income Security Act of 1974 (“ERISA”)),
      of
      which any of the Company or any member of the same controlled group of
      businesses as the Company within the meaning of Section 4001(a)(14) of ERISA
      (an
“ERISA
      Affiliate”)
      is or
      ever was a sponsor or participating employer or as to which the Company or
      any
      of its ERISA Affiliates makes contributions or is required to make
      contributions, and (ii) any similar employment, severance or other arrangement
      or policy of any of the Company or any of its ERISA Affiliates (whether written
      or oral) providing for health, life, vision or dental insurance coverage
      (including self-insured arrangements), workers’ compensation, disability
      benefits, supplemental unemployment benefits, vacation benefits or retirement
      benefits, fringe benefits, or for profit sharing, deferred compensation,
      bonuses, stock options, stock appreciation or other forms of incentive
      compensation or post-retirement insurance, compensation or
      benefits.

    

    (w) Private
      Offering.
      Subject
      to the accuracy of the Purchaser’s representations and warranties set forth in
      Section 2
      hereof,
      (i) the offer, sale and issuance of the Series D Preferred Stock, the Warrants
      and the Existing Facility Warrants, (ii) the issuance of Common Stock pursuant
      to the conversion and/or exercise of such securities into shares of Common
      Stock, each as contemplated by the Primary Documents, are exempt from the
      registration requirements of the Securities Act. The Company agrees that neither
      the Company nor anyone acting on its behalf will offer any of the Series D
      Preferred Stock, the Warrants or any similar securities for issuance or sale,
      or
      solicit any offer to acquire any of the same from anyone so as to render the
      issuance and sale of such securities subject to the registration requirements
      of
      the Securities Act. The Company has not offered or sold the Series D Preferred
      Stock or the Warrants by any form of general solicitation or general
      advertising, as such terms are used in Rule 502(c) under the Securities
      Act.

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    
      	 	
              4.

            	
              CERTAIN
                COVENANTS, ACKNOWLEDGMENTS AND
                RESTRICTIONS

            

    

     

    (a) Transfer
      Restrictions.
      The
      Purchaser acknowledges that (i) neither the Series D Preferred Stock, the
      Warrants nor the Common Stock issuable upon conversion of the Series D Preferred
      Stock or upon exercise of the Warrants have been registered under the Securities
      Act, and such securities may not be transferred unless (A) subsequently
      registered thereunder or (B) they are transferred pursuant to an exemption
      from
      such registration, and (ii) any sale of the Series D Preferred Stock, the
      Warrants or the Common Stock issuable upon conversion, exercise or exchange
      thereof (collectively, the “Securities”)
      made
      in reliance upon Rule 144 under the Securities Act (“Rule
      144”)
      may be
      made only in accordance with the terms of said Rule 144. The provisions of
      Section 4(a)
      and
      4(b)
      hereof,
      together with the rights of the Purchaser under this Agreement and the other
      Primary Documents, shall be binding upon any subsequent transferee of the Series
      D Preferred Stock and the Warrants. 

     

    (b) Restrictive
      Legend.
      The
      Purchaser acknowledges and agrees that, until such time as the Securities shall
      have been registered under the Securities Act or the Purchaser demonstrates
      to
      the reasonable satisfaction of the Company and its counsel that such
      registration shall no longer be required, such Securities may be subject to
      a
      stop-transfer order placed against the transfer of such Securities, and such
      Securities shall bear a restrictive legend in substantially the following
      form:

     

    THESE
      SECURITIES (INCLUDING ANY UNDERLYING SECURITIES) HAVE NOT BEEN REGISTERED UNDER
      THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
      PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE
      REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF
      COUNSEL OR OTHER EVIDENCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
      REGISTRATION SHALL NO LONGER BE REQUIRED.

    

    (c) Filings.
      The
      Company undertakes and agrees that it will make all required filings in
      connection with the sale of the Securities to the Purchaser as required by
      federal and state laws and regulations, or by any domestic securities exchange
      or trading market, and if applicable, the filing of a notice on Form D (at
      such
      time and in such manner as required by the rules and regulations of the
      Commission), and to provide copies thereof to the Purchaser promptly after
      such
      filing or filings. With a view to making available to the holders of the
      Securities the benefits of Rule 144 and any other rule or regulation of the
      Commission that may at any time permit such holder to sell securities of the
      Company to the public without registration or pursuant to a registration on
      Form
      S-3 or Form SB-2, the Company shall (a) at all times make and keep public
      information available, as those terms are understood and defined in Rule 144,
      (b) file on a timely basis with the Commission all information that the
      Commission may require under either of Section 13 or Section 15(d) of the
      Exchange Act and, so long as it is required to file such information, take
      all
      actions that may be required as a condition to the availability of Rule 144
      (or
      any successor exemptive rule hereafter in effect) with respect to the Common
      Stock; and (d) furnish to any holder of the Securities forthwith upon request
      (i) a written statement by the Company as to its compliance with the reporting
      requirements of Rule 144, (ii) a copy of the most recent annual or quarterly
      report of the Company as filed with the Commission, and (iii) any other reports
      and documents that a holder of the Securities may reasonably request in order
      to
      avail itself of any rule or regulation of the Commission allowing such holder
      to
      sell any such Securities without registration.

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    (d) Reservation
      of Common Stock.
      The
      Company will at all times have authorized and reserved for the purpose of
      issuance a sufficient number of shares of Common Stock to provide for the
      conversion of the Series D Preferred Stock and the exercise of the
      Warrants.

     

    (e) Registration
      Requirement.
      Upon
      the execution of this Agreement, the holders of the Securities and the Company
      shall execute a registration rights agreement in the form attached hereto as
      Exhibit C (the “Registration
      Rights Agreement”).

     

    (f) Return
      of Certificates on Conversion and Warrants on Exercise.
      

     

    (i) Upon
      any
      conversion by the Purchaser of less than all of the Series D Preferred Stock
      pursuant to the terms of the Series D Certificate of Designation, the Company
      shall issue and deliver to the Purchaser, within seven business days of the
      date
      of conversion, a new certificate or certificates for, as applicable, the total
      number of shares of the Series D Preferred Stock, which the Purchaser has not
      yet elected to convert (with the number of and denomination of such new
      certificate(s) designated by the Purchaser).

     

    (ii) Upon
      any
      partial exercise by the Purchaser of the Warrants, the Company shall issue
      and
      deliver to the Purchaser, within seven business days of the date on which the
      Warrants is exercised, new Warrants representing the number of adjusted shares
      of Common Stock covered thereby, in accordance with the terms
      thereof.

     

    (g) Replacement
      Certificates and Warrants.
      

     

    (i) The
      certificate(s) representing the shares of the Series D Preferred Stock held
      by
      the Purchaser shall be exchangeable, at the option of the Purchaser at any
      time
      and from time to time at the office of Company, for certificates with different
      denominations representing, as applicable, an equal aggregate number of shares
      of the Series D Preferred Stock as requested by the Purchaser upon surrendering
      the same. No service charge will be made for such registration or transfer
      or
      exchange. 

     

    (ii) The
      Warrants will be exchangeable, at the option of the Purchaser, at any time
      and
      from time to time at the office of the Company, for other Warrants of different
      denominations entitling the holder thereof to purchase in the aggregate the
      same
      number of shares of Common Stock as are purchasable under such Warrants. No
      service charge will be made for such transfer or exchange.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    
      	 	
              5.

            	
              CONDITIONS
                TO THE COMPANY’S OBLIGATION TO ISSUE THE SHARES AND THE
                WARRANTS

            

    

     

    The
      Purchaser understands that the Company’s obligation to issue the Series D
      Preferred Stock on each Closing Date and the Warrants and the Existing Facility
      Warrants on the initial Closing Date to the Purchaser pursuant to this Agreement
      is conditioned upon the following, unless waived in writing by the
      Company:

    

    (a) The
      accuracy on each Closing Date of the representations and warranties of the
      Purchaser contained in this Agreement as if made on each Closing Date and the
      performance by the Purchaser on or before each Closing Date of all covenants
      and
      agreements of the Purchaser required to be performed on or before each Closing
      Date.

     

    (b) The
      absence or inapplicability on each Closing Date of any and all laws, rules
      or
      regulations prohibiting or restricting the transactions contemplated hereby,
      or
      requiring any consent or approval, except for any stockholder or Board of
      Director approval or consent contemplated herein, which shall not have been
      obtained.

     

    (c) All
      regulatory approvals or filings, if any, on each Closing Date necessary to
      consummate the transactions contemplated by this Agreement shall have been
      made
      as of each Closing Date.

     

    (d) The
      receipt of good funds as of each Closing Date.

     

    
      	 	
              6.

            	
              CONDITIONS
                TO THE PURCHASER’S OBLIGATION TO PURCHASE THE SHARES AND THE
                WARRANTS

            

    

     

    The
      Company understands that the Purchaser’s obligation to purchase the Series D
      Preferred Stock on each Closing Date and the Warrants and the Existing Facility
      Warrants on the initial Closing Date pursuant to Sections 1(a) and 1(b) above
      is
      conditioned upon each of the following, unless waived in writing by the
      Purchaser:

    

    (a) The
      Purchaser shall have completed to its satisfaction its due diligence review
      of
      the Company, the Company’s business, assets and liabilities, the Company shall
      have furnished to the Purchaser and its representatives, such information as
      may
      be reasonably requested by them, and the Purchaser shall have approved the
      use
      of proceeds of the sale in its sole discretion.

     

    (b) The
      accuracy on each Closing Date of the representations and warranties of the
      Company contained in this Agreement as if made on such Closing Date, and the
      performance by the Company on or before such Closing Date of all covenants
      and
      agreements of the Company required to be performed on or before such Closing
      Date.

     

    (c) The
      Company shall have executed and delivered to the Purchaser (i) the shares of
      Series D Preferred Stock with respect to each Closing Date and (ii) all of
      the
      Warrants and the Existing Facility Warrants as of the initial Closing
      Date.

     

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

    (d) On
      each
      Closing Date, the Purchaser shall have received from the Company such other
      certificates and documents as it or its representatives, if applicable, shall
      reasonably request, and all proceedings taken by the Company or the Board of
      Directors of the Company, as applicable, in connection with the Primary
      Documents contemplated by this Agreement and the other Primary Documents and
      all
      documents and papers relating to such Primary Documents shall be satisfactory
      to
      the Purchaser.

     

    (e) All
      regulatory approvals or filings, if any, necessary to consummate the
      transactions contemplated by this Agreement shall have been made as of each
      Closing Date.

     

    (f) The
      Company shall have received a Closing Certificate substantially in the form
      attached hereto as Exhibit D.

     

    (g) With
      respect to the initial Closing Date only, the Company shall have reimbursed
      the
      Purchaser the expenses incurred in connection with the negotiation or
      performance of this Agreement pursuant to Section 7
      hereof.

     

    
      	 	
              7.

            	
              FEES
                AND EXPENSES

            

    

     

    The
      Company shall bear its own costs, including attorney’s fees, incurred in the
      negotiation of this Agreement and consummating of the transactions contemplated
      herein and the corporate proceedings of the Company in contemplation hereof
      and
      thereof. At the initial Closing Date, the Company shall reimburse the Purchaser
      for all of the Purchaser’s reasonable out-of-pocket expenses incurred in
      connection with the negotiation or performance of this Agreement, including
      without limitation reasonable fees and disbursements of counsel to the
      Purchaser.

    

    
      	 	
              8.

            	
              SURVIVAL

            

    

     

    The
      agreements, covenants, representations and warranties of the Company and the
      Purchaser shall survive the execution and delivery of this Agreement and the
      delivery of the Securities hereunder for a period of two years from the date
      of
      the Final Closing Date, except that:

     

    (a) the
      Company’s representations and warranties regarding Taxes contained in Section
      3(s)
      of this
      Agreement shall survive as long as the Company remains statutorily liable for
      any obligation referenced in Section 3(s),
      and

     

    (b) the
      Company’s representations and warranties contained in Section 3(b)
      shall
      survive until the Purchaser and any of its affiliates are no longer holders
      of
      any of the Securities purchased hereunder.

     

    
      	 	
              9.

            	
              INDEMNIFICATION

            

    

     

    (a) Each
      of
      the Company and the Purchaser (each in such capacity under this section, the
      “Indemnifying
      Party”)
      agrees
      to indemnify the other party and each officer, director, employee, agent,
      partner, stockholder, member and affiliate of such other party (collectively,
      the “Indemnified
      Parties”)
      for,
      and hold each Indemnified Party harmless from and against: (i) any and all
      damages, losses, claims, diminution in value and other liabilities of any and
      every kind, including, without limitation, judgments and costs of settlement,
      and (ii) any and all reasonable out-of-pocket costs and expenses of any and
      every kind, including, without limitation, reasonable fees and disbursements
      of
      counsel for such Indemnified Parties (all of which expenses periodically shall
      be reimbursed as incurred), in each case, arising out of or suffered or incurred
      in connection with any of the following, whether or not involving a third party
      claim: (a) any misrepresentation or any breach of any warranty made by the
      Indemnifying Party herein or in any of the other Primary Documents, (b) any
      breach or non-fulfillment of any covenant or agreement made by the Indemnifying
      Party herein or in any of the other Primary Documents, or (c) any claim relating
      to or arising out of a violation of applicable federal or state securities
      laws
      by the Indemnifying Party in connection with the sale or issuance of the Series
      D Preferred Stock, the Warrants or the Existing Facility Warrants by the
      Indemnifying Party to the Indemnified Party (collectively, the “Indemnified
      Liabilities”).
      To
      the extent that the foregoing undertaking by the Indemnifying Party may be
      unenforceable for any reason, the Indemnifying Party shall make the maximum
      contribution to the payment and satisfaction of each of the Indemnified
      Liabilities which is permissible under applicable law.

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    No
      indemnification shall be payable in respect of any Indemnified Liability (i)
      where the claiming Indemnified Party had actual knowledge of or notice from
      information set forth in the schedules hereto of the facts giving rise to such
      Indemnified Liability prior to the initial Closing Date or (ii) where such
      Indemnified Party entered into a settlement of an Indemnified Liability without
      the prior written consent of the applicable Indemnifying Party.

     

    
      	 	
              10.

            	
              NOTICES

            

    

     

    Any
      notice required or permitted hereunder shall be given in writing (unless
      otherwise specified herein) and shall be effective upon personal delivery,
      via
      facsimile (upon receipt of confirmation of error-free transmission and mailing
      a
      copy of such confirmation, postage prepaid by certified mail, return receipt
      requested) or two business days following deposit of such notice with an
      internationally recognized courier service, with postage prepaid and addressed
      to each of the other parties thereunto entitled at the following addresses,
      or
      at such other addresses as a party may designate by five days advance written
      notice to each of the other parties hereto.

    

      
        	
                Company:

              	
                Health
                  Systems Solutions, Inc.

              
	 	
                405
                  North Reo Street, Suite 300

              
	 	
                Tampa,
                  Florida 33609

              
	 	
                Attention:
                  Brian M. Milvain, President

              
	 	
                Telephone:
                  813-282-3303

              
	 	
                Facsimile:
                  813-282-8907

              
	 	 
	
                with
                  a copy to:

              	
                Carlton
                  Fields P.A.

              
	 	
                4000
                  International Place 

              
	
              	
                100
                  SE 2nd Street

              
	 	
                Miami,
                  FL 33131

              
	 	
                Attention:
                  Seth P. Joseph

              
	 	
                Telephone:
                  305-530-0050

              
	 	
                Facsimile:
                  305-530-0055

              

      

       

      
        
          
          

        

        
          16

          
            

          

        

        
          
          

        

      

       

      
        	
                Purchaser:

              	
                Stanford
                  International Bank Ltd.

              
	 	
                6075
                  Poplar Avenue

              
	 	
                Memphis,
                  Tennessee 38119

              
	 	
                Attention:
                  James M. Davis, Chief Financial Officer

              
	 	
                Telephone:
                  901-680-5260

              
	 	
                Facsimile:
                  901-680-5265

              
	 	 
	
                with
                  a copy to:

              	
                Stanford
                  Financial Group

              
	 	
                5050
                  Westheimer Road

              
	 	
                Houston,
                  Texas 77056

              
	 	
                Attention:
                  Mauricio Alvarado, Esq.

              
	 	
                Telephone
                  713-964-5145

              
	 	
                Facsimile:
                  713-964-5245

              

      

       

    

    
      	 	
              11.

            	
              GOVERNING
                LAW; JURISDICTION

            

    

     

    This
      Agreement shall be governed by and interpreted in accordance with the laws
      of
      the State of Florida, without regard to its principles of conflict of laws.
      Any
      action or proceeding seeking to enforce any provision of, or based on any right
      arising out of, this Agreement may be brought against any party in the federal
      courts of Florida or the state courts of the State of Florida, Miami-Dade County
      and each of the parties consents to the jurisdiction of such courts and hereby
      waives, to the maximum extent permitted by law, any objection, including any
      objections based on forum non conveniens, to the bringing of any such proceeding
      in such jurisdictions.

     

    
      	 	
              12.

            	
              MISCELLANEOUS

            

    

     

    (a) Entire
      Agreement. This
      Agreement supersedes all prior agreements and understandings among the parties
      hereto with respect to the subject matter hereof. This Agreement, together
      with
      the other Primary Documents, including any certificate, schedule, exhibit or
      other document delivered pursuant to their terms, constitutes the entire
      agreement among the parties hereto with respect to the subject matters hereof
      and thereof, and supersedes all prior agreements and understandings, whether
      written or oral, among the parties with respect to such subject
      matters.

     

    (b) Amendments.
      This
      Agreement may not be amended except by an instrument in writing signed by the
      party to be charged with enforcement. 

     

    (c) Waiver.
      No
      waiver
      of any provision of this Agreement shall be deemed a waiver of any other
      provisions or shall a waiver of the performance of a provision in one or more
      instances be deemed a waiver of future performance thereof.

     

    (d) Construction.
      This
      Agreement and each of the Primary Documents have been entered into freely by
      each of the parties, following consultation with their respective counsel,
      and
      shall be interpreted fairly in accordance with its respective terms, without
      any
      construction in favor of or against either party. 

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    

     

    (e) Binding
      Effect of Agreement. This
      Agreement shall inure to the benefit of, and be binding upon the successors
      and
      assigns of each of the parties hereto, including any transferees of the Series
      D
      Preferred Stock, the Warrants and the Existing Facility Warrants. 

     

    (f) Severability.
      If
      any
      provision of this Agreement shall be invalid or unenforceable in any
      jurisdiction, such invalidity or unenforceability shall not affect the validity
      or enforceability of the remainder of this Agreement or the validity or
      unenforceability of this Agreement in any other jurisdiction. 

     

    (g) Attorneys’
      Fees. If
      any
      action should arise between the parties hereto to enforce or interpret the
      provisions of this Agreement, the prevailing party in such action shall be
      reimbursed for all reasonable expenses incurred in connection with such action,
      including reasonable attorneys’ fees.

     

    (h) Headings.
      The
      headings of this Agreement are for convenience of reference only and shall
      not
      form part of, or affect the interpretation of this Agreement. 

     

    (i) Counterparts.
      This
      Agreement may be signed in one or more counterparts, each of which shall be
      deemed an original and all of which, when taken together, will be deemed to
      constitute one and the same agreement.

     

    [Signatures
      Begin on Following Page]

     

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      this
      Agreement has been duly executed by each of the undersigned as of the date
      first
      written above.

     

    
      	 	 	 
	 	
              HEALTH
                SYSTEMS SOLUTIONS, INC.

            
	 
 	 
 	 
 
	
            	By:  	
              /s/
                B. M. Milvain 

            
	 	
              

            
	 	
              B.
                M. Milvain

              
                President

              

            

    

    
       

      
        	 	 	 
	 	
                
                  STANFORD
                    INTERNATIONAL BANK LTD.

                

              
	 
 	 
 	 
 
	
              	By:  	
                
                  /s/
                    James M. Davis 

                

              
	 	
                

              
	 	
                
                  James
                    M. Davis 
                    Chief
                      Financial Officer

                  

                

              

      

      

      
        
          
          

        

        
          19

          
            

          

        

        
          
          

        

         

      

    

    SCHEDULE
      A

    

    Warrant
      Distribution

     

    
      	
              Name

            	 	
              Address

            	 	
              Distribution

            
	
               

            	 	 	 	
               

            
	
              Stanford
                International Bank, LTD

            	 	
              No.
                11 Pavilion Drive, St. John's, Antigua, W.I.

            	 	
              213,750
                

            
	 	 	 	 	 
	
              Daniel
                T. Bogar

            	 	
              1016
                Sanibel Drive, Hollywood, Fl. 33019

            	 	
              49,430
                

            
	 	 	 	 	 
	
              William
                R. Fusselmann

            	 	
              141
                Crandon Blvd. # 437, Key Biscayne, FL 33149

            	 	
              49,430
                

            
	 	 	 	 	 
	
              OSVALDO
                PI and VIVIAN PI, Trustees, or their successors in trust, under the
                OSVALDO AND VIVIAN PI LIVING TRUST, dated February 13, 2007, and
                any
                amendments thereto

            	 	
              6405
                SW 104th
                Street, Pinecrest, FL 33156

            	 	
              49,430
                

            
	 	 	 	 	 
	
              Ronald
                M. Stein

            	 	
              6520
                Allison Road, Miami Beach, Fl. 33141

            	 	
              49,430
                

            
	 	 	 	 	 
	
              Charles
                M. Weiser

            	 	
              3521
                N. 55th Ave., Hollywood, FL 33021

            	 	
              8,015
                

            
	 	 	 	 	 
	
              Tal
                Kimmel

            	 	
              201
                South Biscayne Blvd, Miami, FL 33131

            	 	
              8,015
                

            
	
               

            	 	 	 	
               

            
	
              TOTAL

            	
               

            	
               

            	 	
              427,500
                

            

    

    

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

    

    SCHEDULE
      B

    

    Existing
      Facility Warrant Distribution

    

    
      	 	 	
              (Exercise
                Price of $.002/Share)

            	 	
               

            
	
               

            	 	 	 	
               

            
	
               

            	 	 	 	
               

            
	
              Name

            	 	
              Address

            	 	
              Distribution

            
	
               

            	 	 	 	
               

            
	
              Stanford
                International Bank, LTD

            	 	
              No.
                11 Pavilion Drive, St. John's, Antigua, W.I.

            	 	
              86,250
                

            
	 	 	 	 	 
	
              Daniel
                T. Bogar

            	 	
              1016
                Sanibel Drive, Hollywood, Fl. 33019

            	 	
              17,250
                

            
	 	 	 	 	 
	
              William
                R. Fusselmann

            	 	
              141
                Crandon Blvd. # 437, Key Biscayne, FL 33149

            	 	
              17,250
                

            
	 	 	 	 	 
	
              OSVALDO
                PI and VIVIAN PI, Trustees, or their successors in trust, under the
                OSVALDO AND VIVIAN PI LIVING TRUST, dated February 13, 2007, and
                any
                amendments thereto

            	 	
              6405
                SW 104th
                Street, Pinecrest, FL 33156

            	 	
              17,250
                

            
	 	 	 	 	 
	
              Ronald
                M. Stein

            	 	
              6520
                Allison Road, Miami Beach, Fl. 33141

            	 	
              17,250
                

            
	 	 	 	 	 
	
              Charles
                M. Weiser

            	 	
              3521
                N. 55th Ave., Hollywood, FL 33021

            	 	
              17,250
                

            
	
               

            	 	 	 	
               

            
	
              TOTAL

            	
               

            	
               

            	 	
              172,500
                

            

    

     

    
      
        
        

      

      
        21

        
          

        

      

      
        
        

      

    

    EXHIBIT
      INDEX

    

      
        	 	 
	
                EXHIBIT
                  A

              	
                CERTIFICATE
                  OF DESIGNATION OF SERIES D $2.00 CONVERTIBLE PREFERRED
                  STOCK

              
	 	 
	
                EXHIBIT
                  B

              	
                FORM
                  OF WARRANT

              
	 	 
	
                EXHIBIT
                  C

              	
                REGISTRATION
                  RIGHTS AGREEMENT

              
	 	 
	
                EXHIBIT
                  D

              	
                CLOSING
                  CERTIFICATE

              

      

    

     

    
      
        
        

      

      
        22

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    

    HEALTH
      SYSTEMS SOLUTIONS, INC.

    a
      Nevada corporation

     

    CERTIFICATE
      OF DESIGNATION

     

    OF

    

    SERIES
      D $2.00 CONVERTIBLE PREFERRED STOCK

     

    Pursuant
      to the Nevada Revised Statutes, Section 78.1955, the undersigned, being an
      officer of Health Systems Solutions, Inc., a Nevada corporation (the
“Corporation”),
      does
      hereby certify that the following resolution was adopted by the unanimous
      consent of the Corporation’s board of directors (the “Board”)
      authorizing the creation and issuance of 4,000,000 shares of Series D $2.00
      Convertible Preferred Stock:

    

    RESOLVED,
      that pursuant to authority expressly granted to and vested in the Board by
      the
      Articles of Incorporation, as amended, of the Corporation, the Board hereby
      creates 4,000,000
      shares of Series D $2.00 Convertible Preferred Stock of the Corporation and
      authorizes the issuance thereof, and hereby fixes the designation thereof,
      and
      the voting powers, preferences and relative, participating, optional and other
      special rights, and the qualifications, limitations or restrictions thereon
      (in
      addition to the designation, preferences and relative, participating and other
      special rights, and the qualifications, limitations or restrictions thereof,
      set
      forth in the Articles of Incorporation, as amended, of the Corporation, which
      are applicable to the preferred stock, if any) as follows:

    

    1. Designation.
      The
      series of preferred stock shall be designated and known as “Series D $2.00
      Convertible Preferred Stock” (the “Series
      D Preferred Stock”).
      The
      number of shares constituting the Series D Preferred Stock shall be 4,000,000.
      Each share of the Series D Preferred Stock shall have a stated value equal
      to
      $2.00 (the “Stated
      Value”).

     

    2. Conversion
      Rights.
      The
      Series D Preferred Stock shall be convertible into the common stock, $0.001
      par
      value, of the Corporation (“Common
      Stock”)
      as
      follows:

     

    (a) Optional
      Conversion.
      Subject
      to and upon compliance with the provisions of this Section 2,
      a
      holder of any shares of the Series D Preferred Stock (a “Holder”)
      shall
      have the right, at such Holder’s option at any time, to convert any of such
      shares of the Series D Preferred Stock held by the Holder into fully paid and
      non-assessable shares of the Common Stock at the then Conversion Rate (as
      defined herein).

     

    (b) Automatic
      Conversion.
      Each
      share of Series D Preferred Stock shall automatically be converted into shares
      of Common Stock at the then-effective Conversion Rate upon the earlier of (i)
      the date specified by vote or written consent or agreement of holders of at
      least two-thirds of the then outstanding shares of the Series D Preferred Stock,
      or (ii) upon the closing of a Qualified Public Offering. As used herein, a
      “Qualified
      Public Offering”
      shall be
      the commitment, underwritten public offering of the Corporation’s Common Stock
      registered under the Securities Act of 1933, as amended (the “Securities
      Act”),
      at a
      public offering price (prior to underwriters’ discounts and expenses) equal to
      or exceeding $3.00 per share of Common Stock (as adjusted for any stock
      dividends, combinations or split with respect to such shares), which generates
      aggregate net proceeds to the Corporation (after deduction for underwriters’
discounts and expenses relating to the issuance, including without limitation
      fees of the Corporation’s counsel) equal to or exceeding
      $15,000,000.

     

    
      
        
        

      

      
        A-1

        
          

        

      

      
        
        

      

    

     

    (c) Conversion
      Rate.
      Each
      share of the Series D Preferred Stock is convertible into the number of shares
      of the Common Stock as shall be calculated by dividing the Stated Value by
      $4.00
      (the “Conversion
      Price”;
      the
      conversion rate so calculated, the “Conversion
      Rate”),
      subject to adjustments as set forth in Section 2(e)
      hereof.

     

    (d) Mechanics
      of Conversion.

     

    (i) The
      Holder may exercise the conversion right specified in Section 2(a)
      by
      giving written notice to the Corporation at any time, that the Holder elects
      to
      convert a stated number of shares of the Series D Preferred Stock into a stated
      number of shares of Common Stock, and by surrendering the certificate or
      certificates representing the Series D Preferred Stock to be converted, duly
      endorsed to the Corporation or in blank, to the Corporation at its principal
      office (or at such other office as the Corporation may designate by written
      notice, postage prepaid, to all Holders) at any time during its usual business
      hours, together with a statement of the name or names (with addresses) of the
      person or persons in whose name the certificate or certificates for Common
      Stock
      shall be issued. Such conversion shall be deemed to have been made immediately
      prior to the close of business on the date of surrender of the shares of Series
      D Preferred Stock to be converted, and the person or persons entitled to receive
      the shares of Common Stock issuable upon such conversion shall be treated for
      all purposes as the record holder or holders of such shares of Common Stock
      on
      such date.

     

    (ii) If
      the
      conversion is in connection with the closing of a Qualified Public Offering,
      the
      conversion may, at the option of any holder tendering shares of Series D
      Preferred Stock for conversion, be conditioned upon the closing of the Qualified
      Public Offering, in which event the person(s) entitled to receive the Common
      Stock upon conversion of the Series D Preferred Stock shall not be deemed to
      have converted such Series D Preferred Stock until immediately prior to the
      closing of the Qualified Public Offering.

     

    (e) Conversion
      Rate Adjustments.
      The
      Conversion Price shall be subject to adjustment from time to time as
      follows:

     

    (i) Consolidation,
      Merger, Sale, Lease or Conveyance.
      In case
      of any consolidation or merger of the Corporation with or into another
      corporation, or in case of any sale, lease or conveyance to another corporation
      of all or substantially all the assets of the Corporation, each share of the
      Series D Preferred Stock shall after the date of such consolidation, merger,
      sale, lease or conveyance be convertible into the number of shares of stock
      or
      other securities or property (including cash) to which the Common Stock issuable
      (at the time of such consolidation, merger, sale, lease or conveyance) upon
      conversion of such share of the Series D Preferred Stock would have been
      entitled upon such consolidation, merger, sale, lease or conveyance; and in
      any
      such case, if necessary, the provisions set forth herein with respect to the
      rights and interests thereafter of the Holder of the shares of the Series D
      Preferred Stock shall be appropriately adjusted so as to be applicable, as
      nearly as may reasonably be, to any shares of stock of other securities or
      property thereafter deliverable on the conversion of the shares of the Series
      D
      Preferred Stock. 

     

    
      
        
        

      

      
        A-2

        
          

        

      

      
        
        

      

    

     

    (ii) Stock
      Dividends, Subdivisions, Reclassification, or Combinations.
      If the
      Corporation shall (i) declare a dividend or make a distribution on its Common
      Stock in shares of its Common Stock, (ii) subdivide or reclassify the
      outstanding shares of Common Stock into a greater number of shares, or (iii)
      combine or reclassify the outstanding Common Stock into a smaller number of
      shares; the Conversion Price in effect at the time of the record date for such
      dividend or distribution or the effective date of such subdivision, combination,
      or reclassification shall be proportionately adjusted so that the Holder of
      any
      shares of the Series D Preferred Stock surrendered for conversion after such
      date shall be entitled to receive the number of shares of Common Stock that
      he
      would have owned or been entitled to receive had such Series D Preferred Stock
      been converted immediately prior to such date. Successive adjustments in the
      Conversion Price shall be made whenever any event specified above shall
      occur.

     

    (iii) Issuances
      of Securities.
      If at
      any time on or before January 15, 2008 the Corporation shall (i) sell or
      otherwise issue shares of the Common Stock at a purchase price per share less
      than the Conversion Price in effect immediately prior to such issuance, or
      (ii)
      sell or otherwise issue the Corporation’s securities which are convertible into
      or exercisable for shares of the Corporation’s Common Stock at a conversion or
      exercise price per share less than the Conversion Price in effect immediately
      prior to such issuance, then immediately upon such issuance or sale, the
      Conversion Price shall be adjusted to a price equal to the purchase price of
      the
      shares of Common Stock or the conversion or exercise price per share of the
      Corporation’s securities sold or issued. If at any time after January 15, 2008,
      the Corporation shall (i) sell or otherwise issue shares of the Common Stock
      at
      a purchase price per share less than the Conversion Price in effect immediately
      prior to such issuance, or (ii) sell or otherwise issue the Corporation’s
      securities which are convertible into or exercisable for shares of the
      Corporation’s Common Stock at a conversion or exercise price per share less than
      the Conversion Price in effect immediately prior to such issuance, then
      immediately upon such issuance or sale, the Conversion Price shall be adjusted
      to a price determined by multiplying the Conversion Price immediately prior
      to
      such issuance by a fraction, the numerator of which shall be the number of
      shares of Common Stock outstanding immediately prior to such issuance or sale,
      plus the number of shares of the Common Stock that the aggregate consideration
      received by the Corporation for such issuance would purchase at such Conversion
      Price; and the denominator of which shall be the number of shares of Common
      Stock outstanding immediately prior to such issuance plus the number of the
      additional shares to be issued at such issuance or sale.

     

    (iv) Excluded
      Transactions.
      No
      adjustment to the Conversion Price shall be required under this Section
      2(e)
      in the
      event of the issuance of shares of Common Stock by the Corporation upon the
      conversion or exercise of or pursuant to any outstanding stock options or stock
      option plan now existing or hereafter approved by the Holders which stock
      options have an exercise or conversion price per share of less than the
      Conversion Price. 

     

    
      
        
        

      

      
        A-3

        
          

        

      

      
        
        

      

    

     

    (v) Reservation,
      Validity of Common Stock.
      The
      Corporation covenants that it will at all times reserve and keep available,
      free
      from preemptive rights, out of the aggregate of its authorized but unissued
      shares of Common Stock for the purpose of effecting conversion of the Series
      D
      Preferred Stock, the full number of shares of Common Stock deliverable upon
      the
      conversion of all outstanding Series D Preferred Stock not therefore converted.
      Before taking any action which would cause an adjustment in the Conversion
      Rate
      such that Common Stock issuable upon the conversion of Series D Preferred Stock
      would be issued in excess of the authorized Common Stock, the Corporation will
      take any corporate action which may, in the opinion of its counsel, be necessary
      in order that the Corporation may validly and legally issue fully-paid and
      non
      assessable shares of Common Stock at such adjusted Conversion Rate. Such action
      my include, but it is not limited to, amending the Corporation’s articles of
      incorporation to increase the number of authorized Common Stock.

     

    (f) Approvals.
      If any
      shares of the Common Stock to be reserved for the purpose of conversion of
      shares of the Series D Preferred Stock require registration with or approval
      of
      any governmental authority under any Federal or state law before such shares
      may
      be validly issued or delivered upon conversion, then the Corporation will in
      good faith and as expeditiously as possible endeavor to secure such registration
      or approval, as the case may be. If, and so long as, any Common Stock into
      which
      the shares of the Series D Preferred Stock are then convertible is listed on
      any
      national securities exchange, the Corporation will, if permitted by the rules
      of
      such exchange, list and keep listed on such exchange, upon official notice
      of
      issuance, all shares of such Common Stock issuable upon conversion.

     

    (g) Valid
      Issuance.
      All
      shares of Common Stock that may be issued upon conversion of shares of the
      Series D Preferred Stock will upon issuance be duly and validly issued, fully
      paid and non-assessable and free from all taxes, liens and charges with respect
      to the issuance thereof, and the Corporation shall take no action that will
      cause a contrary result.

     

    3. Liquidation.

     

    (a) Liquidation
      Preference.
      In the
      event of liquidation, dissolution or winding up of the Corporation, whether
      voluntary or involuntary, the Holders of the Series D Preferred Stock shall
      be
      entitled to receive, prior and before any distribution of assets shall be made
      to the holders of any other classes or series of capital stock or other
      securities of the Corporation, an amount equal to $4.00 per share of Series
      D
      Preferred Stock held by such Holder (the “Liquidation
      Pay Out”).
      After
      payment of the Liquidation Pay Out to each Holder and the payment of the
      respective liquidation preferences of the other preferred stock of the
      Corporation, if any, pursuant to the Corporation’s Articles of Incorporation, as
      amended, each such Holder shall be entitled to share with the holders of the
      Common Stock, the remaining assets of the Corporation available for distribution
      to the Corporation’s stockholders in proportion to the shares of Common Stock
      then held by the holders of the Common Stock and the shares of Common Stock
      which the holders then have the right to acquire upon conversion of the Series
      D
      Preferred Stock.

     

    
      
        
        

      

      
        A-4

        
          

        

      

      
        
        

      

    

     

    (b) Ratable
      Distribution.
      If upon
      any liquidation, dissolution or winding up of the Corporation, the net assets
      of
      the Corporation to be distributed among the Holders shall be insufficient to
      permit payment in full to the Holders of such Series D Preferred Stock, then
      all
      remaining net assets of the Corporation after the provision for the payment
      of
      the Corporation’s debts shall be distributed ratably in proportion to the full
      amounts to which they would otherwise be entitled to receive among the
      Holders.

     

    (c) Merger,
      Reorganization or Sale of Assets.
      For
      purposes of this Section 3,
      (i) any
      acquisition of the Corporation by means of merger or other form of corporate
      reorganization in which outstanding shares of the Corporation are exchanged
      for
      securities or other consideration issued, or caused to be issued, by the
      acquiring corporation or its subsidiary (other than a mere reincorporation
      transaction) or (ii) a sale of all or substantially all of the assets of the
      Corporation, shall be treated as a liquidation, dissolution or winding up of
      the
      Corporation and shall entitle the holders of Series D Preferred Stock to receive
      at the closing in cash, securities or other property amounts as specified in
      Section 3(a)
      above.
      Whenever the distribution provided for in this Section 3
      shall be
      payable in securities or property other than cash, the value of such
      distribution shall be the fair market value of such securities or other property
      as determined in good faith by the Board.

     

    4. Voting
      Rights.
      Except
      as otherwise required under Nevada law, the Holders of the Series D Preferred
      Stock shall be entitled to vote at any meeting of stockholders of the
      Corporation (or any written actions of stockholders in lieu of meetings) with
      respect to any matters presented to the stockholders of the Corporation for
      their action or consideration. For the purposes of such stockholder votes,
      each
      share of Series D Preferred Stock shall be entitled to one vote for each share
      of Common Stock such share of Series D Preferred Stock would be convertible
      into
      at the record date set for such voting. Notwithstanding the foregoing, so long
      as any shares of Series D Preferred Stock remain outstanding, the Corporation
      shall not, without first obtaining the approval of the holders of at least
      a
      majority of the then outstanding shares of Series D Preferred Stock (i) alter
      or
      change the rights, preferences or privileges of the Series D Preferred Stock
      as
      outlined herein, or (ii) create any new class of series of capital stock having
      a preference over the Series D Preferred Stock as to the payment of dividends
      or
      the distribution of assets upon the occurrence of a Liquidation Event
      (“Senior
      Securities”),
      or
      (iii) alter or change the rights, preferences or privileges of any Senior
      Securities so as to adversely affect the Series D Preferred Stock. 

     

    5. Dividends.
      The
      Holders of the Series D Preferred Stock shall not be entitled to receive
      dividends.

     

    6. No
      Preemptive Rights.
      No
      Holders of the Series D Preferred Stock, whether now or hereafter authorized,
      shall, as such Holder, have any preemptive right whatsoever to purchase,
      subscribe for or otherwise acquire, stock of any class of the Corporation nor
      of
      any security convertible into, nor of any warrant, option or right to purchase,
      subscribe for or otherwise acquire, stock of any class of the Corporation,
      whether now or hereafter authorized.

     

    7. Exclusion
      of Other Rights.
      Except
      as may otherwise be required by law, the shares of the Series D Preferred Stock
      shall not have any preferences or relative, participating, optional or other
      special rights, other than those specifically set forth in this resolution
      (as
      such resolution may be amended from time to time) and in the Corporation’s
      Articles of Incorporation, as amended.

     

    
      
        
        

      

      
        A-5

        
          

        

      

      
        
        

      

    

     

    8. Headings
      of Subdivisions.
      The
      headings of the various subdivisions hereof are for convenience of reference
      only and shall not affect the interpretation of any of the provisions
      hereof.

     

    9. Severability
      of Provisions.
      If any
      right, preference or limitation of the Series D Preferred Stock set forth in
      this certificate of designation (“Certificate”)
      (as
      such Certificate may be amended from time to time) is invalid, unlawful or
      incapable of being enforced by reason of any rule of law or public policy,
      all
      other rights, preferences and limitations set forth in this Certificate (as
      so
      amended) which can be given effect without the invalid, unlawful or
      unenforceable right, preference or limitation shall, nevertheless, remain in
      full force and effect, and no right, preference or limitation herein set forth
      shall be deemed dependent upon any other such right, preference or limitation
      unless so expressed herein.

     

    10. Status
      of Reacquired Shares.
      No
      shares of the Series D Preferred Stock which have been issued and reacquired
      in
      any manner or converted into Common Stock may be reissued, and all such shares
      shall be returned to the status of undesignated shares of preferred stock of
      the
      Corporation.

     

    [Remainder
      of Page Intentionally Left Blank]

     

    
      
        
        

      

      
        A-6

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      the
      Corporation has caused this Certificate to be signed in its name and on its
      behalf by its President this ____ day of August 2007.

    

    
      	 	 	 
	 
 	 
 	 
 
	
            	By:  	
            
	 	
              

            
	 	
              Brian
                M. Milvain

              
                President
                  

              

            

    
      
        
        

      

      
        A-7

        
          

        

      

      
        
        

      

    

    EXHIBIT
      B

    

    NEITHER
      THIS WARRANT NOR THE WARRANT STOCK (AS HEREINAFTER DEFINED) HAVE BEEN REGISTERED
      UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS
      OF ANY STATE. THIS WARRANT AND THE WARRANT STOCK MAY BE TRANSFERRED ONLY IN
      COMPLIANCE WITH THE ACT AND SUCH LAWS. THIS LEGEND SHALL BE ENDORSED UPON ANY
      WARRANT ISSUED IN EXCHANGE FOR THIS WARRANT.

    

    THIS
      WARRANT IS SUBJECT TO THE TERMS OF THE PREFERRED STOCK PURCHASE AGREEMENT,
      DATED
      AS OF AUGUST ____, 2007 BETWEEN THE COMPANY AND THE HOLDER HEREOF, A COPY OF
      WHICH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICES OF THE COMPANY, AND ANY
      TRANSFERS AND TRANSFEREES OF THIS WARRANT AND THE WARRANT STOCK ARE SUBJECT
      TO
      THE TERMS AND CONDITIONS OF SUCH AGREEMENT.

     

    Warrant
      No. D-__

    

    WARRANT

    For
      the Purchase of Common Stock of

    HEALTH
      SYSTEMS SOLUTIONS, INC. 

    a
      Nevada corporation

    

    VOID
      AFTER 5:00 P.M., EASTERN STANDARD TIME, ON ____________, 2012.

    

    

    
      	
              _________
                Shares 

            	
              ____________,
                2007

            

    

    

    

    FOR
      VALUE RECEIVED, HEALTH SYSTEMS SOLUTIONS, INC.,
      a
      Nevada corporation (the “Company”),
      hereby
      certifies that __________________________________ (the “Holder”)
      is
      entitled, subject to the provisions of this Warrant, to purchase from the
      Company up to ___________ shares of common stock (the “Common
      Shares”),
      par
      value $0.001 per share (“Common
      Stock”),
      of the
      Company at an exercise price per Common Share equal to $0.001 per Common Share
      (the “Exercise
      Price”),
      during
      the period commencing _________, 2007 and expiring at 5:00 P.M., Eastern
      Standard time, on __________, 2012.

    

    The
      number of Common Shares to be received upon the exercise of this Warrant may
      be
      adjusted from time to time as hereinafter set forth. The Common Shares
      deliverable upon such exercise, or the entitlement thereto upon such exercise,
      and as adjusted from time to time, are hereinafter sometimes referred to as
      “Warrant
      Stock.”
      The
      Warrants issued on the same date hereof bearing the same terms and conditions
      as
      this Warrant shall be collectively referred to as the “Warrants”.

    

    
      
        
        

      

      
        B-1

        
          

        

      

      
        
        

      

    

     

    The
      Holder agrees with the Company that this Warrant is issued, and all the rights
      hereunder shall be held subject to, all of the conditions, limitations and
      provisions set forth herein.

    

    
      	 	
              1.

            	
              EXERCISE
                OF WARRANT

            

    

     

    (a) By
      Payment of Cash.
      This
      Warrant may be exercised by its presentation and surrender to the Company at
      its
      principal office (or such office or agency of the Company as it may designate
      in
      writing to the Holder hereof), commencing on ___________, 2007 (“Date
      of Issuance”)
      and
      expiring at 5:00 P.M., Eastern Standard time, on ___________, 2012, with the
      Warrant Exercise Form attached hereto duly executed and accompanied by payment
      (either in cash or by certified or official bank check or by wire transfer,
      payable to the order of the Company) of the Exercise Price for the number of
      shares specified in such Form.

     

    The
      Company agrees that the Holder hereof shall be deemed the record owner of such
      Common Shares as of the close of business on the date on which this Warrant
      shall have been presented and payment made for such Common Shares as aforesaid
      whether or not the Company or its transfer agent is open for business.
      Certificates for the Common Shares so purchased shall be delivered to the Holder
      hereof within a reasonable time, not exceeding 15 days, after the rights
      represented by this Warrant shall have been so exercised. If this Warrant should
      be exercised in part only, the Company shall, upon surrender of this Warrant
      for
      cancellation, execute and deliver a new Warrant evidencing the rights of the
      Holder hereof to purchase the balance of the shares purchasable hereunder as
      soon as reasonably possible. 

    

    (b) Cashless
      Exercise.
      In lieu
      of the payment method set forth in Section 1(a) above, the Holder may elect
      to
      exchange all or some of this Warrant for the Common Shares equal to the value
      of
      the amount of this Warrant being exchanged on the date of exchange. If the
      Holder elects to exchange this Warrant as provided in this Section 1(b), the
      Holder shall tender to the Company this Warrant for the amount being exchanged,
      along with written notice of the Holder’s election to exchange some or all of
      this Warrant, and the Company shall issue to the Holder the number of Common
      Shares computed using the following formula:

    

      
        	 	
                X
                  =
                   Y
                  (A-B)  

              	 
	 	
                   
                  A

              	 

      

    

     

    
      	        Where:
              	X
              =
              	
              
                 The
                  number of Common Shares to be issued to the
                  Holder.

              

            

      	 	 	 

      	 	
              Y
                =
                

            	
              The
                number of Common Shares purchasable under the amount of this Warrant
                being
                exchanged (as adjusted to the date of such
                calculation).

            

      	 	 	 

      	 	
              A
                =
                 

            	
              The
                Market Price of one Common Share.

            

      	 	 	 

      	 	
              B
                =
                 

            	
              The
                Exercise Price (as adjusted to the date of such
                calculation).

            

    

     

    
      
        
        

      

      
        B-2

        
          

        

      

      
        
        

      

    

     

    The
      Warrant exchange shall take place on the date specified in the notice or if
      the
      date the notice is received by the Company is later than the date specified
      in
      the notice, on the date the notice is received by the Company.

    

    As
      used
      herein in the phrase “Market
      Price”
      at any
      date shall be deemed to be the last reported sale price or the closing price
      of
      the Common Stock on any exchange (including the National Association of
      Securities Dealers Automated Quotation System (“Nasdaq”))
      on
      which the Common Stock is listed or the closing price as quoted on the OTC
      Bulletin Board, whichever is applicable, or, in the case no such reported sale
      takes place on such day, the average of the last reported sales prices or
      quotations for the last five trading days, in either case as officially reported
      or quoted by the principal securities exchange or the OTC Bulletin Board, and
      if
      the Common Stock is not listed or quoted as determined in good faith by
      resolution of the Board of Directors of the Company, based on the best
      information available to it.

    

    (c) “Easy
      Sale” Exercise.
      In lieu
      of the payment method set forth in Section 1(a) above, when permitted by law
      and
      applicable regulations (including rules of Nasdaq and National Association
      of
      Securities Dealers (“NASD”)),
      the
      Holder may pay the aggregate Exercise Price (the “Exercise
      Amount”)
      through
      a “same day sale” commitment from the Holder (and if applicable a broker-dealer
      that is a member of the NASD (an “NASD
      Dealer”)),
      whereby the Holder irrevocably elects to exercise this Warrant and to sell
      a
      portion of the shares so purchased to pay the Exercise Amount and the Holder
      (or, if applicable, the NASD Dealer) commits upon sale (or, in the case of
      the
      NASD Dealer, upon receipt) of such shares to forward the Exercise Amount
      directly to the Company.

    
      

      
        	 	
                2.

              	
                
                  COVENANTS
                    BY THE COMPANY

                

              

      

       

    

    The
      Company covenants and agrees as follows:

     

    (a) Reservation
      of Shares.
      During
      the period within which the rights represented by this Warrant may be exercised,
      the Company shall, at all times, reserve and keep available out of its
      authorized capital stock, solely for the purposes of issuance upon exercise
      of
      this Warrant, such number of its Common Shares as shall be issuable upon the
      exercise of this Warrant. If at any time the number of authorized Common Shares
      shall not be sufficient to effect the exercise of this Warrant, the Company
      will
      take such corporate action as may be necessary to increase its authorized but
      unissued Common Shares to such number of shares as shall be sufficient for
      such
      purpose. The Company shall have analogous obligations with respect to any other
      securities or property issuable upon exercise of this Warrant.

     

    (b) Valid
      Issuance, etc.
      All
      Common Shares which may be issued upon exercise of the rights represented by
      this Warrant included herein will be, upon payment thereof, validly issued,
      fully paid, non-assessable and free from all taxes, liens and charges with
      respect to the issuance thereof.

     

    (c) Taxes.
      All
      original issue taxes payable in respect of the issuance of Common Shares upon
      the exercise of the rights represented by this Warrant shall be borne by the
      Company, but in no event shall the Company be responsible or liable for income
      taxes or transfer taxes upon the issuance or transfer of this Warrant or the
      Warrant Stock.

     

    
      
        
        

      

      
        B-3

        
          

        

      

      
        
        

      

    

     

    (d) Fractional
      Shares.
      The
      Company shall not be required to issue certificates representing fractions
      of
      Common Shares. In lieu of any fractional interests, the Company shall make
      a
      cash payment equal to the Exercise Price multiplied by such
      fraction.

    
      
        

        
          	 	
                  3.

                	
                  
                    
                      EXCHANGE
                        OR ASSIGNMENT OF
                        WARRANT

                    

                  

                

        

         

      

    

    This
      Warrant is exchangeable, without expense, at the option of the Holder, upon
      presentation and surrender hereof to the Company for other Warrants of different
      denominations, entitling the Holder to purchase in the aggregate the same number
      of Common Shares purchasable hereunder. Subject to the provisions of this
      Warrant and the receipt by the Company of any required representations and
      agreements, upon surrender of this Warrant to the Company with the Warrant
      Assignment Form annexed hereto duly executed and funds sufficient to pay any
      transfer tax, the Company shall, without additional charge, execute and deliver
      a new Warrant in the name of the assignee named in such instrument of assignment
      and this Warrant shall promptly be canceled. In the event of a partial
      assignment of this Warrant, the new Warrants issued to the assignee and the
      Holder shall make reference to the aggregate number of shares of Warrant Stock
      issuable upon exercise of this Warrant.

    
      
        

        
          	 	
                  4.

                	
                  
                    
                      
                        RIGHTS
                          OF THE
                          HOLDER

                      

                    

                  

                

        

         

      

    

    The
      Holder shall not, by virtue hereof, be entitled to any voting or other rights
      of
      a stockholder of the Company, either at law or in equity, and the rights of
      the
      Holder are limited to those expressed in this Warrant.

    
      

      
        	 	
                5.

              	
                
                  
                    
                      ADJUSTMENT
                        OF EXERCISE
                        PRICE

                    

                  

                

              

      

       

    

    (a) Common
      Stock Dividends; Common Stock Splits; Reclassification.
      If the
      Company, at any time while this Warrant is outstanding, (a) shall pay a stock
      dividend on its Common Stock, (b) subdivide outstanding shares of Common Stock
      into a larger number of shares (or combine the outstanding shares of Common
      Stock into a smaller number of shares) or (c) issue by reclassification of
      shares of Common Stock any shares of capital stock of the Company, then (i)
      the
      Exercise Price shall be multiplied by a fraction, the numerator of which shall
      be the number of shares of Common Stock outstanding prior to such event and
      the
      denominator of which shall be the number of shares of Common Stock outstanding
      after such event and (ii) the number of shares of the Warrant Stock shall be
      multiplied by a fraction, the numerator of which shall be the number of shares
      of Common Stock outstanding immediately after such event and the denominator
      of
      which shall be the number of shares of Common Stock outstanding immediately
      prior to such event. Any adjustment made pursuant to this Section 5.1 shall
      become effective immediately after the record date for the determination of
      stockholders entitled to receive such dividend or distribution or, in the case
      of a subdivision or re-classification, shall become effective immediately after
      the effective date thereof.

     

    (b) Rights;
      Options; Warrants or Other Securities.
      If the
      Company, at any time while this Warrant is outstanding, shall fix a record
      date
      for the issuance of rights, options, warrants or other securities to all the
      holders of its Common Stock entitling them to subscribe for or purchase, convert
      to, exchange for or otherwise acquire shares of Common Stock for no
      consideration or at a price per share less than the Exercise Price, the Exercise
      Price shall be multiplied by a fraction, the numerator of which shall be the
      number of shares of Common Stock outstanding immediately prior to such issuance
      or sale plus the number of shares of Common Stock which the aggregate
      consideration received by the Company would purchase at the Exercise Price,
      and
      the denominator of which shall be the number of shares of Common Stock
      outstanding immediately prior to such issuance date plus the number of
      additional shares of Common Stock offered for subscription, purchase,
      conversion, exchange or acquisition, as the case may be. Such adjustment shall
      be made whenever such rights, options, warrants or other securities are issued,
      and shall become effective immediately after the record date for the
      determination of stockholders entitled to receive such rights, options, warrants
      or other securities. 

     

    
      
        
        

      

      
        B-4

        
          

        

      

      
        
        

      

    

     

    (c) Subscription
      Rights.
      If the
      Company, at any time while this Warrant is outstanding, shall fix a record
      date
      for the distribution to holders of its Common Stock, evidence of its
      indebtedness or assets or rights, options, warrants or other security entitling
      them to subscribe for or purchase, convert to, exchange for or otherwise acquire
      any security (excluding those referred to in Sections 5(a) and 5(b) above),
      then
      in each such case the Exercise Price at which this Warrant shall thereafter
      be
      exercisable shall be determined by multiplying the Exercise Price in effect
      immediately prior to such record date by a fraction, the numerator of which
      shall be the per-share Market Price on such record date less the then fair
      market value at such record date of the portion of such assets or evidence
      of
      indebtedness so distributed applicable to one outstanding share of Common Stock
      as determined by the Board of Directors in good faith, and the denominator
      of
      which shall be the Exercise Price as of such record date; provided, however,
      that in the event of a distribution exceeding 10% of the net assets of the
      Company, such fair market value shall be determined by an appraiser selected
      in
      good faith by the registered owners of a majority of the Warrant Stock then
      outstanding; and provided, further, that the Company, after receipt of the
      determination by such appraiser shall have the right to select in good faith
      an
      additional appraiser meeting the same qualifications, in which case the fair
      market value shall be equal to the average of the determinations by each such
      appraiser. Such adjustment shall be made whenever any such distribution is
      made
      and shall become effective immediately after the record date mentioned
      above.

     

    (d) Rounding.
      All
      calculations under this Section 5 shall be made to the nearest cent or the
      nearest l/l00th of a share, as the case may be.

     

    (e) Notice
      of Adjustment.
      Whenever
      the Exercise Price is adjusted pursuant to this Section 5, the Company shall
      promptly deliver to the Holder a notice setting forth the Exercise Price after
      such adjustment and setting forth a brief statement of the facts requiring
      such
      adjustment. Such notice shall be signed by the chairman, president or chief
      financial officer of the Company.

     

    (f) Treasury
      Shares.
      The
      number of shares of Common Stock outstanding at any given time shall not include
      shares owned or held by or for the account of the Company, and the disposition
      of any shares so owned or held shall be considered an issue or sale of Common
      Stock by the Company.

     

    (g) Change
      of Control; Compulsory Share Exchange.
      In case
      of (A) any Change of Control Transaction (as defined below) or (B) any
      compulsory share exchange pursuant to which the Common Stock is converted into
      other securities, cash or property (each, an “Event”),
      lawful provision shall be made so that the Holder shall have the right
      thereafter to exercise this Warrant for shares of stock and other securities,
      cash and property receivable upon or deemed to be held by holders of Common
      Stock following such Event, and the Holder shall be entitled upon such Event
      to
      receive such amount of shares of stock and other securities, cash or property
      as
      the shares of the Common Stock of the Company into which this Warrant could
      have
      been exercised immediately prior to such Event (without taking into account
      any
      limitations or restrictions on the exercisability of this Warrant) would have
      been entitled; provided, however, that in the case of a transaction specified
      in
      (A), above, in which holders of the Company’s Common Stock receive cash, the
      Holder shall have the right to exercise the Warrant for such number of shares
      of
      the surviving company equal to the amount of cash into which this Warrant is
      then exercisable, divided by the fair market value of the shares of the
      surviving company on the effective date of such Event. The terms of any such
      Event shall include such terms so as to continue to give to the Holder the
      right
      to receive the securities, cash or property set forth in this Section 5(g)
      upon
      any exercise or redemption following such Event, and, in the case of an Event
      specified in (A), above, the successor corporation or other entity (if other
      than the Company) resulting from such reorganization, merger or consolidation,
      or the person acquiring the properties and assets, or such other controlling
      corporation or entity as may be appropriate, shall expressly assume the
      obligation to deliver the securities or other assets which the Holder is
      entitled to receive hereunder. The provisions of this Section 5(g) shall
      similarly apply to successive Events. “Change
      of Control Transaction”
      means
      the occurrence of any (i) merger or consolidation of the Company with or into
      another entity, unless the holders of the Company’s securities immediately prior
      to such transaction or series of transactions continue to hold at least 50%
      of
      such securities following such transaction or series of transactions, (ii)
      a
      sale, conveyance, lease, transfer or disposition of all or substantially all
      of
      the assets of the Company in one or a series of related transactions or (iii)
      the execution by the Company of an agreement to which the Company is a party
      or
      by which it is bound, providing for any of the events set forth above in (i)
      or
      (ii).

     

    
      
        
        

      

      
        B-5

        
          

        

      

      
        
        

      

    

     

    (h) Issuances
      Below Exercise Price.
      If the
      Company, at any time while this Warrant is outstanding:

     

    (i) issues
      or
      sells, or is deemed to have issued or sold, any Common Stock;

     

    (ii) in
      any
      manner grants, issues or sells any rights, options, warrants, options to
      subscribe for or to purchase Common Stock or any stock or other securities
      convertible into or exchangeable for Common Stock (other than any Excluded
      Securities (as defined below)) (such rights, options or warrants being herein
      called “Options”
      and such
      convertible or exchangeable stock or securities being herein called “Convertible
      Securities”);
      or

     

    (iii) in
      any
      manner issues or sells any Convertible Securities;

     

    for
      (a)
      with respect to paragraph (i) above, a price per share, or (b) with respect
      to
      paragraphs (ii) or (iii) above, a price per share for which Common Stock
      issuable upon the exercise of such Options or upon conversion or exchange of
      such Convertible Securities is, less than the Exercise Price in effect
      immediately prior to such issuance or sale, then, immediately after such
      issuance, sale or grant, the Exercise Price shall be reduced to a price equal
      to
      the price per share of the Common Stock sold or the exercise price or conversion
      price of the Options and Convertible Securities, as applicable. No modification
      of the issuance terms shall be made upon the actual issuance of such Common
      Stock upon conversion or exchange of such Options or Convertible Securities.
      The
      number of Common Shares issuable upon exercise of this Warrant shall be
      increased to an amount equal to the quotient of (A) the product of (x) the
      Exercise Price in effect immediately prior to the adjustment multiplied by
      (y)
      the number of Common Shares issuable upon exercise of this Warrant immediately
      prior to the adjustment, divided by (B) the adjusted Exercise Price. If there
      is
      a change at any time in (i) the exercise price provided for in any Options,
      (ii)
      the additional consideration, if any, payable upon the issuance, conversion
      or
      exchange of any Convertible Securities or (iii) the rate at which any
      Convertible Securities are convertible into or exchangeable for Common Stock,
      then immediately after such change the Exercise Price shall be adjusted to
      Exercise Price which would have been in effect at such time had such Options
      or
      Convertible Securities still outstanding provided for such changed exercise
      price, additional consideration or changed conversion rate, as the case may
      be,
      at the time initially granted, issued or sold; provided that no adjustment
      shall
      be made if such adjustment would result in an increase of the Exercise Price
      then in effect.

    

    
      
        
        

      

      
        B-6

        
          

        

      

      
        
        

      

    

     

    “Excluded
      Securities”
means
      (i) options to be granted pursuant to a stock option plan approved by Stanford
      International Bank Ltd. (“Stanford”);
      (ii)
      shares of Common Stock issued upon conversion or exercise of warrants, options
      or other securities convertible into Common Stock which have been specifically
      disclosed to Stanford in the Securities Purchase Agreement dated as of even
      date
      herewith between the Company and Stanford, or (iii) shares of Common Stock
      or
      securities convertible into or exercisable for shares of Common Stock issued
      or
      deemed to be issued by the Company in connection with a strategic acquisition
      by
      the Company of the assets or business, or division thereof, of another entity
      which acquisition has been approved by Stanford in writing.

    

    (i) Effect
      on Exercise Price of Certain Events.
      For
      purposes of determining the adjusted Exercise Price under Section
      5(h),
      the
      following shall be applicable:

     

    (i) Calculation
      of Consideration Received.
      If any
      Common Stock, Options or Convertible Securities are issued or sold or deemed
      to
      have been issued or sold for cash, the consideration received therefor will
      be
      deemed to be the net amount received by the Company therefor, without deducting
      any expenses paid or incurred by the Company or any commissions or compensations
      paid or concessions or discounts allowed to underwriters, dealers or others
      performing similar services in connection with such issue or sale. In case
      any
      Common Stock, Options or Convertible Securities are issued or sold for a
      consideration other than cash, the amount of the consideration other than cash
      received by the Company will be the fair value of such consideration, except
      where such consideration consists of securities listed or quoted on a national
      securities exchange or national quotation system, in which case the amount
      of
      consideration received by the Company will be the arithmetic average of the
      closing sale price of such security for the five (5) consecutive trading days
      immediately preceding the date of receipt thereof. In case any Common Stock,
      Options or Convertible Securities are issued to the owners of the non-surviving
      entity in connection with any merger in which the Company is the surviving
      entity, the amount of consideration therefor will be deemed to be the fair
      value
      of such portion of the net assets and business of the non-surviving entity
      as is
      attributable to such Common Stock, Options or Convertible Securities, as the
      case may be. The fair value of any consideration other than cash or securities
      will be determined jointly by the Company and the registered owners of a
      majority of the Warrant Stock then outstanding. If such parties are unable
      to
      reach agreement within 10 days after the occurrence of an event requiring
      valuation (the “Valuation
      Event”),
      the
      fair value of such consideration will be determined within 48 hours of the
      10th
      day following the Valuation Event by an appraiser selected in good faith by
      the
      Company and agreed upon in good faith by the registered owners of a majority
      of
      the Warrant Stock then outstanding. The determination of such appraiser shall
      be
      binding upon all parties absent manifest error.

     

    
      
        
        

      

      
        B-7

        
          

        

      

      
        
        

      

    

     

    (ii) Integrated
      Transactions.
      In case
      any Option is issued in connection with the issue or sale of other securities
      of
      the Company, together comprising one integrated transaction in which no specific
      consideration is allocated to such Options by the parties thereto, the Options
      will be deemed to have been issued for an aggregate consideration of
      $.001.

     

    (iii) Record
      Date.
      If the
      Company takes a record of the holders of Common Stock for the purpose of
      entitling them (a) to receive a dividend or other distribution payable in Common
      Stock, Options or in Convertible Securities or (b) to subscribe for or purchase
      Common Stock, Options or Convertible Securities, then such record date will
      be
      deemed to be the date of the issue or sale of the shares of Common Stock deemed
      to have been issued or sold upon the declaration of such dividend or the making
      of such other distribution or the date of the granting of such right of
      subscription or purchase, as the case may be.

     

    (iv) Other
      Events.
      If any
      event occurs that would adversely affect the rights of the Holder of this
      Warrant but is not expressly provided for by this Section 5 (including, without
      limitation, the granting of stock appreciation rights, phantom stock rights
      or
      other rights with equity features), then the Company’s Board of Directors will
      make an appropriate adjustment in the Exercise Price so as to protect the rights
      of the Holder; provided, however, that no such adjustment will increase the
      Exercise Price.

     

    (j) Notice
      of Certain Events.
      If:

     

    (i) the
      Company shall declare a dividend (or any other distribution) on its Common
      Stock; 

     

    (ii) the
      Company shall declare a special nonrecurring cash dividend on or a redemption
      of
      its Common Stock; 

     

    (iii) the
      Company shall authorize the granting to the holders of all of its Common Stock
      rights or warrants to subscribe for or purchase any shares of capital stock
      of
      any class or of any rights;

     

    (iv) the
      approval of any stockholders of the Company shall be required in connection
      with
      any capital reorganization, reclassification of the Company’s capital stock, any
      consolidation or merger to which the Company is a party, any sale or transfer
      of
      all or substantially all of the assets of the Company, or any compulsory share
      exchange whereby the Common Stock is converted into other securities, cash
      or
      property; or

     

    
      
        
        

      

      
        B-8

        
          

        

      

      
        
        

      

    

     

    (v) the
      Company shall authorize the voluntary or involuntary dissolution, liquidation
      or
      winding up of the affairs of the Company;

     

    then
      the
      Company shall cause to be filed at each office or agency maintained for the
      purpose of exercise of this Warrant, and shall cause to be delivered to the
      Holder, at least 30 calendar days prior to the applicable record or effective
      date hereinafter specified, a notice (provided such notice shall not include
      any
      material non-public information) stating (a) the date on which a record is
      to be
      taken for the purpose of such dividend, distribution, redemption, rights or
      warrants, or if a record is not to be taken, the date as of which the holders
      of
      Common Stock of record to be entitled to such dividend, distributions,
      redemption, rights or warrants are to be determined or (b) the date on which
      such reorganization, reclassification, consolidation, merger, sale, transfer
      or
      share exchange is expected to become effective or close, and the date as of
      which it is expected that holders of Common Stock of record shall be entitled
      to
      exchange their shares of Common Stock for securities, cash or other property
      deliverable upon such reorganization, reclassification, consolidation, merger,
      sale, transfer or share exchange; provided, however, that the failure to mail
      such notice or any defect therein or in the mailing thereof shall not affect
      the
      validity of the corporate action required to be specified in such notice.
      Nothing herein shall prohibit the Holder from exercising this Warrant during
      the
      30-day period commencing on the date of such notice.

    

    (k) Increase
      in Exercise Price.
      In no
      event shall any provision in this Section 5 cause the Exercise Price to be
      greater than the Exercise Price on the date of issuance of this Warrant, except
      for a combination of the outstanding shares of Common Stock into a smaller
      number of shares as referenced in Section 5(a) above.

    
      
        

        
          	 	
                  6.

                	
                  
                    
                      
                        RESTRICTIONS
                          ON
                          EXERCISE

                      

                    

                  

                

        

         

      

    

    (a) Investment
      Intent.
      Unless,
      prior to the exercise of the Warrant, the issuance of the Warrant Stock has
      been
      registered with the Securities and Exchange Commission pursuant to the Act,
      the
      Warrant Exercise Form shall be accompanied by a representation of the Holder
      to
      the Company to the effect that such shares are being acquired for investment
      and
      not with a view to the distribution thereof, and such other representations
      and
      documentation as may be required by the Company, unless in the opinion of
      counsel to the Company such representations or other documentation are not
      necessary to comply with the Act.

    
      
        

        
          	 	
                  7.

                	
                  
                    
                      
                        RESTRICTIONS
                          ON
                          TRANSFER

                      

                    

                  

                

        

         

      

    

    (a) Transfer
      to Comply with the Securities Act of 1933.
      Neither
      this Warrant nor any Warrant Stock may be sold, assigned, transferred or
      otherwise disposed of except as follows: (1) to a person who, in the opinion
      of
      counsel satisfactory to the Company, is a person to whom this Warrant or the
      Warrant Stock may legally be transferred without registration and without the
      delivery of a current prospectus under the Act with respect thereto and then
      only against receipt of an agreement of such person to comply with the
      provisions of this Section 7 with respect to any resale, assignment, transfer
      or
      other disposition of such securities; (2) to any person upon delivery of a
      prospectus then meeting the requirements of the Act relating to such securities
      and the offering thereof for such sale, assignment, transfer or disposition;
      or
      (3) to any “affiliate” (as such term is used in Rule 144 promulgated pursuant to
      the Act) of the Holder.

     

    
      
        
        

      

      
        B-9

        
          

        

      

      
        
        

      

    

     

    (b) Legend.
      Subject
      to the terms hereof, upon exercise of this Warrant and the issuance of the
      Warrant Stock, all certificates representing such Warrant Stock shall bear
      on
      the face or reverse thereof substantially the following legend: 

     

    “The
      securities which are represented by this certificate have not been registered
      under the Securities Act of 1933, and may not be sold, transferred, hypothecated
      or otherwise disposed of until a registration statement with respect thereto
      is
      declared effective under such act, or the Company receives an opinion of counsel
      for the Company that an exemption from the registration requirements of such
      act
      is available.”

     

    
      
        	 	
                8.

              	
                
                  
                    
                      LOST,
                        STOLEN OR DESTROYED
                        WARRANTS

                    

                  

                

              

      

       

    

    In
      the
      event that the Holder notifies the Company that this Warrant has been lost,
      stolen or destroyed and provides (a) a letter, in form reasonably satisfactory
      to the Company, to the effect that it will indemnify the Company from any loss
      incurred by it in connection therewith, and/or (b) an indemnity bond in such
      amount as is reasonably required by the Company, the Company having the option
      of electing either (a) or (b) or both, the Company may, in its sole discretion,
      accept such letter and/or indemnity bond in lieu of the surrender of this
      Warrant as required by Section 1 hereof.

    
      
        

        
          	 	
                  9.

                	
                  
                    
                      
                        SUBSEQUENT
                          HOLDERS

                      

                    

                  

                

        

         

      

    

    Every
      Holder hereof, by accepting the same, agrees with any subsequent Holder hereof
      and with the Company that this Warrant and all rights hereunder are issued
      and
      shall be held subject to all of the terms, conditions, limitations and
      provisions set forth in this Warrant, and further agrees that the Company and
      its transfer agent, if any, may deem and treat the registered holder of this
      Warrant as the absolute owner hereof for all purposes and shall not be affected
      by any notice to the contrary.

    
      

      
        	 	
                10.

              	
                
                  
                    
                      NOTICES

                    

                  

                

              

      

       

    

    Any
      notice required or permitted hereunder shall be given in writing (unless
      otherwise specified herein) and shall be effective upon personal delivery,
      via
      facsimile (upon receipt of confirmation of error-free transmission and mailing
      a
      copy of such confirmation, postage prepaid by certified mail, return receipt
      requested) or two business days following deposit of such notice with an
      internationally recognized courier service, with postage prepaid and addressed
      the other party at the following address, or at such other addresses as a party
      may designate by five days advance written notice to the other party
      hereto.

    

    
      
        
        

      

      
        B-10

        
          

        

      

      
        
        

      

    

    
      	
              Company:

            	
              Health
                Systems Solutions, Inc.

            
	 	
              450
                North Reo Street, Suite 300

            
	 	
              Tampa,
                Florida 33609

            
	 	
              Attn:
                Brian M. Milvain, President

            
	 	
              Facsimile:
                813-282-8907

            
	 	 
	
              with
                a copy to:

            	
              Carlton
                Fields P.A.

            
	 	
              4000
                International Place 

            
	 	
              100
                SE 2nd Street

            
	 	
              Miami,
                FL 33131

            
	 	
              Attention:
                Seth P. Joseph

            
	 	
              Facsimile:
                305-530-0055

            
	 	 
	
              Holder:

            	
              Stanford
                International Bank Ltd.

            
	 	
              6075
                Poplar Avenue

            
	 	
              Memphis,
                Tennessee 38119

            
	 	
              Attention:
                James M. Davis, Chief Financial Officer

            
	 	
              Facsimile:
                901-680-5265

            

    

    
      

      
        	 	
                11.

              	
                
                  
                    
                      GOVERNING
                        LAW;
                        JURISDICTION

                    

                  

                

              

      

       

    

    This
      Warrant shall be governed by and interpreted in accordance with the laws of
      the
      State of Florida, without regard to its principles of conflict of laws. Any
      action or proceeding seeking to enforce any provision of, or based on any right
      arising out of, this Warrant may be brought against any party in the federal
      courts of Florida or the state courts of the State of Florida, and each of
      the
      parties consents to the jurisdiction of such courts and hereby waives, to the
      maximum extent permitted by law, any objection, including any objections based
      on forum non conveniens, to the bringing of any such proceeding in such
      jurisdictions.

     

    (Signature
      on the following page)

    

    
      
        
        

      

      
        B-11

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      the
      Company has caused this Warrant to be signed on its behalf, in its corporate
      name, by its duly authorized officer, all as of the day and year first above
      written. 

     

    
      
        	 	 	
                HEALTH
                  SYSTEMS SOLUTIONS, INC. 

              
	 	 	 	 
	
              	 	 	
              
	
              	 	
                By:
                  

              	
                

              
	 	 	
                Name: 

              	
                
 
	 	 	
                Title:
                  

              	
                
 

      

       

    

    
      
        
        

      

      
        B-12

        
          

        

      

      
        
        

      

    

     

    HEALTH
      SYSTEMS SOLUTIONS, INC.

    

    WARRANT
      EXERCISE FORM

    

    The
      undersigned hereby irrevocably elects (A) to exercise the Warrant dated
      __________ _____, 200___ (the “Warrant”),
      pursuant to the provisions of Section 1(a)
      of the
      Warrant, to the extent of purchasing _____________ shares of the common stock,
      par value $.001 per share (the “Common
      Stock”),
      of
      Health Systems Solutions, Inc. and hereby makes a payment of $________ in
      payment therefor, or (B) to exercise the Warrant to the extent of purchasing
      _________ shares of the Common Stock, pursuant to the provisions of Section
      1(b)
      of the
      Warrant. In exercising the Warrant, the undersigned hereby confirms that the
      Common Stock to be issued hereunder is being acquired for investment and not
      with a view to the distribution thereof. Please issue a certificate or
      certificates representing said shares of Common Stock in the name of the
      undersigned or in such other name as is specified below. Please issue a new
      Warrant for the unexercised portion of the attached Warrant in the name of
      the
      undersigned or in such other name as is specified below.

    

    

    
      
Name
      of
      Holder

    

    

    
      
Signature
      of Holder

    or
      Authorized Representative

    

                                       

      

    

    Signature,
      if jointly held

    

    

    
      

    

    Name
      and
      Title of Authorized

    Representative

    
       

      
                                           

          

        

      

    

    
                                         

        

      

      Address
        of Holder

    

     

    
                                         

        

      

    

    Date

    

    
      
        
        

      

      
        B-13

        
          

        

      

      
        
        

      

    

    EXHIBIT
      C

    

    HEALTH
      SYSTEMS SOLUTIONS, INC.

    a
      Nevada corporation

    

    REGISTRATION
      RIGHTS AGREEMENT

    

    THIS
      REGISTRATION RIGHTS AGREEMENT,
      dated as
      of August
      __, 2007
      (the
“Agreement”),
      is
      entered into by and among Health Systems Solutions, Inc., a Nevada corporation
      (the “Company”),
      and
      Stanford International Bank Limited, a banking corporation organized under
      the
      laws of Antigua and Barbuda, and its assigns (the “Investor”).
      Capitalized terms not defined herein shall have the meanings ascribed to them
      in
      the Preferred Stock Purchase Agreement (as hereinafter defined).

    

    WHEREAS,
      simultaneously with the execution and delivery of this Agreement, the Investor
      is agreeing to purchase from the Company, (i) pursuant to the Preferred Stock
      Purchase Agreement dated as of August __, 2007 between the Company and the
      Investor (the “Preferred
      Stock Purchase Agreement”),
      up to
      1,425,000 shares of the Series D Preferred Stock and Warrants to purchase up
      to
      427,500 shares of the Company’s common stock, par value $.001 (the “Common
      Stock”), and (ii) pursuant to the Convertible Debenture Purchase Agreement dated
      as of August ___, 2007 between the Company and the Investor (the “Debenture
      Purchase Agreement”),
      a
      convertible debenture in the principal amount of $5,000,000 convertible into
      2,500,000 shares of the Company’s Series D Preferred Stock and Warrants to
      purchase up to 1,250,000 shares of Common Stock; and

    

    WHEREAS,
      the
      Company desires to grant to the Investors the registration rights set forth
      herein with respect to the shares of Common Stock issuable upon conversion
      of
      the Series D Preferred Stock (the “Conversion
      Shares”),
      the
      shares of Common Stock issuable upon exercise of the Warrants including the
      Existing
      Facility Warrants
      (the
“Warrant
      Shares”),
      the
      shares of Common Stock issuable upon the exercise of the warrants issuable
      in
      the event of a registration default pursuant to Section 4(e)
      (the
“Default
      Warrant Shares”)
      and the
      shares of Common Stock issued as a dividend or other distribution with respect
      to the Conversion Shares, Warrant Shares or Default Warrant Shares (the
“Distribution
      Shares”)
      (all
      the shares of the Series D Preferred Stock, the Conversion Shares, the Merger
      Shares, the Warrant Shares, the Default Warrant Shares and the Distribution
      Shares, collectively and interchangeably, are referred to herein as the
“Securities”).

    

    NOW,
      THEREFORE,
      the
      parties hereto mutually agree as follows:

    

    
      	 	
              1.

            	
              CERTAIN
                DEFINITIONS

            

    

     

    As
      used
      herein the term “Registrable
      Security”
      means
      the Conversion Shares, Warrant Shares, Default Warrant Shares and the
      Distribution Shares, until (i) the Registration Statement (as defined below)
      has
      been declared effective by the Securities and Exchange Commission (the
“Commission”),
      and
      all Securities have been disposed of pursuant to the Registration Statement,
      (ii) all Securities have been sold under circumstances under which all of the
      applicable conditions of Rule 144 (“Rule
      144”)
      (or any
      similar provision then in force) under the Securities Act of 1933, as amended
      (the “Securities
      Act”)
      are
      met, or (iii) such time as, in the opinion of counsel to the Company reasonably
      satisfactory to the Investors and upon delivery to the Investors of such
      executed opinion, all Securities may be sold without any time, volume or manner
      limitations pursuant to Rule 144 (or any similar provision then in effect).
      In
      the event of any merger, reorganization, consolidation, recapitalization or
      other change in corporate structure affecting the Common Stock, such adjustment
      shall be deemed to be made in the definition of “Registrable Security” as is
      appropriate in order to prevent any dilution or enlargement of the rights
      granted pursuant to this Agreement. As used herein the term “Holder”
      means
      any
      Person owning or having the right to acquire Registrable Securities or any
      assignee thereof in accordance with Section 10
      hereof. As used herein “Trading
      Day”
      shall
      mean any business day on which the market on which the Common Stock trades
      is
      open for business.

     

    
      
        
        

      

      
        C-1

        
          

        

      

      
        
        

      

    

    
      

      
        	 	
                2.

              	
                
                  RESTRICTIONS
                    ON TRANSFER

                

              

      

       

    

    Each
      of
      the Investors acknowledges and understands that prior to the registration of
      the
      Securities as provided herein, the Securities are “restricted securities” as
      defined in Rule 144. Each of the Investors understands that no disposition
      or
      transfer of the Securities may be made by any of the Investors in the absence
      of
      (i) an opinion of counsel to such Investor, in form and substance reasonably
      satisfactory to the Company, that such transfer may be made without registration
      under the Securities Act or (ii) such registration.

    
      
        

        
          	 	
                  3.

                	
                  
                    
                      COMPLIANCE
                        WITH REPORTING REQUIREMENTS 

                    

                  

                

        

         

      

    

    With
      a
      view to making available to the Investors the benefits of Rule 144 or any other
      similar rule or regulation of the Commission that may at any time permit the
      holders of the Securities to sell securities of the Company to the public
      pursuant to Rule 144, the Company agrees to:

     

    (a) comply
      with the provisions of paragraph (c)(1) of Rule 144; 

     

    (b) file
      with
      the Commission in a timely manner all reports and other documents required
      to be
      filed with the Commission pursuant to Section 13 or 15(d) under the Securities
      Exchange Act of 1934 (the “Exchange
      Act”)
      by
      companies subject to either of such sections, irrespective of whether the
      Company is then subject to such reporting requirements; and

     

    (c) Upon
      request by any Holder or the Company’s transfer agent, the Company shall provide
      an opinion of counsel, which opinion shall be reasonably acceptable to the
      Holder and/or the Company’s transfer agent, that such Holder has complied with
      the applicable conditions of Rule 144 (or any similar provision then in
      force).

    
      
        

        
          	 	
                  4.

                	
                  
                    
                      REGISTRATION
                        RIGHTS WITH RESPECT TO THE REGISTRABLE
                        SECURITIES

                    

                  

                

        

         

      

    

    (a) The
      Company agrees that it will prepare and file with the Commission, (i) within
      90
      calendar days from the date
      hereof, a registration statement (on Form S-1 or SB-2, or other appropriate
      registration statement form) under the Securities Act (the “Registration
      Statement”),
      and
      (ii) if at least 20% of the Registrable Securities covered under the
      Registration Statement filed under (i) remain unsold during the effective period
      of such Registration Statement, then within 20 days following receipt of a
      written notice from the holders representing a majority of such unsold
      Registrable Securities, another Registration Statement so as to permit a resale
      of the Securities under the Securities Act by the Holders as selling
      stockholders and not as underwriters.

     

    
      
        
        

      

      
        C-2

        
          

        

      

      
        
        

      

    

     

    The
      Company shall use diligent best efforts to cause the Registration Statement
      to
      become effective as soon as practical following the filing of the Registration
      Statement. The Company will notify the Holders and its transfer agent of the
      effectiveness of the Registration Statement within one Trading Day of such
      event.

    

    (b) The
      Company will maintain the Registration Statement or post-effective amendment
      filed under this Section 4
      effective under the Securities Act until the earlier of (i) the date that none
      of the Registrable Securities covered by such Registration Statement are or
      may
      become issued and outstanding, (ii) the date that all of the Registrable
      Securities have been sold pursuant to such Registration Statement, (iii) the
      date all the Holders receive an opinion of counsel to the Company, which counsel
      shall be reasonably acceptable to the Holders, that the Registrable Securities
      may be sold under the provisions of Rule 144 without limitation as to volume,
      (iv) all Registrable Securities have been otherwise transferred to persons
      who
      may trade such shares without restriction under the Securities Act, and the
      Company has delivered a new certificate or other evidence of ownership for
      such
      securities not bearing a restrictive legend, or (v) two years from the Effective
      Date.

     

    (c) All
      fees,
      disbursements and out-of-pocket expenses and costs incurred by the Company
      in
      connection with the preparation and filing of the Registration Statement under
      this Section 4
      and in
      complying with applicable securities and blue sky laws (including, without
      limitation, all attorneys’ fees of the Company) shall be borne by the Company.
      The Company shall also reimburse the fees and expenses of counsel to the Holders
      incurred in connection with such counsel’s review of the Registration Statement
      and advice concerning the Registration Statement and its filing subject to
      a cap
      of $15,000. The Holders shall bear the cost of underwriting and/or brokerage
      discounts, fees and commissions, if any, applicable to the Registrable
      Securities being registered. The Holders and their counsel shall have a
      reasonable period, not to exceed 15 Trading Days, to review the proposed
      Registration Statement or any amendment thereto, prior to filing with the
      Commission, and the Company shall provide the Holders with copies of any comment
      letters received from the Commission with respect thereto within two Trading
      Days of receipt thereof. The Company shall qualify any of the Registrable
      Securities for sale in such states as the Holders reasonably designate and
      shall
      furnish indemnification in the manner provided in Section 7
      hereof.
      However, the Company shall not be required to qualify in any state which will
      require an escrow or other restriction relating to the Company and/or the
      Holders, or which will require the Company to qualify to do business in such
      state or require the Company to file therein any general consent to service
      of
      process. The Company at its expense will supply each of the Investors with
      copies of the applicable Registration Statement and the prospectus included
      therein and other related documents in such quantities as may be reasonably
      requested by any of the Investors.

     

    (d) The
      Company shall not be required by this Section 4
      to
      include the Registrable Securities in any Registration Statement which is to
      be
      filed if, in the opinion of counsel for both the Holders and the Company (or,
      should they not agree, in the opinion of another counsel experienced in
      securities law matters acceptable to counsel for the Holders and the Company)
      the proposed offering or other transfer as to which such registration is
      requested is exempt from applicable federal and state securities laws and would
      result in all purchasers or transferees obtaining securities which are not
      “restricted securities,” as defined in Rule 144.

     

    
      
        
        

      

      
        C-3

        
          

        

      

      
        
        

      

    

     

    (e) In
      the
      event that (i) the Registration Statement is not filed by the Company in a
      timely manner as set forth in Section 4(a);
      or
      (ii) such Registration Statement is not maintained as effective by the Company
      for the period set forth in Section 4(b)
      above (each a “Registration
      Default”),
      then
      the Company will issue to each of the Holders as of the first day of such
      Registration Default and for every consecutive month in which such Registration
      Default is occurring, as liquidated damages, and not as a penalty, warrants
      to
      purchase one (1) share of the Common Stock (“Default
      Warrants”)
      for
      each share of Series D Preferred Stock issued to the Holders pursuant to the
      Preferred Stock Purchase Agreement and the Debenture Purchase Agreement until
      such corresponding Registration Default no longer exists (“Liquidated
      Damages”);
      provided, however, that the issuance of such Default Warrants shall not relieve
      the Company from its obligations to register the Registrable Securities pursuant
      to this Section.

     

    If
      the
      Company does not issue the Default Warrants to the Holders as set forth above,
      the Company will pay any Holder’s reasonable costs of any action in a court of
      law to cause compliance with this Section 4(e),
      including reasonable attorneys’ fees, in addition to the Default Warrants. The
      registration of the Registrable Securities pursuant to this Section shall not
      affect or limit a Holder’s other rights or remedies as set forth in this
      Agreement. 

    

    (f) The
      Company shall be precluded from including in any Registration Statement which
      it
      is required to file pursuant to this Section 4
      any
      other securities apart from the Registrable Securities, without the prior
      written consent of the Holders.

     

    (g) If,
      at
      any time any Registrable Securities are not at the time covered by any effective
      Registration Statement, the Company shall determine to register under the
      Securities Act (including pursuant to a demand of any stockholder of the Company
      exercising registration rights) any of its shares of the Common Stock (other
      than in connection with a merger or other business combination transaction
      that
      has been consented to in writing by holders of the Series D Preferred Stock,
      or
      pursuant to Form S-8 when such filing has been consented to in writing by
      holders of the Series D Preferred Stock), it shall send to each Holder written
      notice of such determination and, if within 20 days after receipt of such
      notice, such Holder shall so request in writing, the Company shall its best
      efforts to include in such registration statement all or any part of the
      Registrable Securities that such Holder requests to be registered.
      Notwithstanding the foregoing, if, in connection with any offering involving
      an
      underwriting of the Common Stock to by issued by the Company, the managing
      underwriter shall impose a limitation on the number of shares of the Common
      Stock included in any such registration statement because, in such underwriter’s
      judgment, such limitation is necessary based on market conditions: (a) if the
      registration statement is for a public offering of common stock on a “firm
      commitment” basis with gross proceeds to the Company of at least $15,000,000 (a
“Qualified
      Public Offering”),
      the
      Company may exclude, to the extent so advised by the underwriters, the
      Registrable Securities from the underwriting; provided, however, that if the
      underwriters do not entirely exclude the Registrable Securities from such
      Qualified Public Offering, the Company shall be obligated to include in such
      registration statement, with respect to the requesting Holder, only an amount
      of
      Registrable Securities equal to the product of (i) the number of Registrable
      Securities that remain available for registration after the underwriter’s
      cutback and (ii) such Holder’s percentage of ownership of all the Registrable
      Securities then outstanding (on an as-converted basis) (the “Registrable
      Percentage”);
      and
      (b) if the registration statement is not for a Qualified Public Offering, the
      Company shall be obligated to include in such registration statement, with
      respect to the requesting Holder, only an amount of Registrable Securities
      equal
      to the product of (i) the number of Registrable Securities that remain available
      for registration after the underwriter’s cutback and (ii) such Holder’s
      Registrable Percentage; provided, however, that the aggregate value of the
      Registrable Securities to be included in such registration may not be so reduced
      to less than 30% of the total value of all securities included in such
      registration. If any Holder disapproves of the terms of any underwriting
      referred to in this paragraph, it may elect to withdraw therefrom by written
      notice to the Company and the underwriter. No incidental right under this
      paragraph shall be construed to limit any registration required under the other
      provisions of this Agreement.

    
      
         

      

    

    
      
        
          
          

        

        
          C-4

          
            

          

        

        
          
          

        

      

      
         

         

        
          	 	
                  5.

                	
                  
                    
                      COOPERATION
                        WITH COMPANY

                    

                  

                

        

         

        Each
          Holder will cooperate with the Company in all respects in connection with
          this
          Agreement, including timely supplying all information reasonably requested
          by
          the Company (which shall include all information regarding such Holder
          and
          proposed manner of sale of the Registrable Securities required to be disclosed
          in any Registration Statement) and executing and returning all documents
          reasonably requested in connection with the registration and sale of the
          Registrable Securities and entering into and performing its obligations
          under
          any underwriting agreement, if the offering is an underwritten offering,
          in
          usual and customary form, with the managing underwriter or underwriters
          of such
          underwritten offering. Nothing in this Agreement shall obligate any Holder
          to
          consent to be named as an underwriter in any Registration Statement. The
          obligation of the Company to register the Registrable Securities shall
          be
          absolute and unconditional as to those Registrable Securities which the
          Commission will permit to be registered without naming any Holder as
          underwriters. Any delay or delays caused by a Holder by failure to cooperate
          as
          required hereunder shall not constitute a Registration Default as to such
          Holder.

        
          
            

            
              	 	
                      6.

                    	
                      
                        
                          REGISTRATION
                            PROCEDURES 

                        

                      

                    

            

             

          

        

        If
          and
          whenever the Company is required by any of the provisions of this Agreement
          to
          effect the registration of any of the Registrable Securities under the
          Securities Act, the Company shall (except as otherwise provided in this
          Agreement), as expeditiously as possible, subject to the Holders’ assistance and
          cooperation as reasonably required with respect to each Registration
          Statement:

         

        (a) (i) prepare
          and file with the Commission such amendments and supplements to the Registration
          Statement and the prospectus used in connection therewith as may be necessary
          to
          keep such Registration Statement effective and to comply with the provisions
          of
          the Securities Act with respect to the sale or other disposition of all
          Registrable Securities covered by such Registration Statement whenever
          any of
          the Holder shall desire to sell or otherwise dispose of the same (including
          prospectus supplements with respect to the sales of Registrable Securities
          from
          time to time in connection with a registration statement pursuant to Rule
          415
          promulgated under the Securities Act) and (ii) take all lawful action such
          that
          each of (A) the Registration Statement and any amendment thereto does not,
          when
          it becomes effective, contain an untrue statement of a material fact or
          omit to
          state a material fact required to be stated therein or necessary to make
          the
          statements therein, in light of the circumstances under which they were
          made,
          not misleading and (B) the prospectus forming part of the Registration
          Statement, and any amendment or supplement thereto, does not at any time
          during
          the Registration Period include an untrue statement of a material fact
          or omit
          to state a material fact required to be stated therein or necessary to
          make the
          statements therein, in light of the circumstances under which they were
          made,
          not misleading;

         

      

    

    
      
        
        

      

      
        C-5

        
          

        

      

      
        
        

      

    

     

    (b) (i) prior
      to
      the filing with the Commission of any Registration Statement (including any
      amendments thereto) and the distribution or delivery of any prospectus
      (including any supplements thereto), provide draft copies thereof to the Holders
      as required by Section 4(c)
      and
      reflect in such documents all such comments as the Holders (and their counsel)
      reasonably may propose; (ii) furnish to each of the Holders such numbers of
      copies of a prospectus including a preliminary prospectus or any amendment
      or
      supplement to any prospectus, as applicable, in conformity with the requirements
      of the Securities Act, and such other documents, as any of the Holders may
      reasonably request in order to facilitate the public sale or other disposition
      of the Registrable Securities owned by such Holder; and (iii) provide to the
      Holders copies of any comments and communications from the Commission relating
      to the Registration Statement, if lawful to do so;

     

    (c) register
      and qualify the Registrable Securities covered by the Registration Statement
      under such other securities or blue sky laws of such jurisdictions as any of
      the
      Holders shall reasonably request (subject to the limitations set forth in
      Section 4(c)
      above), and do any and all other acts and things which may be necessary or
      advisable to enable such Holder to consummate the public sale or other
      disposition in such jurisdiction of the Registrable Securities owned by such
      Holder;

     

    (d) list
      such
      Registrable Securities on the markets where the Common Stock of the Company
      is
      listed as of the effective date of the Registration Statement, if the listing
      of
      such Registrable Securities is then permitted under the rules of such
      markets;

     

    (e) notify
      the Holders at any time when a prospectus relating thereto covered by the
      Registration Statement is required to be delivered under the Securities Act,
      of
      the happening of any event of which it has knowledge as a result of which the
      prospectus included in the Registration Statement, as then in effect, includes
      an untrue statement of a material fact or omits to state a material fact
      required to be stated therein or necessary to make the statements therein not
      misleading in the light of the circumstances then existing, and the Company
      shall prepare and file a curative amendment under Section 6(a)
      as
      quickly as reasonably possible and during such period, the Holders shall not
      make any sales of Registrable Securities pursuant to the Registration Statement;
      

     

    (f) after
      becoming aware of such event, notify each of the Holders who holds Registrable
      Securities being sold (or, in the event of an underwritten offering, the
      managing underwriters) of the issuance by the Commission of any stop order
      or
      other suspension of the effectiveness of the Registration Statement at the
      earliest possible time and take all lawful action to effect the withdrawal,
      rescission or removal of such stop order or other suspension;

     

    
      
        
        

      

      
        C-6

        
          

        

      

      
        
        

      

    

     

    (g) cooperate
      with the Holders to facilitate the timely preparation and delivery of
      certificates for the Registrable Securities to be offered pursuant to the
      Registration Statement and enable such certificates for the Registrable
      Securities to be in such denominations or amounts, as the case may be, as any
      of
      the Holders reasonably may request and registered in such names as any of the
      Holders may request; and, within three Trading Days after a Registration
      Statement which includes Registrable Securities is declared effective by the
      Commission, deliver and cause legal counsel selected by the Company to deliver
      to the transfer agent for the Registrable Securities (with copies to the
      Holders) an appropriate instruction and, to the extent necessary, an opinion
      of
      such counsel;

     

    (h) take
      all
      such other lawful actions reasonably necessary to expedite and facilitate the
      disposition by the Holders of their Registrable Securities in accordance with
      the intended methods therefor provided in the prospectus which are customary
      for
      issuers to perform under the circumstances;

     

    (i) in
      the
      event of an underwritten offering, promptly include or incorporate in a
      prospectus supplement or post-effective amendment to the Registration Statement
      such information as the managers reasonably agree should be included therein
      and
      to which the Company does not reasonably object and make all required filings
      of
      such prospectus supplement or post-effective amendment as soon as practicable
      after it is notified of the matters to be included or incorporated in such
      prospectus supplement or post-effective amendment; and

     

    (j) maintain
      a transfer agent and registrar for the Common Stock.

    
      
        

        
          	 	
                  7.

                	
                  
                    
                      INDEMNIFICATION

                    

                  

                

        

         

      

    

    (a) To
      the
      maximum extent permitted by law, the Company agrees to indemnify and hold
      harmless each of the Holders, each person, if any, who controls any of the
      Holders within the meaning of the Securities Act, and each director, officer,
      shareholder, employee, agent, representative, accountant or attorney of the
      foregoing (each of such indemnified parties, a “Distributing
      Investor”)
      against
      any losses, claims, damages or liabilities, joint or several (which shall,
      for
      all purposes of this Agreement, include, but not be limited to, all reasonable
      costs of defense and investigation and all reasonable attorneys’ fees and
      expenses), to which the Distributing Investor may become subject, under the
      Securities Act or otherwise, insofar as such losses, claims, damages or
      liabilities (or actions in respect thereof) arise out of or are based upon
      any
      untrue statement or alleged untrue statement of any material fact contained
      in
      any Registration Statement, or any related final prospectus or amendment or
      supplement thereto, or arise out of or are based upon the omission or alleged
      omission to state therein a material fact required to be stated therein or
      necessary to make the statements therein not misleading; provided, however,
      that
      the Company will not be liable in any such case to the extent, and only to
      the
      extent, that any such loss, claim, damage or liability arises out of or is
      based
      upon an untrue statement or alleged untrue statement or omission or alleged
      omission made in such Registration Statement, preliminary prospectus, final
      prospectus or amendment or supplement thereto in reliance upon, and in
      conformity with, written information furnished to the Company by the
      Distributing Investor, its counsel, or affiliates, specifically for use in
      the
      preparation thereof or (ii) by such Distributing Investor’s failure to deliver
      to the purchaser a copy of the most recent prospectus (including any amendments
      or supplements thereto). This indemnity agreement will be in addition to any
      liability which the Company may otherwise have.

     

    
      
        
        

      

      
        C-7

        
          

        

      

      
        
        

      

    

     

    (b) To
      the
      maximum extent permitted by law, each Distributing Investor agrees that it
      will
      indemnify and hold harmless the Company, and each officer and director of the
      Company or person, if any, who controls the Company within the meaning of the
      Securities Act, against any losses, claims, damages or liabilities (which shall,
      for all purposes of this Agreement, include, but not be limited to, all
      reasonable costs of defense and investigation and all reasonable attorneys’ fees
      and expenses) to which the Company or any such officer, director or controlling
      person may become subject under the Securities Act or otherwise, insofar as
      such
      losses, claims, damages or liabilities (or actions in respect thereof) arise
      out
      of or are based upon any untrue statement or alleged untrue statement of any
      material fact contained in any Registration Statement, or any related final
      prospectus or amendment or supplement thereto, or arise out of or are based
      upon
      the omission or the alleged omission to state therein a material fact required
      to be stated therein or necessary to make the statements therein not misleading,
      but in each case only to the extent that such untrue statement or alleged untrue
      statement or omission or alleged omission was made in such Registration
      Statement, final prospectus or amendment or supplement thereto in reliance
      upon,
      and in conformity with, written information furnished to the Company by such
      Distributing Investor, its counsel or affiliates, specifically for use in the
      preparation thereof. This indemnity agreement will be in addition to any
      liability which the Distributing Investor may otherwise have under this
      Agreement. Notwithstanding anything to the contrary herein, the Distributing
      Investor shall be liable under this Section 7(b)
      for
      only that amount as does not exceed the net proceeds to such Distributing
      Investor as a result of the sale of Registrable Securities pursuant to the
      Registration Statement. 

     

    (c) Promptly
      after receipt by an indemnified party under this Section 7
      of
      notice of the commencement of any action against such indemnified party, such
      indemnified party will, if a claim in respect thereof is to be made against
      the
      indemnifying party under this Section 7,
      notify
      the indemnifying party in writing of the commencement thereof; but the omission
      so to notify the indemnifying party will not relieve the indemnifying party
      from
      any liability which it may have to any indemnified party except to the extent
      the failure of the indemnified party to provide such written notification
      actually prejudices the ability of the indemnifying party to defend such action.
      In case any such action is brought against any indemnified party, and it
      notifies the indemnifying party of the commencement thereof, the indemnifying
      party will be entitled to participate in, and, to the extent that it may wish,
      jointly with any other indemnifying party similarly notified, assume the defense
      thereof, subject to the provisions herein stated and after notice from the
      indemnifying party to such indemnified party of its election so to assume the
      defense thereof, the indemnifying party will not be liable to such indemnified
      party under this Section 7
      for any
      legal or other expenses subsequently incurred by such indemnified party in
      connection with the defense thereof other than reasonable costs of
      investigation, unless the indemnifying party shall not pursue the action to
      its
      final conclusion. The indemnified parties shall have the right to employ one
      or
      more separate counsel in any such action and to participate in the defense
      thereof, but the fees and expenses of such counsel shall not be at the expense
      of the indemnifying party if the indemnifying party has assumed the defense
      of
      the action with counsel reasonably satisfactory to the indemnified party unless
      (i) the employment of such counsel has been specifically authorized in writing
      by the indemnifying party, or (ii) the named parties to any such action
      (including any interpleaded parties) include both the indemnified party and
      the
      indemnifying party and the indemnified party shall have been advised by its
      counsel that there may be one or more legal defenses available to the
      indemnifying party different from or in conflict with any legal defenses which
      may be available to the indemnified party or any other indemnified party (in
      which case the indemnifying party shall not have the right to assume the defense
      of such action on behalf of such indemnified party, it being understood,
      however, that the indemnifying party shall, in connection with any one such
      action or separate but substantially similar or related actions in the same
      jurisdiction arising out of the same general allegations or circumstances,
      be
      liable only for the reasonable fees and expenses of one separate firm of
      attorneys for the indemnified party, which firm shall be designated in writing
      by the indemnified party). No settlement of any action against an indemnified
      party shall be made without the prior written consent of the indemnified party,
      which consent shall not be unreasonably withheld so long as such settlement
      includes a full release of claims against the indemnified party. 

     

    
      
        
        

      

      
        C-8

        
          

        

      

      
        
        

      

    

     

    All
      fees
      and expenses of the indemnified party (including reasonable costs of defense
      and
      investigation in a manner not inconsistent with this Section and all reasonable
      attorneys’ fees and expenses) shall be paid to the indemnified party, as
      incurred, within 10 Trading Days of written notice thereof to the indemnifying
      party; provided, that the indemnifying party may require such indemnified party
      to undertake to reimburse all such fees and expenses to the extent it is finally
      judicially determined that such indemnified party is not entitled to
      indemnification hereunder.

    
      
        

        
          	 	
                  8.

                	
                  
                    
                      CONTRIBUTION

                    

                  

                

        

         

      

    

    In
      order
      to provide for just and equitable contribution under the Securities Act in
      any
      case in which (i) the indemnified party makes a claim for indemnification
      pursuant to Section 7
      hereof
      but is judicially determined (by the entry of a final judgment or decree by
      a
      court of competent jurisdiction and the expiration of time to appeal or the
      denial of the last right of appeal) that such indemnification may not be
      enforced in such case notwithstanding the fact that the express provisions
      of
      Section 7
      hereof
      provide for indemnification in such case, or (ii) contribution under the
      Securities Act may be required on the part of any indemnified party, then the
      Company and the applicable Distributing Investor shall contribute to the
      aggregate losses, claims, damages or liabilities to which they may be subject
      (which shall, for all purposes of this Agreement, include, but not be limited
      to, all reasonable costs of defense and investigation and all reasonable
      attorneys’ fees and expenses), in either such case (after contribution from
      others) on the basis of relative fault as well as any other relevant equitable
      considerations. The relative fault shall be determined by reference to, among
      other things, whether the untrue or alleged untrue statement of a material
      fact
      or the omission or alleged omission to state a material fact relates to
      information supplied by the Company on the one hand or the applicable
      Distributing Investor on the other hand, and the parties’ relative intent,
      knowledge, access to information and opportunity to correct or prevent such
      statement or omission. The Company and the Distributing Investor agree that
      it
      would not be just and equitable if contribution pursuant to this Section
8
      were
      determined by pro rata allocation or by any other method of allocation which
      does not take account of the equitable considerations referred to in this
      Section 8.
      The
      amount paid or payable by an indemnified party as a result of the losses,
      claims, damages or liabilities (or actions in respect thereof) referred to
      above
      in this Section 8
      shall
      be deemed to include any legal or other expenses reasonably incurred by such
      indemnified party in connection with investigating or defending any such action
      or claim. No person guilty of fraudulent misrepresentation (within the meaning
      of Section 11(f) of the Securities Act) shall be entitled to contribution from
      any person who was not guilty of such fraudulent misrepresentation.

     

    
      
        
        

      

      
        C-9

        
          

        

      

      
        
        

      

    

     

    Notwithstanding
      any other provision of this Section 8,
      in no
      event shall (i) any of the Distributing Investors be required to undertake
      liability to any person under this Section 8
      for any
      amounts in excess of the dollar amount of the proceeds received by such
      Distributing Investor from the sale of such Distributing Investor’s Registrable
      Securities (after deducting any fees, discounts and commissions applicable
      thereto) pursuant to any Registration Statement under which such Registrable
      Securities are registered under the Securities Act and (ii) any underwriter
      be
      required to undertake liability to any person hereunder for any amounts in
      excess of the aggregate discount, commission or other compensation payable
      to
      such underwriter with respect to the Registrable Securities underwritten by
      it
      and distributed pursuant to such Registration Statement.

    
      
        

        
          	 	
                  9.

                	
                  
                    
                      NOTICES

                    

                  

                

        

         

      

    

    Any
      notice required or permitted hereunder shall be given in writing (unless
      otherwise specified herein) and shall be effective upon personal delivery,
      via
      facsimile (upon receipt of confirmation of error-free transmission and mailing
      a
      copy of such confirmation, postage prepaid by certified mail, return receipt
      requested) or two business days following deposit of such notice with an
      internationally recognized courier service, with postage prepaid and addressed
      to each of the other parties thereunto entitled at the following addresses,
      or
      at such other addresses as a party may designate by five days advance written
      notice to each of the other parties hereto.

    

      
        	
                Company:

              	
                Health
                  Systems Solutions, Inc.

              
	 	
                405
                  North Reo Street, Suite 300

              
	 	
                Tampa,
                  Florida 33609

              
	 	
                Attention:
                  Brian M. Milvain, President

              
	 	
                Facsimile:
                  813-282-8907

              
	 	 
	
                with
                  a copy to:

              	
                Carlton
                  Fields, P.A.

              
	 	
                100
                  S.E. Second Street, Suite 4000

              
	 	
                Miami,
                  Florida 33131

              
	 	
                Attention:
                  Seth P. Joseph, Esq.

              
	 	
                Facsimile:
                  305-530-0055

              
	 	 
	
                Investor:

              	
                Stanford
                  International Bank Ltd.

              
	 	
                No.
                  11 Pavilion Drive

              
	 	
                St.
                  John’s, Antigua, West Indies 

              
	 	
                Attention:
                  James M. Davis, Chief Financial
                  Officer

              

      

    

     

    
      
        
        

      

      
        C-10

        
          

        

      

      
        
        

      

    

     

    
      
        
          	 	
                  10.

                	
                  
                    
                      ASSIGNMENT

                    

                  

                

        

         

      

    

    The
      registration rights granted to any Holder under this Agreement may be
      transferred or assigned provided the transferee is bound by the terms of this
      Agreement and the Company is given written notice of such transfer or
      assignment.

    
      
        

        
          	 	
                  11.

                	
                  
                    
                      ADDITIONAL
                        COVENANTS OF THE
                        COMPANY

                    

                  

                

        

         

      

    

    For
      so
      long as it shall be required to maintain the effectiveness of the Registration
      Statement, it shall file all reports and information required to be filed by
      it
      with the Commission in a timely manner and take all such other action so as
      to
      maintain such eligibility for the use of the applicable form.

    
      
        

        
          	 	
                  12.

                	
                  
                    
                      CONFLICTING
                        AGREEMENTS

                    

                  

                

        

         

      

    

    The
      Company shall not enter into any agreement with respect to its securities that
      is inconsistent with the rights granted to the Holders in this Agreement or
      otherwise prevents the Company from complying with all of its obligations
      hereunder.

    
      

      
        	 	
                13.

              	
                
                  
                    GOVERNING
                      LAW;
                      JURISDICTION

                  

                

              

      

       

    

    This
      Agreement shall be governed by and interpreted in accordance with the laws
      of
      the State of Florida, without regard to its principles of conflict of laws.
      Any
      action or proceeding seeking to enforce any provision of, or based on any right
      arising out of, this Agreement may be brought against any party in the federal
      courts of Florida or the state courts of the State of Florida, and each of
      the
      parties consents to the jurisdiction of such courts and hereby waives, to the
      maximum extent permitted by law, any objection, including any objections based
      on forum non conveniens, to the bringing of any such proceeding in such
      jurisdictions.

    
      
        

        
          	 	
                  14.

                	
                  
                    
                      MISCELLANEOUS

                    

                  

                

        

         

      

    

    (a) Entire
      Agreement. This
      Agreement supersedes all prior agreements and understandings among the parties
      hereto with respect to the subject matter hereof. This Agreement, together
      with
      the other Primary Documents, including any certificate, schedule, exhibit or
      other document delivered pursuant to their terms, constitutes the entire
      agreement among the parties hereto with respect to the subject matters hereof
      and thereof, and supersedes all prior agreements and understandings, whether
      written or oral, among the parties with respect to such subject
      matters.

     

    (b) Amendments.
      This
      Agreement may not be amended except by an instrument in writing signed by the
      party to be charged with enforcement. 

     

    (c) Waiver.
      No
      waiver
      of any provision of this Agreement shall be deemed a waiver of any other
      provisions or shall a waiver of the performance of a provision in one or more
      instances be deemed a waiver of future performance thereof.

     

    (d) Construction.
      This
      Agreement and each of the Primary Documents have been entered into freely by
      each of the parties, following consultation with their respective counsel,
      and
      shall be interpreted fairly in accordance with its respective terms, without
      any
      construction in favor of or against either party. 

     

    
      
        
        

      

      
        C-11

        
          

        

      

      
        
        

      

    

     

    (e) Binding
      Effect of Agreement. This
      Agreement shall inure to the benefit of, and be binding upon the successors
      and
      assigns of each of the parties hereto, including any transferees of the
      Securities. 

     

    (f) Severability.
      If
      any
      provision of this Agreement shall be invalid or unenforceable in any
      jurisdiction, such invalidity or unenforceability shall not affect the validity
      or enforceability of the remainder of this Agreement or the validity or
      unenforceability of this Agreement in any other jurisdiction. 

     

    (g) Attorneys’
      Fees. If
      any
      action should arise between the parties hereto to enforce or interpret the
      provisions of this Agreement, the prevailing party in such action shall be
      reimbursed for all reasonable expenses incurred in connection with such action,
      including reasonable attorneys’ fees.

     

    (h) Headings.
      The
      headings of this Agreement are for convenience of reference only and shall
      not
      form part of, or affect the interpretation of this Agreement.

     

    (i) Counterparts.
      This
      Agreement may be signed in one or more counterparts, each of which shall be
      deemed an original and all of which, when taken together, will be deemed to
      constitute one and the same agreement.

     

    [Signatures
      on the following page]

     

    
      
        
        

      

      
        C-12

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF,
      the
      parties hereto have caused this Registration Rights Agreement to be duly
      executed, as
      of the
      date first written above.

    
       

      
        
          	 	 	
                  
                    HEALTH
                      SYSTEMS SOLUTIONS, INC.

                  

                
	 	 	 	 
	
                	 	 	
                
	
                	 	
                  By:
                    

                	
                  

                
	 	 	
                  Name: 

                	
                  
 
	 	 	
                  Title:
                    

                	
                  
 

        

      

    

    
      
         

        
          
            	 	 	
                    
                      
                        INVESTOR:

                      

                    

                  
	 	 	 
	 	 	
                    STANFORD
                      INTERNATIONAL BANK LTD.

                  
	 	 	 	 
	
                  	 	 	
                  
	
                  	 	
                    By:
                      

                  	
                    

                  
	 	 	
                    Name: 

                  	
                    
 
	 	 	
                    Title:
                      

                  	
                    
 

          

        

      

       

    

    
      
        
        

      

      
        C-13

        
          

        

      

      
        
        

      

    

    EXHIBIT
      D

    

    HEALTH
      SYSTEMS SOLUTIONS, INC.

    a
      Nevada corporation

    

    CLOSING
      CERTIFICATE

    

    The
      undersigned, ________________, hereby certifies to Stanford International Bank
      Ltd., an Antiguan banking corporation (“SIBL”),
      that
      he is the duly elected and acting ____________ of Health Systems Solutions,
      Inc., a Nevada corporation (the “Company”),
      and
      hereby further certifies to SIBL as follows:

    

    All
      capitalized terms used herein and not otherwise defined herein shall have the
      meanings ascribed to such terms in the Preferred Stock Purchase Agreement dated
      as of August __, 2007 and entered into by and between the Company and SIBL
      (the
“Securities
      Purchase Agreement”):

    

    
      	
            	1.	
              Representations
                and Warranties.
                The Company’s representations and warranties contained in the Securities
                Purchase Agreement are true and correct in all respects on and as
                of the
                date hereof, as though made on and as of such date, except to the
                extent
                that any such representation or warranty relates solely to an earlier
                date, in which case such representation or warranty is true and correct
                in
                all respects on and as of such earlier
                date.

            

    

     

    
      	
            	2.	
              Covenants
                and Agreements.
                The Company has performed all covenants and agreements required to
                be
                performed pursuant to the Securities Purchase Agreement in all respects
                on
                and as of the date hereof.

            

    

     

    
      	
            	3.	
              Recent
                Events.
                Except as disclosed in the Securities Purchase Agreement, since the
                Closing Date, there has not been any material adverse change or any
                material adverse development in the business, properties, operations,
                financial condition, prospects, outstanding securities or results
                or
                operations of the Company and no event has occurred and no circumstances
                exist that may result in such material adverse change. The Company
                has not
                engaged in any practice, taken any action, or entered into any transaction
                outside its ordinary course of
                business.

            

    

    

    IN
      WITNESS WHEREOF,
      the
      undersigned has executed this Officers’ Certificate this ____ day of
      ____________, 2007.

     

    
      
        	
                By:    

              	 

                

              	 
	
                Name:

              	 

                

              	 
	
                Title:

              	
                 

                
                  
 

              	 

      

    

     

    
      
        
          
          

        

        
          D-1Exhibit
      10.2

     

    CONVERTIBLE
      DEBENTURE PURCHASE AGREEMENT

    

    THIS
      CONVERTIBLE DEBENTURE PURCHASE AGREEMENT
      (this
“Agreement”)
      is
      dated as of 17th
      day of
      August, 2007, between HEALTH SYSTEMS SOLUTIONS, INC., a Nevada corporation
      (the
“Company”),
      and
      STANFORD INTERNATIONAL BANK LIMITED, a corporation organized under the laws
      of
      Antigua and Barbuda (the “Purchaser”).

    

    WHEREAS,
      subject
      to the terms and conditions set forth in this Agreement and pursuant to Section
      4(2) of the Securities Act of 1933, as amended (the “Securities
      Act”),
      the
      Company desires to issue and sell to Purchaser, and Purchaser desires to
      purchase from the Company, a certain debenture of the Company as more fully
      described in this Agreement.

    

    NOW,
      THEREFORE,
      in
      consideration of the premises and the mutual covenants and agreements set forth
      herein, and other good and valuable consideration exchanged between the parties,
      the receipt and sufficiency of which are hereby acknowledged, the parties hereto
      agree that the foregoing recitals are true and correct and further agree as
      follows:

     

    ARTICLE
      I
      - DEFINITIONS

     

    Section
      1.1 Definitions.
      In
      addition to terms defined elsewhere in this Agreement, the following terms
      have
      the meanings indicated which meanings shall be equally applicable to both the
      singular and the plural forms of such terms:

     

    “Affiliate”
shall
      mean any Person which directly or indirectly through one or more intermediaries
      controls, or is controlled by or is under common control, with a Person, as
      such
      terms are used in and construed under Rule 144 under the Securities Act. The
      term “control” means the possession, directly of indirectly, of the power to
      cause the direction of the management and policies of a Person, whether through
      the ownership of voting securities, by contract or otherwise. 

    

    “Closing”
means
      the closing of the purchase and sale of the Debenture pursuant to Section
      2.1.

    

    “Closing
      Date”
means
      August 17, 2007, or such other date as the parties may agree in
      writing.

    

    “Commission”
means
      the Securities and Exchange Commission.

    

    “Common
      Stock”
means
      the common stock of the Company, par value $0.001 per share, and any securities
      into which such common stock shall hereinafter have been reclassified
      into.

     

    “Debenture”
means
      the 8.00% Secured Convertible
      Debenture due
      four
      (4) years from the date of issuance, issued by the Company to Purchaser
      hereunder, in the form of Exhibit
      A.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    “Effective
      Date”
means
      the date that the initial Registration Statement filed by the Company pursuant
      to the Registration Rights Agreement is first declared effective by the
      Commission.

    

    “Exchange
      Act”
means
      the Securities Exchange Act of 1934, as amended.

    

    “GAAP”
shall
      have the meaning ascribed to such term in Section 3.1(h) hereof.

    

    “Liens”
shall
      have the meaning ascribed to such term in Section 3.1(a) hereof.

    

    “Material
      Adverse Effect”
shall
      have the meaning assigned to such term in Section 3.1(b) hereof.

    

    “Person”
means
      an individual or corporation, partnership, trust, incorporated or unincorporated
      association, joint venture, limited liability company, joint stock company,
      government (or an agency or subdivision thereof) or other entity of any
      kind.

    

    “Principal
      Market”
means
      initially the OTC Bulletin Board and shall also include, the NASDAQ Capital
      Market or the NASDAQ Global Market, whichever is at the time the principal
      trading exchange or market for the Common Stock, based upon share
      volume.

    

    “Proceeding”
means
      an action, claim, suit, investigation or proceeding (including, without
      limitation, an investigation or partial proceeding, such as a deposition),
      whether commenced or threatened.

    

    “Registration
      Statement”
means
      the registration statement to be filed by the Company pursuant to the
      Registration Rights Agreement.

    

    “Registration
      Rights Agreement”
means
      the Registration Rights Agreement, dated the Closing Date, between the Company
      and the Purchaser.

    

    “Required
      Approvals”
shall
      have the meaning ascribed to such term in Section 3.1(e) hereof.

    

    “Rule
      144”
means
      Rule 144 promulgated by the Commission pursuant to the Securities Act, as such
      Rule may be amended from time to time, or any similar rule or regulation
      hereafter adopted by the Commission having substantially the same effect as
      such
      Rule.

    

    “SEC
      Reports”
shall
      have the meaning ascribed to such term in Section 3.1(h) hereof.

    

    “Securities”
means
      the Debenture, the Warrants and the Underlying Shares.

    

    “Securities
      Act”
means
      the Securities Act of 1933, as amended.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    “Series
      D Preferred Stock”
means
      the Series D Convertible Preferred Stock of the Company and any securities
      into
      which such preferred stock shall hereinafter have been reclassified into the
      terms of which are as set forth in the Certificate of Designation of Series
      D
      Convertible Preferred Stock. The Series D Preferred Stock shall be convertible
      into shares of Common Stock pursuant to the terms set forth in the Series D
      Certificate of Designation.

    

    “Subscription
      Amount”
      means
      $5,000,000.

    

    “Subsidiary”
means
      any subsidiary of the Company.

     

    “Trading
      Day”
means
      any day during which the Principal Market shall be open for
      business.

    

    “Transaction
      Documents”
means
      this Agreement, the Debenture, the Warrants, the Registration Rights Agreement
      and any other documents or agreements executed in connection with the
      transactions contemplated hereunder.

    

    “Underlying
      Shares”
means
      the shares of Common Stock issuable upon conversion of the Series D Preferred
      Stock issuable upon conversion of the Debenture and upon exercise of the
      Warrants.

    

    “Warrants”
means
      collectively the Common Stock purchase warrants, in the form of Exhibit B
      delivered to Purchaser and to the Persons identified on Schedule 1 hereto at
      the
      Closing in accordance with Section 2.2 hereof. In connection with the purchase
      of the Debenture, the Company shall issue to Purchaser and its assigns 1,250,000
      Warrants.

    

    “Warrant
      Shares”
means
      the shares of Common Stock issuable upon exercise of the Warrants.

     

    Section
      1.2 Accounting
      Terms.
      Accounting terms not specifically defined in this Agreement shall have the
      meaning given to them under accounting principles and practices generally
      accepted in the Ecuador, applied on a consistent basis with the financial
      statements referred to in Section 3.3 hereof, and shall be determined both
      as to
      classification of items and amounts in accordance therewith.

     

    Section
      1.3 Other
      Definitional Provisions.
      The
      words “hereof,” “herein,” and “hereunder” and words of similar import when used
      in this Agreement shall refer to this Agreement as a whole and not to any
      particular provision of this Agreement, and Section, Subsection and Exhibit
      references are to this Agreement unless otherwise specified.

     

    ARTICLE
      II
      - PURCHASE
      AND SALE

     

    Section
      2.1 Purchase
      of Debenture; Closing.
      Upon
      the terms and subject to the conditions set forth herein, concurrent with the
      execution and delivery of this Agreement by the parties hereto, the Company
      agrees to sell, and Purchaser agrees to purchase, the Debenture
      in the
      principal amount of $5,000,000.
      At the
      Closing, Purchaser shall deliver to the Company the Subscription Amount via
      wire
      transfer or a certified check. At the Closing, the Company shall deliver to
      Purchaser the Debenture evidencing a principal amount equal to $5,000,000 and
      the other items set forth in Section 2.2. 

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    Section
      2.2 Conditions
      to Closing.
      Upon
      satisfaction or waiver by the party sought to be benefited thereby of the
      conditions set forth in this Section 2.2, the Closing shall occur.

     

    (a) At
      or
      prior to the Closing, the Company shall deliver or cause to be delivered to
      Purchaser the following:

    

    (i) the
      Debenture duly exacted by the Company and registered in the name of
      Purchaser;

    

    (ii) Warrants
      registered in the names of the Persons set forth on Schedule 1 attached hereto
      to purchase an aggregate of 1,250,000 shares of Common Stock, with a term of
      five (5) years and an initial exercise price equal to $1.00 per share of Common
      Stock, subject to adjustment therein; 

    

    (iii) the
      Registration Rights Agreement duly executed by the Company; and

    

    (iv) this
      Agreement, duly executed by the Company.

    

    (b) At
      or
      prior to the Closing, Purchaser shall deliver or cause to be delivered to the
      Company the following:

    

    (i) the
      Subscription Amount; 

    

    (ii) the
      Registration Rights Agreement duly executed by Purchaser; and

    

    (iii) this
      Agreement, duly executed by Purchaser.

    

    (c) All
      representations and warranties of the other party contained herein shall remain
      true and correct as of the Closing Date and all covenants of the other party
      shall have been performed if due prior to such date.

    

    (d) There
      shall have been no Material Adverse Effect (as defined in Section 3.1(b)) with
      respect to the Company since the date hereof.

    

    (f) The
      Purchaser shall have completed its customary due diligence of the Company,
      including legal and financial review, to its absolute satisfaction.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      III -
      REPRESENTATIONS
      AND WARRANTIES

     

    Section
      3.1 Representations
      and Warranties of the Company.
      The
      Company hereby makes the representations and warranties set forth below to
      Purchaser.

     

    (a) Subsidiaries.
      Except
      for Healthcare Quality Solutions, Inc., VHT Acquisition Company and Carekeeper
      Solutions, Inc., the Company has no direct or indirect subsidiaries. The Company
      owns, directly or indirectly, all of the capital stock or other equity interests
      of each Subsidiary free and clear of any lien, charge, security interest,
      encumbrance, right of first refusal or other restriction (collectively,
“Liens”),
      and
      all the issued and outstanding shares of capital stock of each Subsidiary are
      validly issued and are fully paid, non-assessable and free of preemptive and
      similar rights.

    

    (b) Organization
      and Qualification.
      Each of
      the Company and the Subsidiaries is an entity duly incorporated or otherwise
      organized, validly existing and in good standing under the laws of the
      jurisdiction of its incorporation or organization (as applicable), with the
      requisite power and authority to own and use its properties and assets and
      to
      carry on its business as currently conducted. Neither the Company nor any
      Subsidiary is in violation of any of the provisions of its respective
      certificate or articles of incorporation, bylaws or other organizational or
      charter documents. Each of the Company and the Subsidiaries is duly qualified
      to
      do business and is in good standing as a foreign corporation or other entity
      in
      each jurisdiction in which the nature of the business conducted or property
      owned by it makes such qualification necessary, except where the failure to
      be
      so qualified or in good standing, as the case may be, could not, individually
      or
      in the aggregate: (i) adversely affect the legality, validity or enforceability
      of any Transaction Document, (ii) have or result in or be reasonably likely
      to
      have or result in a material adverse effect on the results of operations,
      assets, prospects, business or condition (financial or otherwise) of the Company
      and the Subsidiaries, taken as a whole, or (iii) adversely impair the Company’s
      ability to perform fully on a timely basis its obligations under any of the
      Transaction Documents (any of (i), (ii) or (iii), a “Material
      Adverse Effect”).

    

    (c) Authorization;
      Enforcement.
      The
      Company has the requisite corporate power and authority to enter into and to
      consummate the transactions contemplated by each of the Transaction Documents
      and otherwise to carry out its obligations hereunder or thereunder. The
      execution and delivery of each of the Transaction Documents by the Company
      and
      the consummation by it of the transactions contemplated hereby or thereby have
      been duly authorized by all necessary action on the part of the Company and
      no
      further consent or action is required by the Company other than Required
      Approvals. Each of the Transaction Documents has been (or upon delivery will
      be)
      duly executed by the Company and, when delivered in accordance with the terms
      hereof, will constitute the valid and binding obligation of the Company
      enforceable against the Company in accordance with its terms, subject to
      applicable bankruptcy, insolvency, fraudulent conveyance, reorganization,
      moratorium and similar laws affecting creditors’ rights and remedies generally
      and general principles of equity. Neither the Company nor any Subsidiary is
      in
      violation of any of the provisions of its respective certificate or articles
      of
      incorporation, by-laws or other organizational or charter
      documents.

     

    (d) No
      Conflicts.
      The
      execution, delivery and performance of the Transaction Documents by the Company
      and the consummation by the Company of the transactions contemplated thereby
      do
      not and will not: (i) conflict with or violate any provision of the Company’s or
      any Subsidiary’s certificate or articles of incorporation, bylaws or other
      organizational or charter documents, or (ii) subject to obtaining the Required
      Approvals, conflict with, or constitute a default (or an event that with notice
      or lapse of time or both would become a default) under, or give to others any
      rights of termination, amendment, acceleration or cancellation (with or without
      notice, lapse of time or both) of, any agreement, credit facility, debt or
      other
      instrument (evidencing a Company or Subsidiary debt or otherwise) or other
      understanding to which the Company or any Subsidiary is a party or by which
      any
      property or asset of the Company or any Subsidiary is bound or affected, or
      (iii) result, in a violation of any law, rule, regulation, order, judgment,
      injunction, decree or other restriction of any court or governmental authority
      to which the Company or a Subsidiary is subject (including federal and state
      securities laws and regulations), or by which any property or asset of the
      Company or a Subsidiary is bound or affected; except in the case of each of
      clauses (ii) and (iii), such as could not, individually or in the aggregate,
      have or result in a Material Adverse Effect.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    (e) Filings,
      Consents and Approvals.
      Neither
      the Company nor any Subsidiary is required to obtain any consent, waiver,
      authorization or order of, give any notice to, or make any filing or
      registration with, any court or other federal, state, local or other
      governmental authority or other Person in connection with the execution,
      delivery and performance by the Company of the Transaction Documents, other
      than
      (i) the filings required under Section 4.7 and (ii) the filing with the
      Commission of the Registration Statement (collectively, the “Required
      Approvals”).

    

    (f) Issuance
      of the Securities.
      The
      Securities are duly authorized and, when issued and paid for in accordance
      with
      the applicable Transaction Documents, will be duly and validly issued, fully
      paid and non-assessable, free and clear of all Liens. The Company has reserved
      from its duly authorized capital stock a number of shares of Common Stock for
      issuance of the Underlying Shares. The Company has not, and to the knowledge
      of
      the Company, no Affiliate of the Company has sold, offered for sale or solicited
      offers to buy or otherwise negotiated in respect of any security (as defined
      in
      Section 2 of the Securities Act) that would be integrated with the offer or
      sale
      of the Securities in a manner that would require the registration under the
      Securities Act of the sale of the Securities to Purchaser, or that would be
      integrated with the offer or sale of the Securities for purposes of the rules
      and regulations of any Principal Market.

    

    (g) Capitalization.
      On the
      date hereof, the authorized capital of the Company consists of (i) 150,000,000
      shares of Common Stock, par value $0.001 per share, of which 6,659,111 shares
      are issued and outstanding excluding shares of Common Stock reserved for
      issuance pursuant to the Company’s employee stock option plan and (ii)
      15,000,000 shares of preferred stock, par value $0.001 per share, of which
      4,050,000 shares of Series C Preferred Stock are issued and outstanding and
      - 0
      - shares of Series D Preferred Stock are outstanding. Except as a result of
      the
      purchase and sale of the Securities, no securities of the Company are entitled
      to preemptive or similar rights, and no Person has any right of first refusal,
      preemptive right, right of participation, or any similar right to participate
      in
      the transactions contemplated by the Transaction Documents. Except as a result
      of the purchase and sale of the Securities, there are no outstanding options,
      warrants, script rights to subscribe to, calls or commitments of any character
      whatsoever relating to, or securities, rights or obligations convertible into
      or
      exchangeable for, or giving any Person any right to subscribe for or acquire,
      any shares of Common Stock, or contracts, commitments, understandings or
      arrangements by which the Company or any Subsidiary is or may become bound
      to
      issue additional shares of Common Stock, or securities or rights convertible
      or
      exchangeable into shares of Common Stock. The issuance and sale of the
      Securities will not obligate the Company to issue shares of Common Stock or
      other securities to any Person (other than Purchaser) and will not result in
      a
      right of any holder of Company securities to adjust the exercise, conversion,
      exchange or reset price under such securities.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    (h) SEC
      Reports; Financial Statements.
      The
      Company has filed all reports required to be filed by it under the Exchange
      Act,
      including pursuant to Section 13(a) or 15(d) thereof, for the two years
      preceding the date hereof (or such shorter period as the Company was required
      by
      law to file such material) (the foregoing materials being collectively referred
      to herein as the “SEC
      Reports”).
      As of
      their respective dates, the SEC Reports complied in all material respects with
      the requirements of the Securities Act and the Exchange Act and the rules and
      regulations of the Commission promulgated thereunder, and none of the SEC
      Reports, when filed, contained any untrue statement of a material fact or
      omitted to state a material fact required to be stated therein or necessary
      in
      order to make the statements therein, in light of the circumstances under which
      they were made, not misleading. The financial statements of the Company included
      in the SEC Reports comply in all material respects with applicable accounting
      requirements and the rules and regulations of the Commission with respect
      thereto as in effect at the time of filing. Such financial statements have
      been
      prepared in accordance with generally accepted accounting principles applied
      on
      a consistent basis during the periods involved (“GAAP”),
      except as may be otherwise specified in such financial statements or the notes
      thereto, and fairly present in all material respects the financial position
      of
      the Company and its consolidated subsidiaries as of and for the dates thereof
      and the results of operations and cash flows for the periods then ended,
      subject, in the case of unaudited statements, to normal, immaterial, year-end
      audit adjustments.

    

    (i) Material
      Changes.
      Since
      the date of the latest audited financial statements included within the SEC
      Reports, except as specifically disclosed in the SEC Reports: (i) there has
      been
      no event, occurrence or development that has had or that could result in a
      Material Adverse Effect, (ii) the Company has not incurred any liabilities
      (contingent or otherwise) other than (A) trade payables and accrued expenses
      incurred in the ordinary course of business consistent with past practice and
      (B) liabilities not required to be reflected in the Company’s financial
      statements pursuant to GAAP or required to be disclosed in filings made with
      the
      Commission, (iii) the Company has not altered its method of accounting or the
      identity of its auditors, (iv) the Company has not declared or made any dividend
      or distribution of cash or other property to its stockholders or purchased,
      redeemed or made any agreements to purchase or redeem any shares of its capital
      stock, and (v) the Company has not issued any equity securities to any officer,
      director or Affiliate, except pursuant to existing Company stock option or
      similar plans or for other compensatory purposes.

    

    (j) Litigation.
      Except
      as disclosed in the SEC Reports, there is no action, suit, inquiry, notice
      of
      violation, proceeding or investigation pending or, to the knowledge of the
      Company, threatened against or affecting the Company, any Subsidiary or any
      of
      their respective properties before or by any court, arbitrator, governmental
      or
      administrative agency or regulatory authority (federal, state, county, local
      or
      foreign) (collectively, an “Action”)
      which:
      (i) adversely affects or challenges the legality, validity or enforceability
      of
      any of the Transaction Documents or the Securities or (ii) could, if there
      were
      an unfavorable decision, individually or in the aggregate, have or reasonably
      be
      expected to result in a Material Adverse Effect. Neither the Company nor any
      Subsidiary, nor any director or officer thereof, is or has been the subject
      of
      any Action involving a claim of violation of or liability under federal or
      state
      securities laws or a claim of breach of fiduciary duty. The Company does not
      have pending before the Commission any request for confidential treatment of
      information. There has not been, and to the knowledge of the Company, there
      is
      not pending or contemplated, any investigation by the Commission involving
      the
      Company or any current or former director or officer of the Company. The
      Commission has not issued any stop order or other order suspending the
      effectiveness of any registration statement filed by the Company or any
      Subsidiary under the Exchange Act or the Securities Act. 

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    (k) Compliance.
      Neither
      the Company nor any Subsidiary: (i) is in default under or in violation of
      (and
      no event has occurred that has not been waived that, with notice or lapse of
      time or both, would result in a default by the Company or any Subsidiary under),
      nor has the Company or any Subsidiary received notice of a claim that it is
      in
      default under or that it is in violation of, any indenture, loan or credit
      agreement or any other agreement or instrument to which it is a party or by
      which it or any of its properties is bound (whether or not such default or
      violation has been waived), (ii) is in violation of any order of any court,
      arbitrator or governmental body, or (iii) is or has been in violation of any
      statute, rule or regulation of any governmental authority, except in each case
      as could not, individually or in the aggregate, have or result in a Material
      Adverse Effect. 

    

    (l) Labor
      Relations.
      No
      material labor dispute exists or, to the knowledge of the Company, is imminent
      with respect to any of the employees of the Company.

    

    (m) Regulatory
      Permits.
      The
      Company and the Subsidiaries possess all certificates, authorizations and
      permits issued by the appropriate federal, state, local or foreign regulatory
      authorities necessary to conduct their respective businesses as described in
      the
      SEC Reports, except where the failure to possess such permits could not,
      individually or in the aggregate, have or reasonably be expected to result
      in a
      Material Adverse Effect (“Material
      Permits”),
      and
      neither the Company nor any Subsidiary has received any notice of proceedings
      relating to the revocation or modification of any Material Permit.

    

    (n) Title
      to Assets.
      The
      Company and the Subsidiaries have good and marketable title in fee simple to
      all
      real property owned by them that is material to the business of the Company
      and
      the Subsidiaries and good and marketable title in all personal property owned
      by
      them that is material to the business of the Company and the Subsidiaries,
      in
      each case free and clear of all Liens, except for Liens that do not materially
      affect the value of such property and do not materially interfere with the
      use
      made and proposed to be made of such property by the Company and the
      Subsidiaries. Any real property and facilities held under lease by the Company
      and the Subsidiaries are held under valid, subsisting and enforceable leases
      of
      which the Company and the Subsidiaries are in compliance.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    (o) Patents
      and Trademarks.
      The
      Company and the Subsidiaries have, or have rights to use, all patents, patent
      applications, trademarks, trademark applications, service marks, trade names,
      copyrights, licenses and other similar rights necessary or material for use
      in
      connection with their respective businesses as described in the SEC Reports
      and
      which the failure to so have could have a Material Adverse Effect (collectively,
      the “Intellectual
      Property Rights”).
      Neither the Company nor any Subsidiary has received a written notice that the
      Intellectual Property Rights used by the Company or any Subsidiary violates
      or
      infringes upon the rights of any Person. To the knowledge of the Company, all
      such Intellectual Property Rights are enforceable and there is no existing
      infringement by another Person of any of the Intellectual Property
      Rights.

    

    (p) Insurance.
      The
      Company and the Subsidiaries are insured by insurers of recognized financial
      responsibility against such losses and risks and in such amounts as are prudent
      and customary in the businesses in which the Company and the Subsidiaries are
      engaged. To the best of Company’s knowledge, such insurance contracts and
      policies are accurate and complete. Neither the Company nor any Subsidiary
      has
      any reason to believe it will not be able to renew its existing insurance
      coverage as and when such coverage expires or to obtain similar coverage from
      similar insurers as may be necessary to continue its business without a
      significant increase in cost.

    

    (q) Transactions
      With Affiliates and Employees.
      Except
      as required to be set forth in the SEC Reports, none of the officers or
      directors of the Company and, to the knowledge of the Company, none of the
      employees of the Company is presently a party to any transaction with the
      Company or any Subsidiary (other than for services as employees, officers and
      directors), including any contract, agreement or other arrangement providing
      for
      the furnishing of services to or by, providing for rental of real or personal
      property to or from, or otherwise requiring payments to or from any officer,
      director or such employee or, to the knowledge of the Company, any entity in
      which any officer, director, or any such employee has a substantial interest
      or
      is an officer, director, trustee or partner.

    

    (r) Certain
      Fees.
      No
      brokerage or finder’s fees or commissions are or will be payable by the Company
      to any broker, financial advisor or consultant, finder, placement agent,
      investment banker, bank or other Person with respect to the transactions
      contemplated by this Agreement, and the Company has not taken any action that
      would cause Purchaser to be liable for any such fees or commissions. The Company
      agrees that Purchaser shall have no obligation with respect to any fees or
      with
      respect to any claims made by or on behalf of any Person for fees of the type
      contemplated by this Section with the transactions contemplated by this
      Agreement.

    

    (s) Private
      Placement.
      Assuming the accuracy of the representations and warranties of Purchaser set
      forth in Sections 3.2(b)-(f), the offer, issuance and sale of the Securities
      to
      Purchaser as contemplated hereby are exempt from the registration requirements
      of the Securities Act. The issuance and sale of the Securities hereunder does
      not contravene the rules and regulations of the Principal Market.

     

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    (t) Listing
      and Maintenance Requirements.
      The
      Company has not, in the 12 months preceding the date hereof, received notice
      from any Principal Market on which the Common Stock is or has been listed or
      quoted to the effect that the Company is not in compliance with the listing
      or
      maintenance requirements of such Principal Market. The Company is, and has
      no
      reason to believe that it will not in the foreseeable future continue to be,
      in
      compliance with all such listing and maintenance requirements.

    

    (u) Registration
      Rights.
      Except
      as disclosed in the SEC Reports, the Company has not granted or agreed to grant
      to any Person any rights (including “piggy-back” registration rights) to have
      any securities of the Company registered with the Commission or any other
      governmental authority that have not been satisfied.

    

    (v) Disclosure.
      The
      Company confirms that neither it nor any other Person acting on its behalf
      has
      provided Purchaser or its agents or counsel with any information that
      constitutes or might constitute material, nonpublic information. The Company
      understands and confirms that Purchaser will rely on the foregoing
      representations in effecting transactions in securities of the Company. All
      disclosure provided to Purchaser regarding the Company, its business and the
      transactions contemplated hereby, including the Schedules to this Agreement,
      furnished by or on behalf of the Company with respect to the representations
      and
      warranties made herein are true and correct with respect to such representations
      and warranties and do not contain any untrue statement of a material fact or
      omit to state any material fact necessary in order to make the statements made
      therein, in light of the circumstances under which they were made, not
      misleading. The Company acknowledges and agrees that Purchaser has not made
      any
      representations or warranties with respect to the transactions contemplated
      hereby other than those specifically set forth in Section 3.2 hereof.

    

    (w)
       Tax
      Status.
      The
      Company and each of its Subsidiaries has made or filed all federal, state and
      foreign income and all other tax returns, reports and declarations required
      by
      any jurisdiction to which it is subject (unless and only to the extent that
      the
      Company and each of its Subsidiaries has set aside on its books provisions
      reasonably adequate for the payment of all unpaid and unreported taxes) and
      has
      paid all taxes and other governmental assessments and charges that are material
      in amount, shown or determined to be due on such returns, reports and
      declarations, except those disclosed in the SEC Reports and being contested
      in
      good faith and has set aside on its books provisions reasonably adequate for
      the
      payment of all taxes for periods subsequent to the periods to which such
      returns, reports or declarations apply. There are no unpaid taxes in any
      material amount claimed to be due by the taxing authority of any jurisdiction,
      and the officers of the Company know of no basis for any such claim, except
      as
      disclosed in the SEC Reports. The Company has not executed a waiver with respect
      to the statute of limitations relating to the assessment or collection of any
      foreign, federal, statue or local tax. None of the Company’s tax returns is
      presently being audited by any taxing authority.

    

    (x) Acknowledgment
      Regarding Purchaser’s Acquisition of Securities.
      The
      Company acknowledges and agrees that Purchaser is acting solely in the capacity
      of an arm’s length purchaser with respect to this Agreement and the transactions
      contemplated hereby. The Company further acknowledges that Purchaser is not
      acting as a financial advisor or fiduciary of the Company (or in any similar
      capacity) with respect to this Agreement and the transactions contemplated
      hereby and any statement made by Purchaser or any of its representatives or
      agents in connection with this Agreement and the transactions contemplated
      hereby is not advice or a recommendation and is merely incidental to Purchaser’s
      purchase of the Securities. The Company further represents to Purchaser that
      the
      Company’s decision to enter into this Agreement has been based solely on the
      independent evaluation of the Company and its representatives.

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    (y) No
      General Solicitation or Advertising in Regard to this
      Transaction.
      Neither
      the Company nor, to the knowledge of the Company, any of its directors or
      officers (i) has conducted or will conduct any general solicitation (as that
      term is used in Rule 502(c) of Regulation D) or general advertising with respect
      to the sale of the Debenture or the Warrants, or (ii) made any offers or sales
      of any security or solicited any offers to buy any security under any
      circumstances that would require registration of the Debenture, the Underlying
      Shares or the Warrants under the Securities Act.

    

    Purchaser
      acknowledges and agrees that the Company does not make or has not made any
      representations or warranties with respect to the transactions contemplated
      hereby other than those specifically se forth in this Section 3.1.

    

    Section
      3.2 Representations
      and Warranties of Purchaser.
      Purchaser hereby represents and warrants to the Company as follows:

     

    (a) Organization;
      Authority.
      Purchaser is an entity duly organized, validly existing and in good standing
      under the laws of the jurisdiction of its organization with the requisite
      corporate or partnership power and authority to enter into and to consummate
      the
      transactions contemplated by the Transaction Documents and otherwise to carry
      out its obligations thereunder. The purchase by Purchaser of the Securities
      hereunder has been duly authorized by all necessary action on the part of
      Purchaser. Each of this Agreement and the Registration Rights Agreement has
      been
      duly executed by Purchaser, and when delivered by Purchaser in accordance with
      the terms hereof, will constitute the valid and legally binding obligation
      of
      Purchaser, enforceable against it in accordance with its terms.

    

    (b) No
      Conflicts.
      The
      execution, delivery and performance of the Transaction Documents by Purchaser
      and the consummation by Purchaser of the transactions contemplated thereby
      do
      not and will not: (i) conflict with or violate any provision of Purchaser’s
      certificate or articles of incorporation, bylaws or other organizational or
      charter documents, or (ii) conflict with, or constitute a default (or an event
      that with notice or lapse of time or both would become a default) under, or
      give
      to others any rights of termination, amendment, acceleration or cancellation
      (with or without notice, lapse of time or both) of, any agreement, credit
      facility, debt or other instrument (evidencing a Purchaser debt or otherwise)
      or
      other understanding to which Purchaser is a party or by which any property
      or
      asset of Purchaser is bound or affected, or (iii) result, in a violation of
      any
      law, rule, regulation, order, judgment, injunction, decree or other restriction
      of any court or governmental authority to which Purchaser is subject (including
      federal and state securities laws and regulations), or by which any property
      or
      asset of Purchaser is bound or affected; except in the case of each of clauses
      (ii) and (iii), such as could not, individually or in the aggregate, have or
      result in a material adverse effect on Purchaser.

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    (c) Investment
      Intent.
      Purchaser is acquiring the Securities as principal for its own account for
      investment purposes only and not with a view to or for distributing or reselling
      such Securities or any part thereof, without prejudice, however, to Purchaser’s
      right, subject to the provisions of this Agreement, at all times to sell or
      otherwise dispose of all or any part of such Securities pursuant to an effective
      registration statement under the Securities Act or under an exemption from
      such
      registration and in compliance with applicable federal and state securities
      laws. Nothing contained herein shall be deemed a representation or warranty
      by
      Purchaser to hold Securities for any period of time. Purchaser is acquiring
      the
      Securities hereunder in the ordinary course of its business. Purchaser does
      not
      have any agreement or understanding, directly or indirectly, with any Person
      to
      distribute any of the Securities.

    

    (d) Purchaser
      Status.
      At the
      time Purchaser was offered the Securities, it was, and at the date hereof it
      is,
      and on each date on which it exercises any Warrants or converts any Debenture
      it
      will be, an “accredited investor” as defined in Rule 501(a) under the Securities
      Act. Purchaser has not been formed solely for the purpose of acquiring the
      Securities. Purchaser is not a registered broker-dealer under Section 15 of
      the
      Exchange Act. 

    

    (e) Experience
      of Purchaser.
      Purchaser, either alone or together with its representatives, has such
      knowledge, sophistication and experience in business and financial matters
      so as
      to be capable of evaluating the merits and risks of the prospective investment
      in the Securities, and has so evaluated the merits and risks of such investment.
      Purchaser is able to bear the economic risk of an investment in the Securities
      and, at the present time, is able to afford a complete loss of such
      investment. Purchaser
      has had the opportunity to ask the representatives of the Company questions
      about the Company’s business and financial condition and the terms of this
      offering and has obtained such information as it has requested to the extent
      it
      has deemed necessary to permit it to fully evaluate the merits and risks of
      its
      investment in the Company. Purchaser also represents that it has had the
      opportunity to examine all material books and records of the Company and all
      material contracts and documents relating to his investment. Further, Purchaser
      has consulted with such other of his investment and/or accounting and/or legal
      and/or tax advisors as it has deemed necessary and appropriate in making its
      decision to invest in the Company on the terms described herein.

    

    (f) General
      Solicitation.
      Purchaser is not purchasing the Securities as a result of any advertisement,
      article, notice or other communication regarding the Securities published in
      any
      newspaper, magazine or similar media or broadcast over television or radio
      or
      presented at any seminar or any other general solicitation or general
      advertisement.

    

    The
      Company acknowledges and agrees that Purchaser does not make or has not made
      any
      representations or warranties with respect to the transactions contemplated
      hereby other than those specifically set forth in this Section 3.2.

     

    ARTICLE
      IV
      - OTHER
      AGREEMENTS OF THE PARTIES

     

    Section
      4.1 Transfer
      Restrictions.

     

    (a) The
      Securities may only be disposed of in compliance with state and federal
      securities laws. In connection with any transfer of Securities other than
      pursuant to an effective registration statement, to the Company or to an
      Affiliate of Purchaser, the Company may require the transferor thereof to
      provide to the Company an opinion of counsel selected by the transferor and
      reasonably acceptable to the Company, the form and substance of which opinion
      shall be reasonably satisfactory to the Company, to the effect that such
      transfer does not require registration of such transferred Securities under
      the
      Securities Act. As a condition of transfer, any such transferee shall agree
      in
      writing to be bound by the terms of this Agreement and shall have the rights
      of
      Purchaser under this Agreement and the Registration Rights
      Agreement.

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    (b) Purchaser
      agrees to the imprinting, so long as is required by this Section 4.1(b), of
      the
      following legend on any certificate evidencing Securities:

    

    [NEITHER]
      THESE SECURITIES [NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
      [EXERCISABLE] [CONVERTIBLE]] HAVE BEEN REGISTERED WITH THE SECURITIES AND
      EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
      AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
      (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
      TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
      TO
      AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
      REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
      APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
      TO
      THE TRANSFEROR REASONABLY ACCEPTABLE TO THE COMPANY TO SUCH EFFECT, THE
      SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE
      SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY
      BE
      PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED
      BY
      SUCH SECURITIES.

    

    (c) Certificates
      evidencing Underlying Shares shall not contain any legend (including the legend
      set forth in Section 4.1(b) hereof): (i) while a registration statement
      (including the Registration Statement) covering the resale of such security
      is
      effective under the Securities Act (unless, subsequent to the date hereof,
      the
      Commission enacts any new rules or regulations which specifically requires
      a
      legend on the certificates until a sale is made by the holder thereof), or
      (ii)
      following any sale of such Underlying Shares pursuant to Rule 144, or (iii)
      if
      such Underlying Shares are eligible for sale under Rule 144(k), or (iv) if
      such
      legend is not required under applicable requirements of the Securities Act
      (including judicial interpretations and pronouncements issued by the staff
      of
      the Commission); provided,
      however,
      in
      connection with the issuance of the Underlying Shares, Purchaser hereby agrees
      to adhere to and abide by all prospectus delivery requirements under the
      Securities Act and rules and regulations of the Commission. If all or any
      portion of the Debenture or Warrant is converted or exercised (as applicable)
      at
      a time when there is an effective registration statement to cover the resale
      of
      the Underlying Shares, or if such Underlying Shares may be sold under Rule
      144(k) or if such legend is not otherwise required under applicable requirements
      of the Securities Act (including judicial interpretations thereof) then such
      Underlying Shares shall be issued free of all legends. The Company agrees that
      following the Effective Date or at such time as such legend is no longer
      required under this Section 4.1(c), it will, no later than three Trading Days
      following the delivery by Purchaser to the Company or the Company’s transfer
      agent of a certificate representing Underlying Shares issued with a restrictive
      legend, deliver or cause to be delivered to Purchaser a certificate representing
      such shares that is free from all restrictive and other legends. The Company
      may
      not make any notation on its records or give instructions to any transfer agent
      of the Company that enlarge the restrictions on transfer set forth in this
      Section.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    Section
      4.2 Acknowledgment
      of Dilution.
      The
      Company acknowledges that the issuance of the Securities may result in dilution
      of the outstanding shares of Common Stock, which dilution may be substantial
      under certain market conditions. The Company further acknowledges that its
      obligations under the Transaction Documents, including without limitation its
      obligation to issue the Underlying Shares pursuant to the Transaction Documents,
      are unconditional and absolute and not subject to any right of set off,
      counterclaim, delay or reduction, regardless of the effect of any such dilution
      or any claim the Company may have against Purchaser and
      regardless of the dilutive effect that such issuance may have on the ownership
      of the other stockholders of the Company.

     

    Section
      4.3 Furnishing
      of Information.
      As long
      as Purchaser owns Securities, the Company covenants to timely file (or obtain
      extensions in respect thereof and file within the applicable grace period)
      all
      reports required to be filed by the Company after the date hereof pursuant
      to
      the Exchange Act. Upon the request of Purchaser, the Company shall deliver
      to
      Purchaser a written certification of a duly authorized officer as to whether
      it
      has complied with the preceding sentence. As long as Purchaser owns Securities,
      if the Company is not required to file reports pursuant to such laws, it will
      prepare and furnish to Purchaser and make publicly available in accordance
      with
      Rule 144(c) such information as is required for Purchaser to sell the Securities
      under Rule 144. The Company further covenants that it will take such further
      action as any holder of Securities may reasonably request, all to the extent
      required from time to time to enable such Person to sell such Securities without
      registration under the Securities Act within the limitation of the exemptions
      provided by Rule 144.

     

    Section
      4.4 Integration.
      The
      Company shall not, and shall use its best efforts to ensure that no Affiliate
      of
      the Company shall, sell, offer for sale or solicit offers to buy or otherwise
      negotiate in respect of any security (as defined in Section 2 of the Securities
      Act) that would be integrated with the offer or sale of the Securities in a
      manner that would require the registration under the Securities Act of the
      sale
      of the Securities to Purchaser, or that would be integrated with the offer
      or
      sale of the Securities for purposes of the rules and regulations of any
      Principal Market.

     

    Section
      4.5 Reservation
      of Securities.

     

    (a)
      The
      Company shall maintain a reserve from its duly authorized shares of Series
      D
      Preferred Stock for issuance pursuant to the Transaction Documents in such
      amount as may be required to fulfill its obligations in full under the
      Transaction Documents. In addition, the Company will at all times have
      authorized and reserved for the purpose of issuance a sufficient number of
      shares of Common Stock to provide for the conversion of the Series D Preferred
      Stock and the exercise of the Warrants.

     

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

     

    (b) The
      Company shall not undertake a reverse or forward stock split or reclassification
      of the Common Stock without the prior written consent of Purchaser.

    

    Section
      4.6 Conversion
      and Exercise Procedures.
      The
      Purchaser acknowledges that, as of the Closing Date, the Series D Preferred
      Stock has not been authorized by the Company. Accordingly, the Purchaser agrees
      that it shall not convert the Debenture pursuant to the terms hereof until
      the
      Series D Preferred Stock has been properly authorized by the Company. The form
      of Notice of Exercise included in the Warrants and the form of Notice of
      Conversion included in the Debenture set
      forth
      the totality of the procedures required of Purchaser in order to exercise the
      Warrants or convert the Debenture. No additional legal opinion or other
      information or instructions shall be required of Purchaser to exercise their
      Warrants or convert the Debenture. The Company shall honor exercises of the
      Warrants and conversions of the Debenture and shall deliver Underlying Shares
      in
      accordance with the terms, conditions and time periods set forth in the
      Transaction Documents. 

     

    Section
      4.7 Securities
      Laws Disclosure; Publicity.
      The
      Company shall, by the fourth Trading Day following the Closing Date, issue
      a
      press release or file a Current Report on Form 8-K reasonably acceptable to
      Purchaser disclosing all material terms of the transactions contemplated hereby.
      The Company and Purchaser shall consult with each other in issuing any press
      releases with respect to the transactions contemplated hereby. Notwithstanding
      the foregoing, other than in any registration statement filed pursuant to the
      Registration Rights Agreement and filings related thereto, the Company shall
      not
      publicly disclose the name of Purchaser, or include the name of Purchaser in
      any
      filing with the Commission or any regulatory agency or Principal Market, without
      the prior written consent of Purchaser, except to the extent such disclosure
      is
      required by law or Principal Market regulations, in which case the Company
      shall
      provide Purchaser with prior notice of such disclosure.

     

    Section
      4.8 Non-Public
      Information.
      The
      Company covenants and agrees that neither it nor any other Person acting on
      its
      behalf will provide Purchaser or its agents or counsel with any information
      that
      the Company believes constitutes material non-public information, unless prior
      thereto Purchaser shall have executed a written agreement regarding the
      confidentiality and use of such information. The Company understands and
      confirms that Purchaser shall be relying on the foregoing representations in
      effecting transactions in securities of the Company.

     

    Section
      4.9 Use
      of
      Proceeds.
      The
      Company shall use the net proceeds from the sale of the Securities hereunder
      for
      acquisitions as well as general working capital purposes and not for the
      satisfaction of any portion of the Company’s debt (other than payment of trade
      payables, capital lease obligations, and accrued expenses in the ordinary course
      of the Company’s business and prior practices), to redeem any Company equity or
      equity-equivalent securities or to settle any outstanding litigation except
      that
      the Company shall be permitted to use up to $400,000 of the net proceeds from
      the sale of the Securities for the settlement of its pending litigation with
      Xpanxion LLC.

     

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

     

    Section
      4.10 Reimbursement.
      If
      Purchaser becomes involved in any capacity in any Proceeding by or against
      any
      Person who is a stockholder of the Company, solely as a result of Purchaser’s
      acquisition of the Securities under this Agreement and without causation by
      any
      other activity, obligation, condition or liability on the part of, or pertaining
      to Purchaser and not to the purchase of Securities pursuant to this Agreement,
      the Company will reimburse Purchaser, to the extent such reimbursement is not
      provided for in Section 4.11, for its reasonable legal and other expenses
      (including the cost of any investigation, preparation and travel in connection
      therewith) incurred in connection therewith, as such expenses are incurred.
      The
      reimbursement obligations (and limitations thereon) of the Company under this
      paragraph shall be in addition to any liability which the Company may otherwise
      have, shall extend upon the same terms and conditions to any Affiliates of
      Purchaser who are actually named in such action, proceeding or investigation,
      and partners, directors, agents, employees and controlling persons (if any),
      as
      the case may be, of Purchaser and any such Affiliate, and shall be binding
      upon
      and inure to the benefit of any successors, assigns, heirs and personal
      representatives of the Company, Purchaser and any such Affiliate and any such
      Person. The Company also agrees that neither Purchaser nor any such Affiliates,
      partners, directors, agents, employees or controlling persons shall have any
      liability to the Company or any Person asserting claims on behalf of or in
      right
      of the Company solely as a result of acquiring the Securities under this
      Agreement except to the extent any covenant or warranty owing to the Company
      is
      breached.

     

    Section
      4.11 Indemnification
      of Purchaser.
      Subject
      to the provisions of this Section 4.11, each party (the “Indemnifying
      Party”)
      will
      indemnify and hold the other parties and their directors, officers,
      shareholders, partners, employees and agents (each, an “Indemnified
      Party”)
      harmless from any and all losses, liabilities, obligations, claims,
      contingencies, damages, costs and expenses, including all judgments, amounts
      paid in settlements, court costs and reasonable attorneys’ fees and costs of
      investigation that any such Indemnified Party may suffer or incur as a result
      of
      or relating to any breach of any of the representations, warranties, covenants
      or agreements made by the Indemnifying Party in this Agreement or in the other
      Transaction Documents. If any action shall be brought against any Indemnified
      Party in respect of which indemnity may be sought pursuant to this Agreement,
      such Indemnified Party shall promptly notify the Indemnifying Party in writing,
      and the Indemnifying Party shall have the right to assume the defense thereof
      with counsel of its own choosing. Any Indemnified Party shall have the right
      to
      employ separate counsel in any such action and participate in the defense
      thereof, but the fees and expenses of such counsel shall be at the expense
      of
      such Indemnified Party except to the extent that (i) the employment thereof
      has
      been specifically authorized by the Indemnifying Party in writing, (ii) the
      Indemnifying Party has failed after a reasonable period of time to assume such
      defense and to employ counsel or (iii) in such action there is, in the
      reasonable opinion of such separate counsel, a material conflict on any material
      issue between the position of the Indemnifying Party and the position of such
      Indemnified Party. The Indemnifying Party will not be liable to any Indemnified
      Party under this Agreement (i) for any settlement by an Indemnified Party
      effected without the Indemnifying Party’s prior written consent, which shall not
      be unreasonably withheld or delayed; or (ii) to the extent, but only to the
      extent that a loss, claim, damage or liability is attributable to any
      Indemnified Party’s breach of any of the representations, warranties, covenants
      or agreements made by Purchaser in this Agreement or in the other Transaction
      Documents. In no event shall the liability of Purchaser hereunder be greater
      in
      amount than the dollar amount of the net proceeds received by Purchaser upon
      the
      sale of the Securities.

     

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

     

    Section
      4.12 Authorization
      of Series D Preferred Stock.
      Promptly after the Closing Date, the Board of Directors of the Company shall
      use
      commercially reasonable efforts to amend the Company’s certificate of
      incorporation to authorize the creation of the Series D Preferred Stock
      including taking all steps necessary to have such amendment approved by the
      shareholders of the Company. Purchaser shall take such actions as may be
      reasonably required to support such shareholder approval. 

     

    Section
      4.13 Preemptive
      Rights.
      At all
      times while the Purchaser (or an affiliate thereof) is a shareholder of the
      Company, the Purchaser shall have the right to purchase a pro rata percentage
      of
      securities the Purchaser owns in the Company, in any privately placed securities
      offering made by the Company. This preemptive right to acquire securities shall
      not apply to any shares granted to employees of the Company or other persons
      in
      connection with any employee or stock ownership plan or otherwise. If the
      Company proposes to issue further equity securities as described above, the
      Company shall provide written notice to the Purchaser setting forth the price,
      terms and conditions upon which the securities are being offered. The Purchaser
      shall have the right to purchase the amount of securities described in this
      Section above, at such price and upon such terms and conditions set forth in
      the
      notice, if within thirty (30) days after the notice thereof, the Purchaser
      gives
      notice to the Company of its intention to exercise its preemptive
      right.

     

    ARTICLE
      V-
      MISCELLANEOUS

     

    Section
      5.1 Fees
      and Expenses.
      The
      Company shall bear its own costs, including attorney’s fees, incurred in the
      negotiation of this Agreement and consummating of the transactions contemplated
      herein and the corporate proceedings of the Company in contemplation hereof
      and
      thereof. The Company shall reimburse Purchaser for all of Purchaser’s reasonable
      out-of-pocket expenses incurred in connection with the negotiation or
      performance of this Agreement, including without limitation reasonable fees
      and
      disbursements of counsel to the Purchaser. The Company shall pay all transfer
      agent fees, stamp taxes and other taxes and duties levied in connection with
      the
      issuance of any Securities.

     

    Section
      5.2 Entire
      Agreement.
      The
      Transaction Documents, together with the exhibits and schedules thereto, contain
      the entire understanding of the parties with respect to the subject matter
      hereof and supersede all prior agreements and understandings, oral or written,
      with respect to such matters, which the parties acknowledge have been merged
      into such documents, exhibits and schedules.

     

    Section
      5.3 Notices.
      Any
      notice required or permitted hereunder shall be given in writing (unless
      otherwise specified herein) and shall be effective upon personal delivery,
      via
      facsimile (upon receipt of confirmation of error-free transmission and mailing
      a
      copy of such confirmation, postage prepaid by certified mail, return receipt
      requested) or two business days following deposit of such notice with an
      internationally recognized courier service, with postage prepaid and addressed
      to each of the other parties thereunto entitled at the following addresses,
      or
      at such other addresses as a party may designate by five days advance written
      notice to each of the other parties hereto.

     

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    

     

    
      
        	
                Company:

              	 	
                Health
                  Systems Solutions, Inc.

              
	 	 	
                405
                  North Reo Street, Suite 300

              
	 	 	
                Tampa,
                  Florida 33609

              
	 	 	
                Attention:
                  Brian M. Milvain, President

              
	 	 	
                Facsimile:
                  813-282-8907

              
	 	 	 
	
                with
                  a copy to:

              	 	
                Carlton
                  Fields, P.A.

              
	 	 	
                100
                  S.E. Second Street, Suite 4000

              
	 	 	
                Miami,
                  Florida 33131

              
	 	 	
                Attention:
                  Seth P. Joseph, Esq.

              
	 	 	
                Facsimile:
                  305-530-0055

              
	 	 	 
	
                Purchaser:

              	 	
                Stanford
                  International Bank Ltd.

              
	 	 	
                No.
                  11 Pavilion Drive

              
	 	 	
                St.
                  John’s, Antigua, West Indies

              
	 	 	
                Attention:
                  James M. Davis, Chief Financial
                  Officer

              

      

    

     

    Section
      5.4 Amendments;
      Waivers.
      No
      provision of this Agreement may be waived or amended except in a written
      instrument signed, in the case of an amendment, by the Company and Purchaser
      or,
      in the case of a waiver, by the party against whom enforcement of any such
      waiver is sought. No waiver of any default with respect to any provision,
      condition or requirement of this Agreement shall be deemed to be a continuing
      waiver in the future or a waiver of any subsequent default or a waiver of any
      other provision, condition or requirement hereof, nor shall any delay or
      omission of either party to exercise any right hereunder in any manner impair
      the exercise of any such right.

     

    Section
      5.5 Construction.
      The
      headings herein are for convenience only, do not constitute a part of this
      Agreement and shall not be deemed to limit or affect any of the provisions
      hereof. The language used in this Agreement will be deemed to be the language
      chosen by the parties to express their mutual intent, and no rules of strict
      construction will be applied against any party.

     

    Section
      5.6 Successors
      and Assigns.
      This
      Agreement shall be binding upon and inure to the benefit of the parties and
      their successors and permitted assigns. The Company may not assign this
      Agreement or any rights or obligations hereunder without the prior written
      consent of Purchaser. Purchaser may assign its rights under this Agreement
      and
      the Registration Rights Agreement to any Person to whom Purchaser assigns or
      transfers any Securities.

     

    Section
      5.7 No
      Third-Party Beneficiaries.
      This
      Agreement is intended for the benefit of the parties hereto and their respective
      successors and permitted assigns and is not for the benefit of, nor may any
      provision hereof be enforced by, any other Person.

     

    Section
      5.8 Governing
      Law; Venue; Waiver of Jury Trial.
      All
      questions concerning the construction, validity, enforcement and interpretation
      of this Agreement shall be governed by and construed and enforced in accordance
      with the internal laws of the State of Florida, without regard to the principles
      of conflicts of law thereof. Each party hereby irrevocably submits to the
      exclusive jurisdiction of the state and federal courts sitting in Miami-Dade
      County, Florida for the adjudication of any dispute hereunder or in connection
      herewith or with any transaction contemplated hereby or discussed herein
      (including with respect to the enforcement of any of the Transaction Documents),
      and hereby irrevocably waives, and agrees not to assert in any suit, action
      or
      proceeding, any claim that it is not personally subject to the jurisdiction
      of
      any such court, that such suit, action or proceeding is improper or inconvenient
      venue for such proceeding. Each party hereby irrevocably waives personal service
      of process and consents to process being served in any such suit, action or
      proceeding by mailing a copy thereof via registered or certified mail or
      overnight delivery (with evidence of delivery) to such party at the address
      in
      effect for notices to it under this Agreement and agrees that such service
      shall
      constitute good and sufficient service of process and notice thereof. Nothing
      contained herein shall be deemed to limit in any way any right to serve process
      in any manner permitted by law. The parties hereby waive all rights to a trial
      by jury. If either party shall commence an action or proceeding to enforce
      any
      provisions of this Agreement, then the prevailing party in such action or
      proceeding shall be reimbursed by the other party for its attorneys’ fees and
      other costs and expenses incurred with the investigation, preparation and
      prosecution of such action or proceeding.

     

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    

     

    Section
      5.9 Survival.
      The
      representations, warranties, agreements and covenants contained herein shall
      survive the Closing and the delivery, exercise and/or conversion of the
      Securities, as applicable for the applicable statue of limitations.

     

    Section
      5.10 Execution.
      This
      Agreement may be executed in two or more counterparts, all of which when taken
      together shall be considered one and the same agreement and shall become
      effective when counterparts have been signed by each party and delivered to
      the
      other party, it being understood that both parties need not sign the same
      counterpart. In the event that any signature is delivered by facsimile
      transmission, such signature shall create a valid and binding obligation of
      the
      party executing (or on whose behalf such signature is executed) with the same
      force and effect as if such facsimile signature page were an original
      thereof.

     

    Section
      5.11 Severability.
      If any
      provision of this Agreement is held to be invalid or unenforceable in any
      respect, the validity and enforceability of the remaining terms and provisions
      of this Agreement shall not in any way be affected or impaired thereby and
      the
      parties will attempt to agree upon a valid and enforceable provision that is
      a
      reasonable substitute therefor, and upon so agreeing, shall incorporate such
      substitute provision in this Agreement.

     

    Section
      5.12 Remedies.
      In
      addition to being entitled to exercise all rights provided herein or granted
      by
      law, including recovery of damages, Purchaser and the Company will be entitled
      to specific performance under the Transaction Documents. The parties agree
      that
      monetary damages may not be adequate compensation for any loss incurred by
      reason of any breach of obligations described in the foregoing sentence and
      hereby agrees to waive in any action for specific performance of any such
      obligation the defense that a remedy at law would be adequate.

     

    Section
      5.13 Payment
      Set Aside.
      To the
      extent that the Company makes a payment or payments to Purchaser pursuant to
      any
      Transaction Document or Purchaser enforces or exercises its rights thereunder,
      and such payment or payments or the proceeds of such enforcement or exercise
      or
      any part thereof are subsequently invalidated, declared to be fraudulent or
      preferential, set aside, recovered from, disgorged by or are required to be
      refunded, repaid or otherwise restored to the Company, a trustee, receiver
      or
      any other person under any law (including, without limitation, any bankruptcy
      law, state or federal law, common law or equitable cause of action), then to
      the
      extent of any such restoration the obligation or part thereof originally
      intended to be satisfied shall be revived and continued in full force and effect
      as if such payment had not been made or such enforcement or setoff had not
      occurred.

     

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

     

    Section
      5.14 No
      Usury.
      To the
      extent it may lawfully do so, the Company hereby agrees not to insist upon
      or
      plead or in any manner whatsoever claim, and will resist any and all efforts
      to
      be compelled to take the benefit or advantage of, usury laws wherever enacted,
      now or at any time hereafter in force, in connection with any claim, action
      or
      proceeding that may be brought by Purchaser in order to enforce any right or
      remedy under any Transaction Document. Notwithstanding any provision to the
      contrary contained in any Transaction Document, it is expressly agreed and
      provided that the total liability of the Company under the Transaction Documents
      for payments in the nature of interest shall not exceed the maximum lawful
      rate
      authorized under applicable law (the “Maximum
      Rate”),
      and,
      without limiting the foregoing, in no event shall any rate of interest or
      default interest, or both of them, when aggregated with any other sums in the
      nature of interest that the Company may be obligated to pay under the
      Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum
      contract rate of interest allowed by law and applicable to the Transaction
      Documents is increased or decreased by statute or any official governmental
      action subsequent to the date hereof, the new maximum contract rate of interest
      allowed by law will be the Maximum Rate applicable to the Transaction Documents
      from the effective date forward, unless such application is precluded by
      applicable law. If under any circumstances whatsoever, interest in excess of
      the
      Maximum Rate is paid by the Company to Purchaser with respect to indebtedness
      evidenced by the Transaction Documents, such excess shall be applied by
      Purchaser to the unpaid principal balance of any such indebtedness or be
      refunded to the Company, the manner of handling such excess to be at Purchaser’s
      election.

     

    [Signatures
      Begin on Following Page]

     

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the parties hereto have caused this Debenture Purchase
      Agreement to be duly executed by their respective authorized signatories as
      of
      the date first indicated above.

     

    
      	 	 	 
	 	
              HEALTH
                SYSTEMS SOLUTIONS, INC.

            
	 
 	 
 	 
 
	
            	By:  	/s/
              B.
              M. Milvain
	 	
              

              B.M.
                Milvain 

            
	 	
              President

            

    

     

    
      	 	 	 
	 	
              STANFORD
                INTERNATIONAL BANK LIMITED

            
	 
 	 
 	 
 
	
            	By:  	/s/
              James M. Davis
	 	
              

              James
                M. Davis

            
	 	
              Chief
                Financial Officer

            

    

     

    
      
        
        

      

      
        21

        
          

        

      

      
        
        

      

    

     

    SCHEDULE
      1

    

    Warrants
      Distribution

     

    
      	
              Name

            	 	
              Address

            	 	
              Distribution

            
	 	 	 	 	 
	
              Stanford
                International Bank, LTD

            	 	
              No.
                11 Pavilion Drive, St. John's, Antigua, W.I.

            	 	
              625,000
                

            
	
              Daniel
                T. Bogar

            	 	
              1016
                Sanibel Drive, Hollywood, Fl. 33019

            	 	
              144,531
                

            
	
              William
                R. Fusselmann

            	 	
              141
                Crandon Blvd. # 437, Key Biscayne, FL 33149

            	 	
              144,531
                

            
	
              OSVALDO
                PI and VIVIAN PI, Trustees, or their successors in trust, under the
                OSVALDO AND VIVIAN PI LIVING TRUST, dated February 13, 2007, and
                any
                amendments thereto

            	 	
              6405
                SW 104th
                Street, Pinecrest, FL 33156

            	 	
              144,531
                

            
	
              Ronald
                M. Stein

            	 	
              6520
                Allison Road, Miami Beach, Fl. 33141

            	 	
              144,531
                

            
	
              Charles
                M. Weiser

            	 	
              3521
                N. 55th Ave., Hollywood, FL 33021

            	 	
              23,438
                

            
	
              Tal
                Kimmel

            	 	
              201
                South Biscayne Blvd, Miami, FL 33131

            	 	
              23,438
                

            
	 	 	 	 	 
	
              TOTAL

            	 	 	 	
              1,250,000
                

            

    

     

    
      
        
        

      

      
        22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]